<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0094">
    <title>76 Special Phenotypic Methods for Detecting Antibacterial Resistance*</title>
    <sect1 id="ch0094s0001">
      <title>76 Special Phenotypic Methods for Detecting Antibacterial Resistance*</title>
      <anchor id="ch0094s000001a0001"/>
      <anchor id="ch0094s000000a0001"/>
      <anchor id="ch0094s000000a0002"/>
      <para role="chapterAuthor"><phrase role="center">PATRICIA J. SIMNER AND ROMNEY M. HUMPHRIES</phrase>
      </para>
      <sect2 id="ch0094s0001s0001">
        <title>INTRODUCTION</title>
        <anchor id="ch0094s000001a0002"/>
        <anchor id="ch0094s000000a0003"/>
        <para id="ch0094s000000p0001">Special phenotypic tests may be performed as an adjunct or surrogate to standard antimicrobial susceptibility testing (AST) methods to help characterize an isolate’s antimicrobial susceptibility to a drug or drug class or detect a particular resistance mechanism or phenotype. Many of these phenotypic tests are incorporated into standard of care testing as required or are optional tests. Results from some of these tests can be used to guide therapy, whereas others are used for epidemiological purposes. Herein, we describe the different types of special phenotypic tests available for both Gram-positive and Gram-negative organisms and their uses.<anchor id="ch0094s000000a0004"/><link linkend="ch0094s000000a0012">Table 1</link> summarizes the special phenotypic methods for detecting antibacterial resistance discussed in this chapter.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0094s0002">
      <title>Classification of Special Phenotypic Tests for Detection of Resistance</title>
      <anchor id="ch0094s000002a0001"/>
      <anchor id="ch0094s000000a0005"/>
      <para id="ch0094s000000p0002">The Clinical and Laboratory Standards Institute (CLSI) provides definitions of the different types of special phenotypic susceptibility tests in the current M100S document (<link linkend="ch0094s000000li0001">1</link>). Special phenotypic susceptibility tests are categorized into supplemental tests, screening tests, surrogate agent tests, and equivalent agent tests (<link linkend="ch0094s000000a0012">Table 1</link>). By these definitions, a supplemental test is one that detects susceptibility or resistance to a drug or drug class by a method other than the routine disk or broth/agar MIC method and does not require additional tests to confirm susceptibility. Supplemental tests may be required, as is the case when the routine disk or MIC method cannot detect clinically relevant resistance mechanisms, or may be optional. Optional supplemental tests are typically used for epidemiological or infection control purposes. An example of a required supplemental test is the detection of inducible clindamycin resistance in isolates of <emphasis>Staphylococcus aureus</emphasis>, coagulase-negative staphylococci, <emphasis>Streptococcus pneumoniae</emphasis>, or β-hemolytic <emphasis>Streptococcus</emphasis> spp. that are resistant to erythromycin but susceptible or intermediate to clindamycin. An example of an optional supplemental test is the extended-spectrum β-lactamase (ESBL) test for isolates of <emphasis>Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca</emphasis>, or <emphasis>Proteus mirabilis</emphasis> that display reduced susceptibility to cephalosporins. Screening tests, in contrast, are those that provide only presumptive results and require confirmatory testing if certain results are obtained, for example, use of a vancomycin agar screening to detect vancomycin-resistant <emphasis>Enterococcus</emphasis> spp. In this case, if the screening is positive, a confirmatory vancomycin MIC test is required. Surrogate agent tests are those that are performed with an antimicrobial agent that replaces a test performed with the antimicrobial agent of interest. Surrogate agents are used when there is an issue with the performance of the agent of interest or in some cases due to availability of tests for the specific agent of interest. A common example of surrogate agent testing is the use of cefoxitin MIC or disk diffusion to predict susceptibility to oxacillin in <emphasis>S. aureus.</emphasis> Another example of a surrogate agent is the use of oxacillin disk diffusion to predict penicillin susceptibility for <emphasis>S. pneumoniae.</emphasis> In all cases, the surrogate agent itself should not be reported, but rather the agent of interest; for example, oxacillin should be reported in place of cefoxitin for <emphasis>S. aureus</emphasis>, or penicillin in place of oxacillin for <emphasis>S. pneumoniae.</emphasis> Finally, equivalent agent tests are tests performed with an agent that predicts the results of a closely related agent of the same drug class. Equivalent agent testing increases efficiency in the laboratory. In the M100 document, equivalent agents are identified by the presence of an “or” between the two agents in <link linkend="ch0094s000000a0012">Tables 1</link> and <anchor id="ch0094s000000a0006"/><link linkend="ch0094s000000a0038">2</link> or in the comments section of these tables (<link linkend="ch0094s000000li0001">1</link>). Examples of equivalent agents are cefotaxime and ceftriaxone for the <emphasis>Enterobacterales</emphasis>.</para>
    </sect1>
    <sect1 id="ch0094s0003">
      <title>Phenotypic Testing Directly from Specimens versus Cultured Isolates</title>
      <anchor id="ch0094s000003a0001"/>
      <anchor id="ch0094s000000a0007"/>
      <para id="ch0094s000000p0003">Phenotypic methods for the detection of resistance have been developed for use with both clinical specimens and cultured growth. For the most part, phenotypic detection of resistance from clinical specimens is performed to detect patients colonized with multidrug-resistant (MDR) pathogens, such as methicillin-resistant<emphasis>Staphylococcus aureus</emphasis> (MRSA), vancomycin-resistant enterococci (VRE), or carbapenem-resistant Gram-negative organisms (CRO), for infection control purposes, so that patients can be placed on contact precautions to reduce spread within the hospital setting. Testing from cultured organism growth can be used to inform treatment decisions and/or for epidemiological purposes. The application of each phenotypic test is discussed in further detail below.</para>
      <anchor id="ch0094s000000a0008"/>
      <beginpage pagenum="1458"/>
      <anchor id="ch0094s000000a0009"/>
      <beginpage pagenum="1459"/>
      <anchor id="ch0094s000000a0010"/>
      <beginpage pagenum="1460"/>
      <anchor id="ch0094s000000a0011"/>
      <beginpage pagenum="1461"/>
      <table id="ch0094s000000t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0094s000000a0012"/><link linkend="ch0094s000000a0004">TABLE 1</link></phrase></emphasis> Special phenotypic tests for detecting antibacterial resistance described in this chapter<superscript><emphasis><anchor id="ch0094s000000a0013"/><link linkend="ch0094s000000a0020">a</link></emphasis></superscript>
</title>
        
        <tgroup cols="5">
          <tbody>
            <row>
              <entry><phrase role="center">Phenotypic test</phrase>
              </entry>
              <entry><phrase role="center">Organisms</phrase>
              </entry>
              <entry><phrase role="center">Test description</phrase>
              </entry>
              <entry><phrase role="center">Testing scenario</phrase>
              </entry>
              <entry><phrase role="center">Reporting and other considerations</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Required Supplemental Tests<superscript><emphasis><anchor id="ch0094s000000a0014"/><link linkend="ch0094s000000a0021">b</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Inducible clindamycin resistance</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Staphylococcus aureus</emphasis>, SOSA, <emphasis>Streptococcus pneumoniae, Streptococcus</emphasis> spp. β-hemolytic group</phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution or D-zone disk diffusion test with clindamycin and erythromycin tested together</phrase>
              </entry>
              <entry><phrase role="left">Isolates that test erythromycin resistant and clindamycin susceptible or intermediate before reporting the isolate as clindamycin susceptible</phrase>
              </entry>
              <entry><phrase role="left">Isolates that demonstrate inducible clindamycin resistance should be reported as clindamycin resistant with a comment based on CLSI guidelines, whereas EUCAST recommends adding a comment only.</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Detection of β-lactamase production among penicillin-susceptible isolates</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. aureus</emphasis>, SOSA</phrase>
              </entry>
              <entry><para id="ch0094s000000p0004"><phrase role="left">Chromogenic cephalosporin (<emphasis>S. aureus</emphasis>); if chromogenic cephalosporin negative, must perform penicillin disk diffusion zone edge test</phrase>
                </para>
                <para id="ch0094s000000p0005"><phrase role="left">Chromogenic cephalosporin (SOSA)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">Isolates that test penicillin susceptible, before reporting the isolate as penicillin susceptible</phrase>
              </entry>
              <entry><para id="ch0094s000000p0006"><phrase role="left">β-Lactamase producers should be reported as penicillin resistant.</phrase>
                </para>
                <para id="ch0094s000000p0007"><phrase role="left">Any <emphasis>S. aureus</emphasis> isolate that is penicillin susceptible and β-lactamase negative by a chromogenic cephalosporin must be confirmed by the penicillin zone edge test prior to reporting. If positive by the zone edge test, report as penicillin resistant.</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">HLAR by BMD or agar dilution</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Enterococcus</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left">BMD with 500 μg of gentamicin/ml or 1,000 μg streptomycin/ml or BHI agar with 500 μg of gentamicin/ml or 2,000 μg streptomycin/ml</phrase>
              </entry>
              <entry><phrase role="left">Detects HLAR</phrase>
              </entry>
              <entry><para id="ch0094s000000p0008"><phrase role="left">If positive, report as HLAR.</phrase>
                </para>
                <para id="ch0094s000000p0009"><phrase role="left">CLSI recommends the use of BHI broth only for detection of HLAR by BMD; MHA is also acceptable by EUCAST and some commercial manufacturers use MHA or MHB.</phrase>
                </para>
                <para id="ch0094s000000p0010"><phrase role="left">Testing is required only on isolates from serious infections.</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Optional Supplemental Tests<superscript><emphasis><anchor id="ch0094s000000a0015"/><link linkend="ch0094s000000a0022">c</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">β-Lactamase testing (i.e., penicillinase, AmpC, ESBL, and carbapenemase)</phrase>
              </entry>
              <entry><phrase role="left">Gram-negative bacilli</phrase>
              </entry>
              <entry><phrase role="left">See <anchor id="ch0094s000000a0016"/><link linkend="ch0094s000000a0069">Table 3</link></phrase>
              </entry>
              <entry><phrase role="left">See <link linkend="ch0094s000000a0069">Table 3</link></phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><phrase role="center">Detection of β-lactamase production among penicillin-susceptible isolates</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Enterococcus</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left">Chromogenic cephalosporin</phrase>
              </entry>
              <entry><phrase role="left">Because of the rarity of β-lactamase-positive enterococci, this test need not be performed routinely but can be used in selected cases.</phrase>
              </entry>
              <entry><para id="ch0094s000000p0011"><phrase role="left">β-Lactamase producers should be reported as penicillin resistant.</phrase>
                </para>
                <para id="ch0094s000000p0012"><phrase role="left">Penicillin resistance among the enterococci due to β-lactamase production has been reported very rarely.</phrase>
                </para>
                <para id="ch0094s000000p0013"><phrase role="left">Penicillin resistance due to β-lactamase production is not reliably detected by routine methods but is detected using a direct, nitrocefin-based β-lactamase test.</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Oxacillin salt agar to detect MRSA</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>S. aureus</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Agar dilution; MHA with 4% NaCl and 6 μg/ml oxacillin</phrase>
              </entry>
              <entry><phrase role="left">Detecting MRSA</phrase>
              </entry>
              <entry><para id="ch0094s000000p0014"><phrase role="left">Report as oxacillin resistant</phrase>
                </para>
                <para id="ch0094s000000p0015"><phrase role="left">Cefoxitin surrogate agent tests are preferred over oxacillin salt agar to detect MRSA supplemental test.</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Detection of PBP2a</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. aureus</emphasis>, SOSA</phrase>
              </entry>
              <entry><phrase role="left">Latex agglutination or immunochromatogenic assays</phrase>
              </entry>
              <entry><phrase role="left">Predicts the production of <emphasis>mecA</emphasis>-mediated oxacillin resistance</phrase>
              </entry>
              <entry><para id="ch0094s000000p0016"><phrase role="left">If positive, report as MRSA.</phrase>
                </para>
                <para id="ch0094s000000p0017"><phrase role="left">Induction may be required.</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Detection of hVISA</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>S. aureus</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Gradient diffusion strips with vancomycin and teicoplanin</phrase>
              </entry>
              <entry/>
              <entry><para id="ch0094s000000p0018"><phrase role="left">Reporting is not defined. MIC testing should be performed to report a vancomycin MIC.</phrase>
                </para>
                <para id="ch0094s000000p0019"><phrase role="left">Not endorsed by CLSI or EUCAST.</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">High-level mupirocin resistance</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>S. aureus</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Disk diffusion (200 μg disk) or single-well BMD (256 μg/ml)</phrase>
              </entry>
              <entry><phrase role="left">Detects high-level mupirocin resistance.</phrase>
              </entry>
              <entry><phrase role="left">If positive, report as high-level mupirocin resistant.</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <table id="ch0094s000000t0002"><title>Table 2 (continued)</title>
        
        <tgroup cols="5">
          <tbody>
            <row>
              <entry><phrase role="center">Colistin resistance</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii</emphasis> complex</phrase>
              </entry>
              <entry><para id="ch0094s000000p0020"><phrase role="left">Rapid chromogenic polymyxin NP and derivatives</phrase>
                </para>
                <para id="ch0094s000000p0021"><phrase role="left">CBDE method: tube dilution using colistin disks as antimicrobial agent source</phrase>
                </para>
                <para id="ch0094s000000p0022"><phrase role="left">CAT: modified agar dilution method</phrase>
                </para>
              </entry>
              <entry><para id="ch0094s000000p0023"><phrase role="left">Polymyxin NP and derivatives: detects isolates that are colistin-resistant</phrase>
                </para>
                <para id="ch0094s000000p0024"><phrase role="left">CBDE and CAT: determines colistin MIC</phrase>
                </para>
              </entry>
              <entry><para id="ch0094s000000p0025"><phrase role="left">Polymyxin NP and derivatives: if positive, report as colistin-resistant.</phrase>
                </para>
                <para id="ch0094s000000p0026"><phrase role="left">CBDE and CAT: report MIC and/or interpretive criteria.</phrase>
                </para>
                <para id="ch0094s000000p0027"><phrase role="left">CBDE and CAT are endorsed by CLSI for <emphasis>Enterobacterales</emphasis> and <emphasis>P. aeruginosa.</emphasis></phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Screening Tests<superscript><emphasis><anchor id="ch0094s000000a0017"/><link linkend="ch0094s000000a0023">d</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Vancomycin agar screening</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. aureus, Enterococcus</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left">Agar dilution; BHI with 6 μg/ml vancomycin</phrase>
              </entry>
              <entry><phrase role="left">If the screening test is positive, confirm vancomycin resistance by MIC</phrase>
              </entry>
              <entry><para id="ch0094s000000p0028"><phrase role="left">Do not report screening test results.</phrase>
                </para>
                <para id="ch0094s000000p0029"><phrase role="left">Confirm presumptive reduced vancomycin susceptibility by a MIC method.</phrase>
                </para>
                <para id="ch0094s000000p0030"><phrase role="left">Some vancomycin-intermediate <emphasis>S. aureus</emphasis> isolates may fail to grow.</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">HLAR by disk diffusion</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Enterococcus</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left">Disk diffusion with gentamicin and streptomycin</phrase>
              </entry>
              <entry><phrase role="left">If the screening test is inconclusive, MIC testing is required</phrase>
              </entry>
              <entry><para id="ch0094s000000p0031"><phrase role="left">Inconclusive results need to be confirmed by a MIC method.</phrase>
                </para>
                <para id="ch0094s000000p0032"><phrase role="left">Susceptible or resistant results can be reported as the presence of synergy with cell wall agents or not, respectively.</phrase>
                </para>
                <para id="ch0094s000000p0033"><phrase role="left">There is no inconclusive zone based on EUCAST guidelines, and thus, the results are not required to be confirmed.</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">EUCAST benzylpenicillin (penicillin G) 1-U disk screening for β-lactam resistance</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>Haemophilus influenzae</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Disk diffusion</phrase>
              </entry>
              <entry><phrase role="left">Screen all isolates for β-lactam resistance, including β-lactamase production and other β-lactam resistance mechanisms (i.e., PBP)</phrase>
              </entry>
              <entry><para id="ch0094s000000p0034"><phrase role="left">For zone diameters ≥12 mm, report susceptible to all β-lactam agents with EUCAST established clinical breakpoints.</phrase>
                </para>
                <para id="ch0094s000000p0035"><phrase role="left">For zone diameters &lt;12 mm, test for β-lactamase production. If positive, report as resistant to ampicillin, amoxicillin, and piperacillin. Test all other β-lactam agents by routine AST methods if intended for clinical use.</phrase>
                </para>
                <para id="ch0094s000000p0036"><phrase role="left">If β-lactamase negative, test and report β-lactam agents using routine AST methods.</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Surrogate Agent Tests<superscript><emphasis><anchor id="ch0094s000000a0018"/><link linkend="ch0094s000000a0024">e</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Cefoxitin testing to predict methicillin (oxacillin) resistance</phrase>
              </entry>
              <entry><phrase role="left">Staphylococci; See <link linkend="ch0094s000000a0038">Table 2</link></phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution or disk diffusion (see <link linkend="ch0094s000000a0038">Table 2</link>)</phrase>
              </entry>
              <entry><phrase role="left">Predicts results for <emphasis>mecA</emphasis>-mediated methicillin (oxacillin) resistance</phrase>
              </entry>
              <entry><phrase role="left">Report oxacillin based on cefoxitin results (susceptible or resistant)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Cefazolin to predict oral cephalosporin agents for uUTIs</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution or disk diffusion</phrase>
              </entry>
              <entry><phrase role="left">When used for therapy of uncomplicated UTIs, predicts results for certain oral cephalosporin agents</phrase>
              </entry>
              <entry><para id="ch0094s000000p0037"><phrase role="left">Based on CLSI guidelines, cefazolin AST results are used to predict certain oral cephalosporins for treatment of uUTIs.</phrase>
                </para>
                <para id="ch0094s000000p0038"><phrase role="left">Cefpodoxime, cefdinir, and cefuroxime may be tested individually, because some isolates may be susceptible to these agents while testing resistant to cefazolin.</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Pefloxacin disk to predict ciprofloxacin susceptibility</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Salmonella</emphasis> species</phrase>
              </entry>
              <entry><phrase role="left">Disk diffusion</phrase>
              </entry>
              <entry><phrase role="left">Predicts results to ciprofloxacin</phrase>
              </entry>
              <entry><para id="ch0094s000000p0039"><phrase role="left">Pefloxacin disks are not available in the United States.</phrase>
                </para>
                <para id="ch0094s000000p0040"><phrase role="left">CLSI encourages the use of MIC-based testing for ciprofloxacin over disk diffusion and pefloxacin surrogate testing.</phrase>
                </para>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <table id="ch0094s000000t0003"><title>Table 3 (continued)</title>
        
        <tgroup cols="5">
          <tbody>
            <row>
              <entry><phrase role="center">Oxacillin disk screening to detect penicillin resistance</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>S. pneumoniae</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Disk diffusion</phrase>
              </entry>
              <entry><phrase role="left">Predicts penicillin susceptibility if oxacillin zone is ≥20 mm. If oxacillin zone is ≤19 mm, penicillin MIC must be performed</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> isolates from CSF or blood should be tested by a MIC method rather than the oxacillin disk test.</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Surveillance Culture Tests<superscript><emphasis><anchor id="ch0094s000000a0019"/><link linkend="ch0094s000000a0025">f</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Detection of MRSA from nasal swabs</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>S. aureus</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Chromogenic media</phrase>
              </entry>
              <entry><phrase role="left">Selective and differential media for detection of MRSA</phrase>
              </entry>
              <entry><phrase role="left">The use of chromogenic media for primary detection of MRSA directly from clinical specimens has also been described for respiratory specimens, positive blood cultures, wounds, and stools.</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Detection of VRE from surveillance specimens (stool and perirectal or rectal swabs)</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Enterococcus faecium</emphasis> and <emphasis>Enterococcus faecalis</emphasis> (differentiated by different chromogens in the media)</phrase>
              </entry>
              <entry><phrase role="left">Chromogenic media</phrase>
              </entry>
              <entry><phrase role="left">Selective and differential media for detection of VRE</phrase>
              </entry>
              <entry><phrase role="left">Sensitivity is increased with an extended incubation or with a pre-enrichment step.</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Detection of ESBL producers from surveillance specimens</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>Enterobacterales</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Broth enrichment, selective culture and chromogenic media</phrase>
              </entry>
              <entry><phrase role="left">Select for expanded-spectrum cephalosporin-resistant Gram-negative organisms</phrase>
              </entry>
              <entry><para id="ch0094s000000p0041"><phrase role="left">ID and AST of growth may be required.</phrase>
                </para>
                <para id="ch0094s000000p0042"><phrase role="left">Detection of ESBL producers will require additional phenotypic or genotypic testing.</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Detection of CRO from surveillance specimens</phrase>
              </entry>
              <entry><para id="ch0094s000000p0043"><phrase role="left">
                    <emphasis>Enterobacterales</emphasis>
                  </phrase>
                </para>
                <para id="ch0094s000000p0044"><phrase role="left">Glucose-nonfermenting Gram-negative bacilli</phrase>
                </para>
              </entry>
              <entry><phrase role="left">Broth enrichment, selective culture, and chromogenic media</phrase>
              </entry>
              <entry><phrase role="left">Select for carbapenem-resistant Gram-negative organisms</phrase>
              </entry>
              <entry><para id="ch0094s000000p0045"><phrase role="left">ID and AST of growth may be required.</phrase>
                </para>
                <para id="ch0094s000000p0046"><phrase role="left">Detection of carbapenemase-producers will require additional phenotypic or genotypic testing.</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Detection of fluoroquinolone-resistant Gram-negative bacilli from fecal specimens</phrase>
              </entry>
              <entry><phrase role="left">Gram-negative bacilli</phrase>
              </entry>
              <entry><phrase role="left">Broth enrichment, selective culture</phrase>
              </entry>
              <entry><phrase role="left">Select for fluoroquinolone-resistant Gram-negative bacilli</phrase>
              </entry>
              <entry><phrase role="left">ID and AST of growth may be required.</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Detection of colistin-resistant Gram-negative bacilli from fecal specimens</phrase>
              </entry>
              <entry><phrase role="left">Gram-negative bacilli</phrase>
              </entry>
              <entry><phrase role="left">Selective culture and chromogenic media</phrase>
              </entry>
              <entry><phrase role="left">Select for colistin-resistant Gram-negative bacilli</phrase>
              </entry>
              <entry><phrase role="left">ID and AST of growth may be required.</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0020"/><link linkend="ch0094s000000a0013">a</link></emphasis></superscript>Modified with permission from reference <link linkend="ch0094s000000li0001">1</link> (note that M100 is updated annually and more frequently than this <emphasis>Manual</emphasis>). CAT, colistin agar test; CBDE, colistin broth disk elution; SOSA, <emphasis>Staphylococcus</emphasis> spp. other than <emphasis>Staphylococcus aureus</emphasis>; UTI, urinary tract infection; uUTI, uncomplicated urinary tract infection.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0021"/><link linkend="ch0094s000000a0014">b</link></emphasis></superscript>Tests that are required to detect susceptibility or resistance to a drug or drug class by a method other than routine AST and does not require additional tests to confirm susceptibility or resistance.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0022"/><link linkend="ch0094s000000a0015">c</link></emphasis></superscript>Tests that are optionally performed to detect susceptibility or resistance to a drug or drug class by a method other than routine AST and does not require additional tests to confirm susceptibility or resistance.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0023"/><link linkend="ch0094s000000a0017">d</link></emphasis></superscript>Tests that provide presumptive results; additional testing is typically needed only for a specific result (e.g., only if screening is positive).</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0024"/><link linkend="ch0094s000000a0018">e</link></emphasis></superscript>Tests performed with an agent that replaces a test performed with the antimicrobial agent of interest and is used when the agent of interest cannot be tested due to availability or performance issues (e.g., surrogate agent performs better than the agent of interest).</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0025"/><link linkend="ch0094s000000a0019">f</link></emphasis></superscript>Selective and/or differential culture techniques to identify a particular resistance phenotype performed directly from surveillance specimens to detect colonization.</para>
    </sect1>
    <sect1 id="ch0094s0004">
      <title>Advantages and Disadvantages of Phenotypic versus Genotypic Resistance Detection</title>
      <anchor id="ch0094s000004a0001"/>
      <anchor id="ch0094s000000a0026"/>
      <para id="ch0094s000000p0047">In general, phenotypic methods for detection of resistance are inexpensive alternatives to genotypic methods. Phenotypic methods may also provide the advantage of casting a broad net for detecting expression of multiple mechanisms mediating resistance rather than targeted resistance genes. This is most important in Gram-negative bacteria, where mechanisms of resistance tend to be heterogeneous. For example, rather than detecting targeted carbapenemase genes by molecular testing, phenotypic carbapenemase detection methods may detect all carbapenemase producers, regardless of the enzyme being produced. In addition, phenotypic methods have the advantage of detecting expression rather than simply the presence of a gene that may or may not be expressed, providing a better correlation with phenotypic AST results (<link linkend="ch0094s000000li0002">2</link>). In general, phenotypic methods are less rapid than genotypic methods, which can be performed in some cases in under an hour. This paradigm may change in the near future, as newer chromogenic and immunochromatogenic methods are emerging that can detect phenotypic resistance within the same time frame as molecular tests (<link linkend="ch0094s000000li0003">3</link>, <link linkend="ch0094s000000li0004">4</link>).</para>
    </sect1>
    <sect1 id="ch0094s0005">
      <title>Quality Control Considerations</title>
      <anchor id="ch0094s000005a0001"/>
      <anchor id="ch0094s000000a0027"/>
      <para id="ch0094s000000p0048">As with any test reported by clinical microbiology laboratories, appropriate quality control (QC) is required when testing and reporting detection of phenotypic resistance for clinical care, including infection control purposes. Positive and negative controls should be set up at the time of testing, or according to the laboratory’s individualized quality control plan (IQCP). Recommendations on appropriate QC strains are available from CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines, as well as from the manufacturers of commercial tests (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0005">5</link>).</para>
    </sect1>
    <sect1 id="ch0094s0006">
      <title>Reporting Considerations</title>
      <anchor id="ch0094s000006a0001"/>
      <anchor id="ch0094s000000a0028"/>
      <para id="ch0094s000000p0049">Dependent on the test, confirmation of results may be required prior to reporting some or any results of phenotypic resistance testing. Furthermore, some tests may be used for reporting resistance for therapeutic management whereas others are used to detect a specific phenotype for infection control purposes. The need for confirmation testing and resulting considerations for each test are described in further detail below.</para>
      <sect2 id="ch0094s0006s0001">
        <title>PHENOTYPIC DETECTION OF RESISTANCE AMONG GRAM-POSITIVE ORGANISMS</title>
        <anchor id="ch0094s000006a0002"/>
        <anchor id="ch0094s000000a0029"/>
      </sect2>
    </sect1>
    <sect1 id="ch0094s0007">
      <title>Detection of β-Lactam Resistance in Gram-Positive Organisms</title>
      <anchor id="ch0094s000007a0001"/>
      <anchor id="ch0094s000000a0030"/>
      <sect2 id="ch0094s0007s0001">
        <title>β-Lactamase Testing for Staphylococci</title>
        <anchor id="ch0094s000007a0002"/>
        <anchor id="ch0094s000000a0031"/>
        <para id="ch0094s000000p0050">Penicillin resistance in staphylococci is due to production of penicillinase, encoded by the<emphasis>blaZ</emphasis> gene, which is usually plasmid borne and inducible. Among most U.S. <emphasis>Staphylococcus</emphasis> isolates, penicillin susceptibility rates are &lt;10%, and penicillin is rarely considered as a therapeutic option for staphylococcal infections. The exception to this is <emphasis>Staphylococcus lugdunensis</emphasis>, where roughly 50% of isolates are penicillin susceptible and penicillin is a first-line treatment option (<link linkend="ch0094s000000li0006">6</link>). Similarly, penicillin-susceptible <emphasis>S. aureus</emphasis> isolates are common in some European countries (<link linkend="ch0094s000000li0007">7</link>) and may be re-emerging in U.S. hospitals (<link linkend="ch0094s000000li0008">8</link>). In these cases, penicillin may be considered for use in cases where prolonged therapy is required (e.g., osteomyelitis) and testing for penicillin susceptibility is warranted. The staphylococcal breakpoint for penicillin susceptibility is ≤0.125 μg/ml (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0009">9</link>). Rare isolates with penicillin MICs in the susceptible range may produce β-lactamase, and so current recommendations state that a supplemental β-lactamase test must be performed on staphylococcal isolates that test susceptible to penicillin, prior to reporting of the isolate as penicillin susceptible (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0009">9</link>). Depending on local epidemiology and practices, laboratories may choose to perform this supplemental testing routinely or by special request alone.</para>
        <para id="ch0094s000000p0051">Commercial chromogenic cephalosporin disks, such as the nitrocefin disk, lack sensitivity for detection of<emphasis>blaZ</emphasis> in <emphasis>S. aureus.</emphasis> One study demonstrated that of 28 <emphasis>blaZ</emphasis>-positive <emphasis>S. aureus</emphasis> isolates with penicillin MICs of ≤0.125 μg/ml, only 11 (39%) were detected as β-lactamase positive by the nitrocefin disk (<link linkend="ch0094s000000li0010">10</link>). In contrast, the penicillin disk zone edge test detected 20 of 28 (71%) <emphasis>blaZ</emphasis>-positive strains (<link linkend="ch0094s000000li0010">10</link>). Based on subsequent unpublished studies that demonstrated improved performance of the zone edge test, both CLSI and EUCAST recommend performing the penicillin zone edge test for <emphasis>S. aureus</emphasis> isolates prior to reporting them as penicillin susceptible (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0009">9</link>). By this test, isolates with a sharp zone edge (otherwise known as a “cliff”) are positive for β-lactamase and reported as penicillin resistant. Those with a feathered edge (“beach”) are negative for β-lactamase and reported as penicillin susceptible. Interpretation of the zone edge can be subjective, and so zone edges should be carefully inspected using reflected light.</para>
        <para id="ch0094s000000p0052">The penicillin zone edge test is not recommended for<emphasis>Staphylococcus</emphasis> spp. other than <emphasis>S. aureus</emphasis> (SOSA). In particular, the specificity of this test is poor for <emphasis>S. lugdunensis</emphasis> (<link linkend="ch0094s000000li0006">6</link>). CLSI recommends performing an induced (growth taken from the zone margin surrounding a penicillin or cefoxitin disk test) nitrocefin-based test for SOSA, including <emphasis>S. lugdunensis</emphasis>, prior to reporting these as penicillin susceptible (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0006">6</link>). In contrast, EUCAST does not require supplemental testing prior to reporting <emphasis>S. lugdunensis</emphasis> as susceptible to penicillin and cautions that no currently available method can reliably detect penicillinase production in other SOSA species (<link linkend="ch0094s000000li0009">9</link>).</para>
        <para id="ch0094s000000p0053">In instances where penicillin is used therapeutically for β-lactamase-negative, penicillin-susceptible infections, CLSI recommends that MIC and β-lactamase tests be performed on all subsequent<emphasis>Staphylococcus</emphasis> isolates from the same patient, due to the imperfect performance of any β-lactamase test for the staphylococci (<link linkend="ch0094s000000li0001">1</link>).</para>
        <para id="ch0094s000000p0054">Recently, several<emphasis>in vitro</emphasis> and <emphasis>in vivo</emphasis> studies have documented a cefazolin inoculum effect (CzIE) by some <emphasis>blaZ</emphasis>-expressing <emphasis>S. aureus</emphasis> strains (<link linkend="ch0094s000000li0011">11</link>, <link linkend="ch0094s000000li0012">12</link>). The clinical impact of the CzIE has been debated, and CLSI is evaluating standardized testing methods for the CzIE. Currently, the only standardized method for detection of CzIE is the use of a high (~5.0 × 10<superscript>7</superscript> CFU/mL) <emphasis>S. aureus</emphasis> inoculum for cefazolin broth microdilution (BMD) MIC testing. A positive test result is a cefazolin MIC of ≥16 μg/ml by the high-inoculum BMD method and a MIC of ≤8 μg/ml using a standard inoculum (<link linkend="ch0094s000000li0012">12</link>).</para>
      </sect2>
      <sect2 id="ch0094s0007s0002">
        <title>β-Lactamase Testing for Enterococci</title>
        <anchor id="ch0094s000007a0003"/>
        <anchor id="ch0094s000000a0032"/>
        <para id="ch0094s000000p0055">Penicillin resistance among the enterococci is predominantly mediated via overexpression of low-affinity penicillin-binding proteins (PBPs) or alterations to PBPs. Isolates of<emphasis>Enterococcus</emphasis> that are susceptible to penicillin are predictably susceptible to ampicillin (<link linkend="ch0094s000000li0013">13</link>), but penicillin-resistant, ampicillin-susceptible phenotypes are observed; such isolates are also resistant to piperacillin and imipenem (<link linkend="ch0094s000000li0014">14</link>). Occasionally, isolates of <emphasis>Enterococcus</emphasis>, predominantly <emphasis>Enterococcus faecalis</emphasis>, have been reported that harbor the <emphasis>blaZ</emphasis> gene described above. The first documented occurrence of a clinical isolate of <emphasis>E. faecalis</emphasis> that produced β-lactamase was in 1981 (<link linkend="ch0094s000000li0015">15</link>). Since that report, β-lactamase producing <emphasis>E. faecalis</emphasis> and <emphasis>Enterococcus faecium</emphasis> isolates were sporadically reported throughout the 1990s (<link linkend="ch0094s000000li0016">16</link>–<link linkend="ch0094s000000li0018">18</link>), with the most recent report involving an <emphasis>E. faecium</emphasis> isolate from Italy in 2010 (<link linkend="ch0094s000000li0019">19</link>). Many of these isolates tested susceptible to penicillin but positive by direct β-lactamase tests using nitrocefin-based assays. Today, β-lactamase-producing enterococci are rare, with no recent reports documenting their occurrence. Therefore, it is not necessary to perform β-lactamase testing routinely for enterococci (<link linkend="ch0094s000000li0020">20</link>), but this test may be considered in cases of apparent treatment failure with penicillin therapy.</para>
        <anchor id="ch0094s000000a0033"/>
        <beginpage pagenum="1462"/>
      </sect2>
      <sect2 id="ch0094s0007s0003">
        <title>Oxacillin Disk Screening Test for Detection of Penicillin Resistance in Pneumococci</title>
        <anchor id="ch0094s000007a0004"/>
        <anchor id="ch0094s000000a0034"/>
        <para id="ch0094s000000p0056">A screening test in which a 1-μg oxacillin disk is used to detect penicillin resistance in pneumococci was first described following an outbreak caused by<emphasis>S. pneumoniae</emphasis> strains resistant to multiple antimicrobial agents in South Africa in the 1970s (<link linkend="ch0094s000000li0021">21</link>). Since then, this test has been used extensively and was shown to be highly sensitive, but not specific, for detection of penicillin not susceptible pneumococci, by the meningitis breakpoint of ≤0.06 μg/ml (<link linkend="ch0094s000000li0022">22</link>). Both CLSI and EUCAST indicate that nonmeningitis strains that exhibit oxacillin zone diameters of ≥20 mm can be considered susceptible to all β-lactams with activity against <emphasis>S. pneumoniae</emphasis>, with no further testing (<link linkend="ch0094s000000li0001">1</link>). However, strains identified as not susceptible by this method may be penicillin susceptible, intermediate, or resistant. According to CLSI guidance, penicillin MIC tests must be performed on any strain that produces a zone diameter of ≤19 mm to determine if it is resistant (<link linkend="ch0094s000000li0020">20</link>, <link linkend="ch0094s000000li0022">22</link>). In contrast, EUCAST indicates that such isolates are resistant to penicillin by the meningitis breakpoints and that a MIC test must be performed for indications other than meningitis (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0005">5</link>).</para>
      </sect2>
      <sect2 id="ch0094s0007s0004">
        <title>Detection of Oxacillin Resistance among Staphylococci</title>
        <anchor id="ch0094s000007a0005"/>
        <anchor id="ch0094s000000a0035"/>
        <para id="ch0094s000000p0057">Strains of<emphasis>S. aureus</emphasis> that are resistant to oxacillin are still referred to as MRSA, even though methicillin is no longer available; the abbreviation MRSA has persisted and therefore is also used here. At least four different resistance mechanisms can confer resistance to oxacillin in <emphasis>S. aureus</emphasis>: (i) expression of the acquired chromosomal <emphasis>mecA</emphasis> gene to produce a supplemental PBP, designated PBP2a, with decreased affinity for penicillins; (ii) production of a different PBP variant by the <emphasis>mecC</emphasis> gene; (iii) inactivation of the drug by increased production of β-lactamase (organisms that exhibit this mechanism are referred to as borderline oxacillin-resistant <emphasis>S. aureus</emphasis> [BORSA]); and (iv) production of modified intrinsic PBPs with altered drug affinity (organisms that exhibit this mechanism are referred to as modified oxacillin-resistant <emphasis>S. aureus</emphasis> [MOD-SA]) (<link linkend="ch0094s000000li0023">23</link>). Resistance mediated by <emphasis>mecA</emphasis> is by far the most common mechanism of oxacillin resistance in <emphasis>S. aureus</emphasis> and SOSA worldwide. The rarity of BORSA and MOD-SA precludes a clear understanding of clinical relevance. Experimental studies suggest that these resistance mechanisms may not have a significant impact on outcomes (<link linkend="ch0094s000000li0024">24</link>). Until it is shown that BORSA or MOD-SA is clinically significant, laboratory focus on detection of <emphasis>mecA</emphasis>- and <emphasis>mecC</emphasis>-mediated resistance alone is a reasonable approach.</para>
        <para id="ch0094s000000p0058">Rapid and reliable detection of<emphasis>mecA</emphasis>-mediated resistance is recognized as a crucial component of laboratory testing, and numerous laboratory methods for this purpose have been described. Phenotypic detection of <emphasis>mecA</emphasis> resistance among the staphylococci is complex. The oxacillin MIC range for <emphasis>mecA</emphasis>-expressing staphylococci differs by species, with higher MICs observed for <emphasis>S. aureus</emphasis> and <emphasis>S. lugdunensis</emphasis> than other species, necessitating species-specific breakpoints (<link linkend="ch0094s000000a0038">Table 2</link>). Implementation of these breakpoints has become possible through routine identification of staphylococci to the species level by clinical laboratories via use of matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS). Compounding species complexity is the not infrequent occurrence of heterogeneous expression of <emphasis>mecA</emphasis> within a single species (<link linkend="ch0094s000000li0025">25</link>, <link linkend="ch0094s000000li0026">26</link>), which may result in oxacillin MICs near the breakpoint and misinterpretation of such isolates as susceptible. Use of 2% NaCl, incubation at 35°C (as opposed to 37°C), and use of the surrogate agent cefoxitin (<link linkend="ch0094s000000li0027">27</link>) are all methods shown to enhance <emphasis>in vitro</emphasis> expression of <emphasis>mecA</emphasis> in <emphasis>S. aureus.</emphasis> These methods work to various degrees for other staphylococcal species harboring the <emphasis>mecA</emphasis> gene, again requiring species-specific guidance (<link linkend="ch0094s000000li0028">28</link>, <link linkend="ch0094s000000li0029">29</link>). As an example, cefoxitin is a poor inducer of <emphasis>mecA</emphasis> expression in the veterinary staphylococci <emphasis>Staphylococcus pseudintermedius</emphasis> and <emphasis>Staphylococcus schleiferi</emphasis>, requiring exclusive use of oxacillin disk or MIC tests for these species (<link linkend="ch0094s000000li0030">30</link>, <link linkend="ch0094s000000li0031">31</link>). Similarly, the cefoxitin disk diffusion test fails to reliably classify <emphasis>mecA-</emphasis>positive strains of <emphasis>Staphylococcus simulans</emphasis> as resistant (<link linkend="ch0094s000000li0028">28</link>). In contrast, incomplete induction of <emphasis>mecA</emphasis> expression by oxacillin disk diffusion tests can result in light or hazy growth within the zone of growth inhibition for many species, leading both CLSI and EUCAST to eliminate oxacillin disk diffusion as an approved method for most staphylococci (<link linkend="ch0094s000000li0028">28</link>, <link linkend="ch0094s000000li0032">32</link>). Recent studies by CLSI suggested that oxacillin disk diffusion performs well for <emphasis>Staphylococcus epidermidis</emphasis> (<link linkend="ch0094s000000li0033">33</link>), and CLSI recently reintroduced this test, enabling both oxacillin and cefoxitin disk diffusion methods for <emphasis>S. epidermidis</emphasis> (<link linkend="ch0094s000000a0038">Table 2</link>). Importantly, the performance of phenotypic oxacillin or cefoxitin tests for many staphylococci is unknown, and use of a <emphasis>mecA</emphasis>-specific molecular test, or detection of PBP2a, may be preferred for serious infections.</para>
        <sect3 id="ch0094s0007s0004s0001">
          <title>Detection of mecC</title>
          <anchor id="ch0094s000007a0006"/>
          <anchor id="ch0094s000000a0036"/>
          <para id="ch0094s000000p0059">Since its description in 2011,<emphasis>mecC</emphasis>-mediated resistance has been identified in <emphasis>S. aureus</emphasis> from human, livestock, and other animal isolates, but it appears to have a low prevalence overall, even among persons with high rates of animal exposure (<link linkend="ch0094s000000li0034">34</link>–<link linkend="ch0094s000000li0036">36</link>). Isolates of <emphasis>S. aureus</emphasis> that test positive for <emphasis>mecC</emphasis> are often susceptible to oxacillin (<link linkend="ch0094s000000li0037">37</link>). Cefoxitin disk diffusion testing has been shown to perform well for detection of <emphasis>mecC</emphasis> in <emphasis>S. aureus</emphasis> (<link linkend="ch0094s000000li0038">38</link>).</para>
        </sect3>
        <sect3 id="ch0094s0007s0004s0002">
          <title>Detection of BORSA and MOD-SA</title>
          <anchor id="ch0094s000007a0007"/>
          <anchor id="ch0094s000000a0037"/>
          <para id="ch0094s000000p0060">Non-<emphasis>mecA-</emphasis>mediated resistance in <emphasis>S. aureus</emphasis> due to BORSA or MOD-SA results in oxacillin MICs near the breakpoint (<link linkend="ch0094s000000li0039">39</link>). BORSA-type resistance can usually be distinguished from <emphasis>mecA</emphasis>-mediated resistance or MOD-SA resistance by the addition of a β-lactamase inhibitor (e.g., clavulanic acid) to the oxacillin MIC test, which lowers the MIC by two dilutions or more. Recent data suggest BORSA <emphasis>blaZ</emphasis> strains express extended-spectrum activity due to the E112A mutation, leading to enhanced oxacillin hydrolysis (<link linkend="ch0094s000000li0040">40</link>). Isolates that are resistant by either the BORSA or the MOD-SA mechanism usually do not have the multidrug resistance seen with typical MRSA strains. Cefoxitin will not detect either MOD-SA or BORSA strains; only tests using oxacillin will detect these resistance mechanisms.</para>
          <table id="ch0094s000000t0004"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0094s000000a0038"/><link linkend="ch0094s000000a0006">TABLE 2</link></phrase></emphasis> Phenotypic MIC and disk diffusion tests for detection of <emphasis>mecA</emphasis>-mediated resistance in staphylococci
</title>
            
            <tgroup cols="9">
              <tbody>
                <row>
                  <entry><phrase role="left">Species</phrase>
                  </entry>
                  <entry><phrase role="center">Cefoxitin MIC</phrase>
                  </entry>
                  <entry><phrase role="center">Cefoxitin disk</phrase>
                  </entry>
                  <entry><phrase role="center">Oxacillin MIC</phrase>
                  </entry>
                  <entry><phrase role="center">Oxacillin disk</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="center">Susceptible</phrase>
                  </entry>
                  <entry><phrase role="center">Resistant</phrase>
                  </entry>
                  <entry><phrase role="center">Susceptible</phrase>
                  </entry>
                  <entry><phrase role="center">Resistant</phrase>
                  </entry>
                  <entry><phrase role="center">Susceptible</phrase>
                  </entry>
                  <entry><phrase role="center">Resistant</phrase>
                  </entry>
                  <entry><phrase role="center">Susceptible</phrase>
                  </entry>
                  <entry><phrase role="center">Resistant</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left">
                      <emphasis>Staphylococcus aureus</emphasis>
                    </phrase>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                </row>
                <row>
                  <entry><phrase role="left">CLSI</phrase>
                  </entry>
                  <entry><phrase role="left">≤4 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">≥8 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">≥22 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤21 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤2 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">≥4 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">DNT<superscript><emphasis><anchor id="ch0094s000000a0039"/><link linkend="ch0094s000000a0043">a</link></emphasis></superscript></phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left">EUCAST</phrase>
                  </entry>
                  <entry><phrase role="left">≤2 mg/liter<superscript><emphasis><anchor id="ch0094s000000a0040"/><link linkend="ch0094s000000a0044">b</link></emphasis></superscript></phrase>
                  </entry>
                  <entry><phrase role="left">&gt;4 mg/liter<superscript><emphasis><link linkend="ch0094s000000a0044">b</link></emphasis></superscript></phrase>
                  </entry>
                  <entry><phrase role="left">≥22 mm</phrase>
                  </entry>
                  <entry><phrase role="left">&lt;22 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤1 mg/liter</phrase>
                  </entry>
                  <entry><phrase role="left">&gt;2 mg/liter</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left">
                      <emphasis>Staphylococcus coagulans</emphasis>
                    </phrase>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                </row>
                <row>
                  <entry><phrase role="left">CLSI<superscript><emphasis><anchor id="ch0094s000000a0041"/><link linkend="ch0094s000000a0045">c</link></emphasis></superscript></phrase>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                </row>
                <row>
                  <entry><phrase role="left">EUCAST</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry><phrase role="left">≥20 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤20 mm</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left">
                      <emphasis>Staphylococcus lugdunensis</emphasis>
                    </phrase>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                </row>
                <row>
                  <entry><phrase role="left">CLSI</phrase>
                  </entry>
                  <entry><phrase role="left">≤4 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">≥8 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">≥22 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤21 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤2 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">≥4 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left">EUCAST</phrase>
                  </entry>
                  <entry><phrase role="left">≤2 mg/liter<superscript><emphasis><link linkend="ch0094s000000a0044">b</link></emphasis></superscript></phrase>
                  </entry>
                  <entry><phrase role="left">&gt;4 mg/liter<superscript><emphasis><link linkend="ch0094s000000a0044">b</link></emphasis></superscript></phrase>
                  </entry>
                  <entry><phrase role="left">≥27 mm</phrase>
                  </entry>
                  <entry><phrase role="left">&lt;27 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤1 mg/liter</phrase>
                  </entry>
                  <entry><phrase role="left">&gt;2 mg/liter</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left">
                      <emphasis>Staphylococcus epidermidis</emphasis>
                    </phrase>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                </row>
                <row>
                  <entry><phrase role="left">CLSI</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">≥25 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤24 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤0.5 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">≥1 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">≥18 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤17 mm</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left">EUCAST</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">≥27 mm</phrase>
                  </entry>
                  <entry><phrase role="left">&lt;27 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤0.25 mg/liter</phrase>
                  </entry>
                  <entry><phrase role="left">&gt;0.25 mg/liter</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left">
                      <emphasis>Staphylococcus pseudintermedius</emphasis>
                    </phrase>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                </row>
                <row>
                  <entry><phrase role="left">CLSI</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">≤0.5 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">≥1 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">≥18 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤17 mm</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left">EUCAST</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry><phrase role="left">≥20 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤20 mm</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left">
                      <emphasis>Staphylococcus schleiferi</emphasis>
                    </phrase>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                </row>
                <row>
                  <entry><phrase role="left">CLSI</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">≤0.5 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">≥1 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">≥18 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤17 mm</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left">EUCAST</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry><phrase role="left">≥20 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤20 mm</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left">
                      <emphasis>Staphylococcus saprophyticus</emphasis>
                    </phrase>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                </row>
                <row>
                  <entry><phrase role="left">CLSI<superscript><emphasis><anchor id="ch0094s000000a0042"/><link linkend="ch0094s000000a0046">d</link></emphasis></superscript></phrase>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                </row>
                <row>
                  <entry><phrase role="left">EUCAST</phrase>
                  </entry>
                  <entry><phrase role="left">≤4 mg/liter<superscript><emphasis><link linkend="ch0094s000000a0044">b</link></emphasis></superscript></phrase>
                  </entry>
                  <entry><phrase role="left">&gt;8 mg/liter<superscript><emphasis><link linkend="ch0094s000000a0044">b</link></emphasis></superscript></phrase>
                  </entry>
                  <entry><phrase role="left">≥22 mm</phrase>
                  </entry>
                  <entry><phrase role="left">&lt;22 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤1 mg/liter</phrase>
                  </entry>
                  <entry><phrase role="left">&gt;2 mg/liter</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left"><emphasis>Staphylococcus</emphasis> not listed above</phrase>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                  <entry/>
                </row>
                <row>
                  <entry><phrase role="left">CLSI</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">≥25 mm</phrase>
                  </entry>
                  <entry><phrase role="left">&lt;25 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤0.5 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">≥1 μg/ml</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="left">EUCAST</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">≥25 mm</phrase>
                  </entry>
                  <entry><phrase role="left">&lt;25 mm</phrase>
                  </entry>
                  <entry><phrase role="left">≤0.25 mg/liter</phrase>
                  </entry>
                  <entry><phrase role="left">&gt;0.25 mg/liter</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                  <entry><phrase role="left">DNT</phrase>
                  </entry>
                </row>
              </tbody>
            </tgroup>
          </table>
          <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0043"/><link linkend="ch0094s000000a0039">a</link></emphasis></superscript>DNT, do not perform test.</para>
          <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0044"/><link linkend="ch0094s000000a0040">b</link></emphasis></superscript>Cefoxitin disk diffusion preferred.</para>
          <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0045"/><link linkend="ch0094s000000a0041">c</link></emphasis></superscript>CLSI does not provide specific guidance for <emphasis>S. coagulans.</emphasis></para>
          <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0046"/><link linkend="ch0094s000000a0042">d</link></emphasis></superscript>CLSI does not provide specific guidance for <emphasis>S. saprophyticus</emphasis>; refer to “<emphasis>Staphylococcus</emphasis> not listed above.”</para>
        </sect3>
        <sect3 id="ch0094s0007s0004s0003">
          <title>Oxacillin-Salt Agar Supplemental Test for S. aureus</title>
          <anchor id="ch0094s000007a0008"/>
          <anchor id="ch0094s000000a0047"/>
          <anchor id="ch0094s000000a0048"/>
          <para id="ch0094s000000p0061">The oxacillin-salt agar supplemental test, which applies 6 μg/ml oxacillin and 4% NaCl in Mueller-Hinton agar (MHA), has been used widely as a method to detect oxacillin-resistant<emphasis>S. aureus</emphasis> and is published by CLSI (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0020">20</link>). Inoculum suspensions are prepared by selecting colonies from overnight growth on a nonselective agar plate. The colonies are transferred to broth (e.g., tryptic soy broth) or saline to produce a suspension that matches the turbidity of a 0.5 McFarland standard. This suspension is used to inoculate the oxacillin agar screening plate by either (i) dipping a cotton swab into the test suspension, expressing the excess liquid from the swab, and inoculating an area 10 to 15 mm in diameter (or streaking the swab onto a quadrant of the agar surface) or (ii) spotting an area 10 to 15 mm in diameter with a 1-μl loop that has been dipped in the suspension. Test plates are incubated for a full 24 h at 33 to 35°C in ambient air and examined for growth of more than one colony, which indicates resistance. It is important that the incubation temperature not exceed 35°C, as MRSA may not be detected with this method if plates are incubated at higher temperatures (<link linkend="ch0094s000000li0001">1</link>).</para>
          <para id="ch0094s000000p0062">The oxacillin-salt-agar method is less sensitive than cefoxitin disk diffusion to detect oxacillin-resistant<emphasis>S. aureus</emphasis> (<link linkend="ch0094s000000li0041">41</link>–<link linkend="ch0094s000000li0043">43</link>). Occasionally, a heteroresistant <emphasis>mecA</emphasis>-positive strain is not detected by the oxacillin-salt agar method, which may in part be due to a low frequency of resistance expression (<link linkend="ch0094s000000li0044">44</link>) or to lot-to-lot or manufacturer-to-manufacturer variation in the test medium (<link linkend="ch0094s000000li0045">45</link>, <link linkend="ch0094s000000li0046">46</link>). The test may also not detect borderline-resistant strains with non-<emphasis>mecA-</emphasis>mediated resistance mechanisms. In one study, reference and commercial methods for detection of <emphasis>mecA</emphasis> were studied with a collection of <emphasis>S. aureus</emphasis> strains expressing either borderline oxacillin MICs (oxacillin MICs of 1 to 4 μg/ml) or for which previous results with oxacillin tests were discrepant by disk and MIC testing (<link linkend="ch0094s000000li0032">32</link>). In that study, MIC and disk diffusion tests using cefoxitin performed significantly better than those using oxacillin, including the oxacillin-salt agar screening test and oxacillin MIC tests for detection of <emphasis>mecA</emphasis>-mediated resistance. The oxacillin-salt agar screening test cannot be used for detecting oxacillin resistance in SOSA because it uses 6 μg of oxacillin per ml, which is higher than the breakpoint for SOSA (<link linkend="ch0094s000000li0001">1</link>). A modification of this method, using 2 μg/ml of oxacillin and 2% NaCl in MHA, was recently shown to be more sensitive than cefoxitin disk diffusion for detection of <emphasis>mecA</emphasis> in <emphasis>S. lugdune</emphasis><emphasis>nsis</emphasis> (<link linkend="ch0094s000000li0047">47</link>).</para>
        </sect3>
        <sect3 id="ch0094s0007s0004s0004">
          <title>Other Tests for Detection of Oxacillin Resistance in Staphylococci</title>
          <anchor id="ch0094s000007a0009"/>
          <anchor id="ch0094s000000a0049"/>
          <para id="ch0094s000000p0063">Other commercial methods for the rapid detection of oxacillin resistance in staphylococci include (i) direct culture of patient specimens (usually nasal swabs) onto agar media containing antimicrobial agents with a chromogenic indicator, (ii) detection of the presence of PBP 2′ by latex agglutination tests, and (iii) automated PCR assays (refer to<ulink url="ch0098#ch0098s0001">chapter 80</ulink>).</para>
          <anchor id="ch0094s000000a0050"/>
          <beginpage pagenum="1464"/>
          <para id="ch0094s000000p0064">Several selective chromogenic agars are now FDA cleared for detection of MRSA from surveillance specimens. The exact components of these media are proprietary and vary by manufacturer, but they typically contain both chromogenic and selective components. The chromogenic indicator results in<emphasis>S. aureus</emphasis> colonies demonstrating a characteristic color that differentiates them from other <emphasis>Staphylococcus</emphasis> species on the medium, and the selective component inhibits growth of bacteria that are not oxacillin resistant. These media can be used for direct plating from surveillance swabs and interpreted as early as 24 h postinoculation; in this way, they can reduce the time to MRSA detection by 1 to 3 days relative to that of traditional culture. Although the performances of specific chromogenic agars vary, numerous studies have demonstrated good correlations compared to both conventional culture-based tests for detection of MRSA colonization and similar performances among different commercial chromogenic agars (<link linkend="ch0094s000000li0048">48</link>–<link linkend="ch0094s000000li0051">51</link>).</para>
          <anchor id="ch0094s000000a0051"/>
          <beginpage pagenum="1465"/>
          <para id="ch0094s000000p0065">The impact of such agars has been especially dramatic for surveillance cultures performed for specific patient populations, such as cystic fibrosis patients, in whom cocolonization with methicillin-susceptible<emphasis>S. aureus</emphasis> or multiple bacterial species is likely. In two recent studies, the inclusion of chromogenic agar improved the sensitivity by 9% to 50% and decreased the turnaround time by 24 to 48 h (<link linkend="ch0094s000000li0048">48</link>, <link linkend="ch0094s000000li0052">52</link>). However, some have pointed out that addition of a broth enrichment step prior to plating on MRSA-selective agar is important to maximize the sensitivity of selective chromogenic agars, especially when the colonization burden is low (<link linkend="ch0094s000000li0050">50</link>, <link linkend="ch0094s000000li0053">53</link>). Additionally, the performance of these media for the detection of <emphasis>mecC-</emphasis>mediated resistance is variable (<link linkend="ch0094s000000li0054">54</link>).</para>
          <para id="ch0094s000000p0066">Although not all chromogenic agars are FDA cleared for clinical use in the United States, studies have validated the performance of these media for detection of MRSA in clinical specimens. In one study of specimens that are typically polymicrobial, including samples from superficial wounds, endotracheal aspirates, and sputa, inclusion of chromogenic agar improved detection of MRSA by 21% overall and decreased the turnaround time by 1 day (<link linkend="ch0094s000000li0055">55</link>). Another study of clinical specimens demonstrated better performances of chromogenic selective agar than of traditional methods across multiple specimen types, including wounds, respiratory specimens, stools, and positive blood cultures (<link linkend="ch0094s000000li0056">56</link>). In studies focusing only on positive blood cultures containing Gram-positive cocci, MRSA-selective chromogenic agar demonstrated excellent sensitivity and specificity and enabled detection of MRSA 12 to 24 h earlier than conventional methods (<link linkend="ch0094s000000li0051">51</link>, <link linkend="ch0094s000000li0057">57</link>, <link linkend="ch0094s000000li0058">58</link>).</para>
          <para id="ch0094s000000p0067">Commercial rapid methods that detect the presence of PBP 2a in staphylococci by using latex agglutination include the PBP 2′ latex agglutination test (Oxoid Limited, Basingstoke, United Kingdom) and the Alere PBP2a culture colony test, an immunochromatographic assay (Abbott). The Oxoid PBP 2′ latex agglutination test was approved by the FDA for testing of both<emphasis>S. aureus</emphasis> and SOSA, with the latter requiring induction with oxacillin or cefoxitin. Neither test detects the presence of <emphasis>mecC</emphasis>-encoded PBP2a (<link linkend="ch0094s000000li0059">59</link>), but the performance of both for <emphasis>mecA</emphasis>-encoded PBP2a is good (<link linkend="ch0094s000000li0060">60</link>).</para>
        </sect3>
      </sect2>
    </sect1>
    <sect1 id="ch0094s0008">
      <title>Detection of Vancomycin Resistance in Enterococcus and Staphylococcus</title>
      <anchor id="ch0094s000008a0001"/>
      <anchor id="ch0094s000000a0052"/>
      <sect2 id="ch0094s0008s0001">
        <title>Detection of Vancomycin Resistance in Enterococci</title>
        <anchor id="ch0094s000008a0002"/>
        <anchor id="ch0094s000000a0053"/>
        <para id="ch0094s000000p0068">As defined by CLSI, the MIC interpretive criteria for vancomycin in the enterococci are ≤4 μg/ml for susceptible, 8 to 16 μg/ml for intermediate, and ≥32 μg/ml for resistant. EUCAST publishes alternative breakpoints of ≤4 μg/ml for susceptible and &gt;4 μg/ml for resistant. The three most common phenotypes of resistance are (i) high-level vancomycin resistance (MICs, ≥64 μg/ml) with accompanying teicoplanin resistance (MICs, ≥16 μg/ml) (VanA phenotype); (ii) moderate- to high-level vancomycin resistance (MICs, 16 to 512 μg/ml), most commonly without teicoplanin resistance (VanB phenotype); and (iii) intrinsic low-level resistance associated with<emphasis>Enterococcus gallinarum</emphasis> and <emphasis>Enterococcus casseliflavus</emphasis> (MICs, 2 to 32 μg/ml) (VanC phenotype) (<link linkend="ch0094s000000li0061">61</link>). Both the VanA and VanB phenotypes are most commonly seen in <emphasis>E. faecalis</emphasis> and <emphasis>E. faecium</emphasis> but have been found in other species, including <emphasis>E. casseliflavus</emphasis> and <emphasis>E. gallinarum</emphasis> (<link linkend="ch0094s000000li0061">61</link>). Additional genes conferring vancomycin resistance have also been described, including <emphasis>vanD</emphasis> (<link linkend="ch0094s000000li0062">62</link>), <emphasis>vanE</emphasis> (<link linkend="ch0094s000000li0063">63</link>), <emphasis>vanG</emphasis> (<link linkend="ch0094s000000li0064">64</link>), <emphasis>vanL</emphasis> (<link linkend="ch0094s000000li0064">64</link>), <emphasis>vanN</emphasis> (<link linkend="ch0094s000000li0065">65</link>), and <emphasis>vanM</emphasis> (<link linkend="ch0094s000000li0066">66</link>). Detailed information that explains the phenotypes associated with these, including the usual MICs of vancomycin and teicoplanin and species in which they are found, is described in <ulink url="ch0039#ch0039s0001">chapter 23</ulink> of this <emphasis>Manual.</emphasis> Recently, vancomycin-variable enterococci were described. These isolates initially appear phenotypically susceptible to vancomycin but possess the <emphasis>vanA</emphasis> gene and can develop a vancomycin-resistant phenotype <emphasis>in vivo</emphasis> (<link linkend="ch0094s000000li0067">67</link>). CLSI recommends reporting <emphasis>vanA</emphasis>-positive, vancomycin-susceptible isolates of <emphasis>Enterococcus</emphasis> as vancomycin resistant (<link linkend="ch0094s000000li0001">1</link>).</para>
        <para id="ch0094s000000p0069">Methods commonly used by clinical laboratories, including disk diffusion and the Vitek 2 (bioMérieux, Durham, NC), Phoenix (BD, Sparks, MD) and MicroScan (Beckman Coulter, Sacramento, CA) systems, accurately detect vancomycin resistance in enterococci (<link linkend="ch0094s000000li0068">68</link>–<link linkend="ch0094s000000li0071">71</link>). Disk diffusion testing requires 24 h of incubation and examination of zones under transmitted light. EUCAST provides additional guidance for the disk diffusion test, indicating that vancomycin-susceptible enterococci display sharp zone edges and do not exhibit colonies in the inhibition zone. Transmitted light is recommended for evaluation of vancomycin disk diffusion results (<link linkend="ch0094s000000li0009">9</link>).</para>
        <para id="ch0094s000000p0070">The vancomycin agar screening test first described by Willey et al. (<link linkend="ch0094s000000li0072">72</link>) was adopted by CLSI in 1993 (<link linkend="ch0094s000000li0073">73</link>). Sensitivity and specificity levels of 96 to 99% and 100%, respectively, were noted at that time. Agar plates are prepared with brain heart infusion (BHI) agar supplemented with 6 μg of vancomycin per ml (BHI-V6). Using growth from an 18- to 24-h agar plate, a suspension equivalent in turbidity to a 0.5 McFarland standard is made and used to inoculate the plates by spotting 1 to 10 μl or swabbing an area 10 to 15 mm in diameter. The final inoculum is 10<superscript>5</superscript> to 10<superscript>6</superscript> CFU per spot. After inoculation, the plates are incubated for a full 24 h in ambient air at 35°C. The presence of more than one colony of growth indicates presumptive resistance.</para>
        <para id="ch0094s000000p0071">One limitation of the vancomycin agar screening assay is the confusion about its use for characterization of susceptibility or resistance for the<emphasis>vanC</emphasis>-containing enterococci, <emphasis>E. gallinarum</emphasis> and <emphasis>E. casseliflavus.</emphasis> The growth of these species is variable on agar screening plates. Both of these species intrinsically contain a <emphasis>vanC</emphasis> gene, but the MICs of vancomycin for them range from 2 to 32 μg/ml (<link linkend="ch0094s000000li0061">61</link>). Since the vancomycin MICs for these strains are often &gt;4 μg/ml, the strains are likely to grow on agar screening plates, where a larger inoculum and a richer medium may promote growth. Because of this, identification of enterococci that grow on the vancomycin agar screening should be performed, such as by MALDI-TOF MS. Clinical outcome data are sparse for the treatment of <emphasis>E. casseliflavus</emphasis> and <emphasis>E. gallinarum</emphasis> (<link linkend="ch0094s000000li0074">74</link>), but CLSI recommends reporting these as resistant to vancomycin, regardless of the MIC (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0020">20</link>).</para>
        <para id="ch0094s000000p0072">Several selective chromogenic agars are FDA cleared for detection of VRE from surveillance specimens. As is the case for such media that detect MRSA, the exact components of VRE chromogenic media are proprietary and vary by manufacturer. The chromogenic indicator results in<emphasis>E. faecalis</emphasis> and <emphasis>E. faecium</emphasis> colonies demonstrating a characteristic color that differentiates them from other species on the medium, and the selective component inhibits growth of bacteria that are not vancomycin resistant. Some media generate different colors for <emphasis>E. faecium</emphasis> and <emphasis>E. faecalis.</emphasis> Sensitivity for the detection of VRE on these media ranged from 50 to &gt;90% compared to standard culture-based methods (<link linkend="ch0094s000000li0075">75</link>–<link linkend="ch0094s000000li0080">80</link>). In low-prevalence populations, sensitivity can be improved by incubating plates for 48 h (as opposed to 24 h) and performing a pre-enrichment step consisting of overnight incubation at 35°C in BHI with 3 μg/ml vancomycin (<link linkend="ch0094s000000li0077">77</link>).</para>
      </sect2>
      <sect2 id="ch0094s0008s0002">
        <title>Detection of Vancomycin Resistance in Staphylococci</title>
        <anchor id="ch0094s000008a0003"/>
        <anchor id="ch0094s000000a0054"/>
        <para id="ch0094s000000p0073">In January 2006, CLSI vancomycin interpretive categories for<emphasis>S. aureus</emphasis> were changed to ≤2 μg/ml for susceptible, 4 to 8 μg/ml for intermediate, and ≥16 μg/ml for resistant. Interpretive categories for SOSA are ≤4 μg/ml for susceptible, 8 to 16 μg/ml for intermediate, and ≥32 μg/ml for resistant (<link linkend="ch0094s000000li0001">1</link>). In contrast, EUCAST breakpoints are ≤2 mg/liter (susceptible) and &gt;2 mg/liter (resistant) for <emphasis>S. aureus</emphasis> and ≤4 mg/ liter (susceptible) and &gt;4 mg/ liter (resistant) for SOSA, with no intermediate category. The rationale for a lower <emphasis>S. aureus</emphasis> susceptible breakpoint includes the facts that (i) isolates with a vancomycin MIC of 4 μg/ml, although rare, likely represent a population of organisms with heteroresistance and (ii) limited outcome data suggested that infections with these isolates were likely to fail vancomycin monotherapy (<link linkend="ch0094s000000li0081">81</link>). Vancomycin-intermediate <emphasis>S. aureus</emphasis> strains (MICs of 4 to 8 μg/ml) are commonly referred to as VISA, and those that are vancomycin resistant (MICs of ≥16 μg/ml) are known as VRSA. While EUCAST does not technically publish an intermediate category for vancomycin, they continue to recognize VISA terminology but consider these isolates clinically resistant (<link linkend="ch0094s000000li0005">5</link>). SOSA isolates with reduced susceptibility to vancomycin are referred to here as vancomycin-intermediate <emphasis>Staphylococcus</emphasis> species other than <emphasis>S. aure</emphasis><emphasis>us</emphasis> (VISS).</para>
        <para id="ch0094s000000p0074">As of January 2020, 52 VRSA strains have been documented globally, including 14 in the United States, 16 in India, 11 in Iran, 9 in Pakistan, 1 in Brazil, and 1 in Portugal (<link linkend="ch0094s000000li0082">82</link>). All VRSA isolates identified to date contain the <emphasis>vanA</emphasis> gene and were isolated from patients who had underlying medical conditions, including prior infection or colonization with MRSA and/or vancomycin-resistant enterococci (VRE); most patients also had received previous vancomycin therapy. The vancomycin MICs for VRSA strains range from 32 to 1,024 μg/ml; all display no zone of inhibition with a 30-μg vancomycin disk.</para>
        <para id="ch0094s000000p0075">Resistance in VISA is not due to acquisition of a<emphasis>van</emphasis> gene but is thought to be due to changes in the cell wall that render such strains less susceptible to vancomycin (<link linkend="ch0094s000000li0083">83</link>, <link linkend="ch0094s000000li0084">84</link>). At present, no single genetic change has been linked to the VISA phenotype, and it is believed that several different mutations can lead to VISA. The incidence of VISA strains is greater than that of VRSA strains, although the true prevalence is difficult to know, because when VISA first began to appear, some routine susceptibility testing methods failed to detect vancomycin-intermediate staphylococci (<link linkend="ch0094s000000li0085">85</link>). No <emphasis>van</emphasis> gene-mediated vancomycin resistance has been reported for VISS, but there are reports of SOSA isolates with elevated vancomycin MICs that are also thought to be due to cell wall changes (<link linkend="ch0094s000000li0086">86</link>, <link linkend="ch0094s000000li0087">87</link>).</para>
        <para id="ch0094s000000p0076">The CLSI reference broth microdilution method is reliable for detection of VISA and VRSA, and presumably VISS. However, the disk diffusion test cannot detect VISA or VISS, because these isolates produce zone diameters within the susceptible range (≥15 mm). Because of this, all parameters for the disk diffusion test were removed from document M100 in 2014. However, a vancomycin disk diffusion test result of 6 mm (no zone) can still detect<emphasis>S. aureus</emphasis> isolates that contain <emphasis>vanA</emphasis>; if such results are encountered, both the purity and the identity of the isolate should be confirmed, and a vancomycin MIC test should be performed. The use of BHI-V6 screening agar, used to detect VRE, is a sensitive method for detection of <emphasis>S. aureus</emphasis> isolates for which the vancomycin MICs are ≥8 μg/ml, but its performance is variable for detection of <emphasis>S. aureus</emphasis> isolates for which the vancomycin MIC is 4 μg/ml (<link linkend="ch0094s000000li0088">88</link>), and it cannot be used to detect VISS. Most available susceptibility testing methods can now detect VRSA strains, although accurate detection of VISA strains is still problematic. Additional testing is needed to confirm vancomycin resistance. First, the identity and purity of the isolate should be confirmed. The MIC of the isolate should then be determined using a validated method. For many laboratories, the most available method is the Etest (bioMérieux). However, studies have shown that the Etest method tends to result in slightly higher vancomycin MICs than those obtained by broth microdilution (<link linkend="ch0094s000000li0088">88</link>, <link linkend="ch0094s000000li0089">89</link>). It is recommended that any <emphasis>S. aureus</emphasis> isolate for which the vancomycin MIC is ≥8 μg/ml be sent to a reference laboratory for confirmation. In the United States, several states request that VISA and/or VRSA be reported to the public health authority.</para>
      </sect2>
      <sect2 id="ch0094s0008s0003">
        <title>Detection of Heteroresistant VISA</title>
        <anchor id="ch0094s000008a0004"/>
        <anchor id="ch0094s000000a0055"/>
        <para id="ch0094s000000p0077">Heteroresistant vancomycin-intermediate<emphasis>S. aureus</emphasis> (hVISA) are isolates of <emphasis>S. aureus</emphasis> that normally test susceptible by standard methods but contain a subpopulation of cells (typically 1 in every 10<superscript>5</superscript> to 10<superscript>6</superscript> cells) for which the vancomycin MICs do not indicate susceptibility, i.e., ≥4 μg/ml. This phenomenon was first described in 1997 (<link linkend="ch0094s000000li0090">90</link>). Some hVISA isolates are detected by standard methods because the population MIC is 4 μg/ml; some, however, continue to be missed because the population MIC is ≤2 μg/ml. There is no agreement about the incidence of hVISA or its clinical significance. The gold standard for detection of hVISA is population analysis/area-under-the-curve analysis, a technique that is unsuitable for routine use (<link linkend="ch0094s000000li0091">91</link>). No standardized technique that will detect these isolates is available to clinical laboratories. However, there are two Etest methods that have been developed: (i) the macro Etest and (ii) Etest GRD. The macro Etest method uses a large inoculum spread onto BHI agar plates and separate vancomycin and teicoplanin strips; MICs of ≥8 μg/ml for both agents or ≥12 μg/ml for teicoplanin alone are considered positive (<link linkend="ch0094s000000li0092">92</link>). Several studies evaluating the macro Etest method for hVISA detection found it to be relatively insensitive (range of 57 to 89% sensitivity, with positive predictive values ranging from 21 to 71%) (<link linkend="ch0094s000000li0093">93</link>, <link linkend="ch0094s000000li0094">94</link>). The Etest GRD method is performed by using MHA with 5% sheep blood, an inoculum equivalent to a 0.5 McFarland standard, and a single strip impregnated with both vancomycin and teicoplanin; specific MICs of the two agents are then interpreted as positive or negative (<link linkend="ch0094s000000li0095">95</link>). Published sensitivities of the Etest GRD method range from 57 to 100%, with positive predictive values of 16 to 80% (<link linkend="ch0094s000000li0093">93</link>, <link linkend="ch0094s000000li0094">94</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0094s0009">
      <title>Detection of High-Level Aminoglycoside Resistance among Enterococci</title>
      <anchor id="ch0094s000009a0001"/>
      <anchor id="ch0094s000000a0056"/>
      <para id="ch0094s000000p0078">Because aminoglycosides have poor activity against enterococci (MICs range from 8 to 256 μg/ml), they cannot be used as single agents for therapy (<link linkend="ch0094s000000li0096">96</link>). This intrinsic, moderate-level resistance is due to poor uptake of aminoglycosides by the cell (<link linkend="ch0094s000000li0097">97</link>). Acquired aminoglycoside resistance in enterococci is due either to mutations resulting in decreased binding of the agent to the ribosome, as occurs with streptomycin (called ribosomal resistance), or, more commonly, to the acquisition of new genes that encode enzymes that modify aminoglycosides (called acquired resistance). Acquired aminoglycoside resistance usually corresponds to MICs that are significantly above the concentrations normally tested in routine susceptibility tests, e.g., ≥2,000 μg/ml for streptomycin and ≥500 μg/ml for gentamicin, and is designated high-level aminoglycoside resistance (HLAR) (see also <ulink url="ch0039#ch0039s0001">chapters 23</ulink> and <ulink url="ch0090#ch0090s0001">72</ulink>) (<link linkend="ch0094s000000li0097">97</link>).</para>
      <anchor id="ch0094s000000a0057"/>
      <beginpage pagenum="1466"/>
      <para id="ch0094s000000p0079">Synergy between an aminoglycoside and a cell wall-active agent can be determined directly by performing complex time-kill studies or can be predicted by using less cumbersome screening tests. Gentamicin and streptomycin are the only two agents that should be tested on a routine basis. Enterococci that are resistant to gentamicin are considered resistant to tobramycin and amikacin as well, because gentamicin resistance is most commonly due to the bifunctional enzyme encoded by<emphasis>aac(6</emphasis>′<emphasis>)-<emphasis>Ic-aph</emphasis>(2</emphasis>″<emphasis>)-Ia</emphasis>, which also confers resistance to other aminoglycosides except streptomycin. Resistance to streptomycin is mediated by a different resistance mechanism, and consequently, streptomycin resistance must be determined separately from gentamicin resistance. Isolates of <emphasis>E. faecium</emphasis> are intrinsically resistant to the synergistic actions of amikacin, kanamycin, tobramycin, and netilmicin with cell wall-active agents, irrespective of <emphasis>in vitro</emphasis> testing results for HLAR (<link linkend="ch0094s000000li0098">98</link>). <emphasis>E. faecalis</emphasis> strains that are susceptible to gentamicin may be resistant to tobramycin, netilmicin, kanamycin, and amikacin (<link linkend="ch0094s000000li0099">99</link>) by means of various other aminoglycoside-modifying enzymes, but optimal methods for testing have not been determined.</para>
      <para id="ch0094s000000p0080">The following genes for three additional enzymes that mediate gentamicin resistance have been described:<emphasis>aph(2″)-Ic</emphasis> (<link linkend="ch0094s000000li0033">33</link>), <emphasis>aph(2″)-Id</emphasis> (<link linkend="ch0094s000000li0100">100</link>), and <emphasis>aph(2″)-Ib</emphasis> (<link linkend="ch0094s000000li0099">99</link>). All of these genes confer resistance to ampicillin-gentamicin synergism; however, the first [<emphasis>aph(2″)-Ic</emphasis>] may not be detected using the screening methods described below, since its presence seems to lead to intermediate, not high-level, resistance. The second gene, <emphasis>aph(2″)-Id</emphasis>, if detected by the screening methods described here, would be assumed to confer resistance to synergy with amikacin, although this may not be the case. Only time-kill or molecular studies for the specific enzymes will detect their presence. For any serious enterococcal infection (e.g., endocarditis), results of the screening test for HLAR to gentamicin and streptomycin should be reported in concert with the results of the testing of the cell wall-active agent (penicillin, ampicillin, or vancomycin), because synergy would not be expected if resistance to any one of the agents was reported. However, with the challenges associated with very resistant enterococci, HLAR may be reported even if resistance to penicillin, ampicillin, or vancomycin is seen, as other agents, such as daptomycin, have been shown to have synergy with aminoglycoside, but only in isolates without HLAR (<link linkend="ch0094s000000li0101">101</link>). High-level aminoglycoside resistance determined by a MIC screening method can be reported without further confirmation. With the disk diffusion test, results can be reported unless the test is inconclusive, in which case an agar dilution or broth microdilution test should be done to clarify the result.</para>
      <sect2 id="ch0094s0009s0001">
        <title>Agar Dilution Screening Method for HLAR</title>
        <anchor id="ch0094s000009a0002"/>
        <anchor id="ch0094s000000a0058"/>
        <para id="ch0094s000000p0081">According to CLSI protocols, agar plates are prepared with BHI agar with the addition of 500 μg of gentamicin per ml or 2,000 μg of streptomycin per ml (<link linkend="ch0094s000000li0001">1</link>). The plates are inoculated by spotting 10 μl of a suspension that is equivalent to a 0.5 McFarland standard, prepared from growth on an 18- to 24-h agar plate, giving a final inoculum of 10<superscript>6</superscript> CFU per spot. The plates are incubated for a full 24 h in ambient air. The growth of more than one colony should be read as presumptive resistance. For streptomycin, the plates should be incubated for an additional 24 h if there is no growth at 24 h. MHA, MHA plus 5% sheep blood, or dextrose phosphate agar may be substituted for BHI agar, but because growth is better on BHI agar, it is the preferred medium. Commercially prepared agar screening plates are available and have performed well (<link linkend="ch0094s000000li0102">102</link>, <link linkend="ch0094s000000li0103">103</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0094s0010">
      <title>Broth Microdilution Screening Method for HLAR</title>
      <anchor id="ch0094s000010a0001"/>
      <anchor id="ch0094s000000a0059"/>
      <para id="ch0094s000000p0082">According to CLSI protocols, broth dilution tests are prepared using a single well or a tube containing BHI broth with the addition of 500 μg of gentamicin per ml or 1,000 μg of streptomycin per ml. In contrast, EUCAST recommends testing enterococci for HLAR to aminoglycosides with concentrations of aminoglycoside just above the epidemiological cutoff, i.e., 128 mg/liter for gentamicin, or 512 mg/liter for streptomycin (<link linkend="ch0094s000000li0009">9</link>). The final inoculum concentration is that recommended for routine broth microdilution testing, i.e., 5 × 10<superscript>5</superscript> CFU/ml. The plates are incubated for 24 h in ambient air. For streptomycin, the test samples should be incubated for an additional 24 h if there is no growth at 24 h, although EUCAST does not have this requirement. Any growth is interpreted as denoting resistance.</para>
      <para id="ch0094s000000p0083">The CLSI-recommended streptomycin concentration for use in the broth microdilution screening is half that used in the agar dilution screening test. Because this test is often included as part of a routine MIC panel for Gram-positive organisms, the inoculum is that commonly used in broth microdilution testing (5 × 10<superscript>5</superscript> CFU/ml). The total number of cells tested in the agar dilution screening procedure (10<superscript>6</superscript> CFU/spot) is 20-fold larger than that normally used in the broth microdilution test (5 × 10<superscript>4</superscript> CFU/0.1-ml well). To provide a test that uses a small inoculum and at the same time maximizes the detection of HLAR to streptomycin, it was necessary to lower the concentration recommended for testing streptomycin from 2,000 to 1,000 μg/ml in the broth microdilution test. Because of poorer growth and the smaller inoculum, Mueller-Hinton broth was deemed inadequate for use in the broth microdilution screening test by CLSI (<link linkend="ch0094s000000li0104">104</link>); however, EUCAST, as well as some commercial manufacturers, uses Mueller-Hinton broth for this test. The performance of other aminoglycosides in this test has not been evaluated.</para>
    </sect1>
    <sect1 id="ch0094s0011">
      <title>Disk Diffusion Screening Method for HLAR</title>
      <anchor id="ch0094s000011a0001"/>
      <anchor id="ch0094s000000a0060"/>
      <para id="ch0094s000000p0084">The standard disk diffusion procedure (<link linkend="ch0094s000000li0105">105</link>) described in <ulink url="ch0092#ch0092s0001">chapter 74</ulink> (with unsupplemented MHA) is used for HLAR detection, except that special high-content disks (gentamicin at 120 μg [CLSI] or 30 μg [EUCAST] and streptomycin at 300 μg [CLSI and EUCAST]) are required (<link linkend="ch0094s000000li0106">106</link>). Zones are measured after 18 to 24 h of incubation in ambient air at 35°C. As a result of differences in disk potency, differences exist in the interpretation of disk diffusion results between CLSI and EUCAST. By CLSI standards, isolates for which either the gentamicin or streptomycin zone diameters are ≥10 mm are categorized as susceptible. The absence of a zone of inhibition corresponds to the presence of HLAR. Strains for which the zones of inhibition are 7 to 9 mm usually display HLAR, but a few are strains for which the MICs are only moderately elevated (<link linkend="ch0094s000000li0104">104</link>). Therefore, strains for which the zone diameters are 7 to 9 mm should be tested by either the standard agar or broth microdilution screening method to determine susceptibility or resistance. In contrast, EUCAST breakpoints for HLAR to gentamicin are ≥8 mm for susceptible and &lt;8 mm for resistant, and for streptomycin, ≥14 mm is interpreted as susceptible and &lt;14 mm is considered resistant.</para>
      <anchor id="ch0094s000000a0061"/>
      <beginpage pagenum="1467"/>
    </sect1>
    <sect1 id="ch0094s0012">
      <title>Detection of Inducible Clindamycin Resistance in Staphylococci and Streptococci</title>
      <anchor id="ch0094s000012a0001"/>
      <anchor id="ch0094s000000a0062"/>
      <para id="ch0094s000000p0085">Although erythromycin and clindamycin are in separate antimicrobial agent classes, i.e., macrolides and lincosamides, respectively, their mechanisms of action (inhibition of protein synthesis) and mechanisms of resistance are similar. The two main mechanisms of macrolide resistance are (i) an efflux pump that affects only macrolides and (ii) a methylase that alters the ribosomal binding site for both antimicrobial agents. The efflux mechanism of resistance, which confers resistance to macrolides only (designated M-type resistance, for macrolide), is mediated in staphylococci by<emphasis>msrA.</emphasis> The target modification type of resistance, which confers resistance to macrolides, lincosamides, and streptogramin B agents (designated MLS<subscript>B</subscript>-type resistance, for macrolide-lincosamide-streptogramin B), is mediated by an <emphasis>erm</emphasis> gene (usually <emphasis>ermA</emphasis> or <emphasis>ermC</emphasis>). In staphylococci, MLS<subscript>B</subscript>-type resistance can be either constitutive or inducible; if it is inducible, the isolate appears to be susceptible to the lincosamide (i.e., clindamycin) by routine testing methods unless it is induced by a macrolide (i.e., erythromycin). It is important to determine if resistance (whether inducible or constitutive) to clindamycin exists when it is being considered for therapy. A detailed explanation of these resistance mechanisms can be found in <ulink url="ch0090#ch0090s0001">chapter 72</ulink>.</para>
      <para id="ch0094s000000p0086">Phenotypically, if an isolate has M-type resistance, it is resistant to erythromycin but susceptible to clindamycin. If an isolate has MLS<subscript>B</subscript>-type resistance, it is erythromycin resistant and may test as susceptible or resistant to clindamycin, depending on whether expression is constitutive or inducible for that drug. For strains that are erythromycin resistant but clindamycin susceptible or intermediate, it is important to determine whether inducible clindamycin resistance exists (due to an <emphasis>erm</emphasis> gene) or if the strain remains clindamycin susceptible (due to an efflux gene). The importance of determining erythromycin and clindamycin resistance phenotypes and detecting inducible clindamycin resistance in streptococci follows the same logic as that for staphylococci; however, the genes responsible for the resistance differ from those in staphylococci and can occur in β-hemolytic streptococci, <emphasis>S. pneumoniae</emphasis>, and viridans group streptococci. The M phenotype (i.e., erythromycin resistance and clindamycin susceptibility) in streptococci is due to <emphasis>mefA</emphasis>, and the gene responsible for the MLS<subscript>B</subscript>type (constitutive or inducible) is usually <emphasis>ermB</emphasis> or, more rarely, <emphasis>ermTR</emphasis> (<link linkend="ch0094s000000li0107">107</link>).</para>
      <para id="ch0094s000000p0087">There are two test methods recommended for detecting inducible clindamycin resistance in both staphylococci and streptococci: (i) the D-zone test (CLSI and EUCAST method) and (ii) a broth dilution test that uses a single well or tube containing erythromycin and clindamycin (CLSI method). The test methods are described below.</para>
      <para id="ch0094s000000p0088">The incidence of inducible clindamycin resistance in staphylococci can be highly variable, both by geographic area and by organism group (i.e., hospital-associated MRSA, community-associated MRSA [CA-MRSA], and coagulase-negative staphylococci [CoNS]). CLSI now recommends that isolates that are D-zone test positive or grow well in the combination be reported as clindamycin resistant (<link linkend="ch0094s000000li0001">1</link>). Although some have suggested that clindamycin may be effective in some situations where inducible resistance is demonstrated (<link linkend="ch0094s000000li0108">108</link>), CLSI recommends that inducible clindamycin-resistant strains be reported as resistant, with a comment stating that “this isolate is presumed to be resistant based on detection of inducible clindamycin resistance” (<link linkend="ch0094s000000li0001">1</link>). EUCAST, in contrast, recommends including a comment regarding the potential use of clindamycin for short-term therapy of less serious infections caused by isolates with inducible clindamycin resistance, as emergence of resistance is not anticipated during treatment (<link linkend="ch0094s000000li0009">9</link>). If the test is not offered routinely, it should be available by request when clindamycin is being considered for therapy. Although routine testing of β-hemolytic streptococci is not required because penicillin- or ampicillin-nonsusceptible isolates are extremely rare (or in fact do not exist, for <emphasis>Streptococcus pyogenes</emphasis>), a publication documented the clinical significance of inducible clindamycin resistance in β-hemolytic streptococci in an animal model (<link linkend="ch0094s000000li0109">109</link>). The authors recommended that tests to detect inducible resistance in streptococci be performed and reported routinely. The CDC also recommends that when susceptibility testing is clinically indicated, colonizing isolates of group B streptococci from penicillin-allergic pregnant women should be tested for inducible clindamycin resistance (<link linkend="ch0094s000000li0110">110</link>).</para>
      <sect2 id="ch0094s0012s0001">
        <title>D-Zone Test</title>
        <anchor id="ch0094s000012a0002"/>
        <anchor id="ch0094s000000a0063"/>
        <para id="ch0094s000000p0089">Detection of inducible clindamycin resistance can easily be accomplished using a disk diffusion procedure by placing a 15-μg erythromycin disk adjacent to a 2-μg clindamycin disk and looking for a flattening of the clindamycin zone, which looks like the letter D and is therefore referred to as a D zone. For laboratories that are already performing disk diffusion testing, this may be done for staphylococci by placing the disks 15 to 26 mm apart (CLSI method) (<link linkend="ch0094s000000li0111">111</link>) or 12 to 20 mm apart (EUCAST method), along with the other disks tested on an MHA plate. For streptococci, disks must be placed 12 mm apart on MHA supplemented with 5% sheep’s blood (CLSI method) (<link linkend="ch0094s000000li0112">112</link>), or 12 to 16 mm apart on MH-F (MHA with supplemented with defibrinated horse blood and β-NAD; EUCAST method). Some disk dispensers may position disks more than 26 mm apart, even if the disks are placed in adjacent positions. Therefore, because dispensers may vary and the distance is critical, the distance should be verified before the test is adopted as a standard procedure, and one of the disks may need to be placed on the plates by hand instead of with a disk dispenser.</para>
        <para id="ch0094s000000p0090">For laboratories that routinely perform antimicrobial susceptibility test methods other than disk diffusion testing, Raney et al. and Jorgensen et al. have shown that the test can be performed on a standard blood agar plate used for purity checks by streaking one-third of the plate for confluent growth and then streaking for isolation on the rest of the plate (<link linkend="ch0094s000000li0112">112</link>, <link linkend="ch0094s000000li0113">113</link>). In those studies, the investigators showed that dilutions of up to 1:250 of inoculum equivalent to a 0.5 McFarland standard can be used for staphylococci. The disks are placed 15 mm apart on the portion of the plate where confluent growth would occur. In a later study, it was determined that the BBL Prompt system (BD, Sparks, MD) should not be used to inoculate the purity plate for D-zone determination (<link linkend="ch0094s000000li0114">114</link>). In that study, the investigators suggested that no more than a 1:20 dilution of a suspension equivalent to a 0.5 McFarland standard should be used to inoculate the purity plate. When the Prompt inoculum wand was used directly to inoculate the plate, it delivered an inadequate inoculum. Organisms that show a blunting or flattening of the clindamycin zone are considered D-zone test positive; those that show no flattening are D-zone test negative.</para>
        <anchor id="ch0094s000000a0064"/>
        <beginpage pagenum="1468"/>
      </sect2>
      <sect2 id="ch0094s0012s0002">
        <title>Single-Well Broth Dilution Method</title>
        <anchor id="ch0094s000012a0003"/>
        <anchor id="ch0094s000000a0065"/>
        <para id="ch0094s000000p0091">For staphylococci, the single-well broth dilution test is performed by preparing microdilution wells (containing no less than 100 μl per well) or tubes of cation-adjusted Mueller-Hinton broth (CAMHB) with a combination of 4 μg of erythromycin per ml and 0.5 μg of clindamycin per ml. The combination is prepared by combining equal amounts of 2× concentrations of the agents, i.e., 8 μg of erythromycin per ml and 1 μg of clindamycin per ml, and transferring the appropriate volume to a microdilution well or tube. The final concentrations in the well or tube are 4 μg/ml of erythromycin and 0.5 μg/ml of clindamycin. The wells or tubes are then inoculated by use of routine inoculation procedures for broth microdilution or macrodilution. The test should be interpreted only for those staphylococcal strains that are erythromycin resistant, i.e., with MICs of ≥8 μg/ml, and clindamycin susceptible or intermediate, i.e., with MICs of ≤2 μg/ml. Growth indicates inducible clindamycin resistance; no growth indicates no inducible clindamycin resistance.</para>
        <para id="ch0094s000000p0092">For streptococci, the single-well broth dilution test is performed by preparing microdilution wells (containing no less than 100 μl per well) or tubes of CAMHB with 3% lysed horse blood with a combination of 1 μg/ml of erythromycin and 0.5 μg/ml of clindamycin. The combination is prepared by combining equal amounts of 2× concentrations of the agents, i.e., 2 μg/ml of erythromycin and 1 μg/ml of clindamycin, and transferring the appropriate volume to a microdilution well or tube. The final concentrations in the well or tube are 1 μg/ml of erythromycin and 0.5 μg/ml of clindamycin. The wells or tubes are then inoculated using routine inoculation procedures for broth microdilution or macrodilution. The test should be interpreted only for streptococcal strains that are erythromycin resistant, i.e., with MICs of ≥1 μg/ml, and clindamycin susceptible or intermediate, i.e., with MICs of ≤0.5 μg/ml. Growth indicates inducible clindamycin resistance; no growth indicates no inducible clindamycin resistance.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0094s0013">
      <title>Detection of High-Level Mupirocin Resistance in Staphylococci</title>
      <anchor id="ch0094s000013a0001"/>
      <anchor id="ch0094s000000a0066"/>
      <para id="ch0094s000000p0093">Mupirocin is a topical antibacterial agent that is used for treatment of skin infection and eradication of nasal carriage of<emphasis>S. aureus</emphasis> (<link linkend="ch0094s000000li0115">115</link>). Resistance to mupirocin is either low level, associated with MICs of 8 to 256 μg/ml, or high level, associated with MICs of ≥512 μg/ml (<link linkend="ch0094s000000li0116">116</link>). High-level resistance (HLR) usually implies the presence of the <emphasis>mupA</emphasis> gene, although strains with HLR have occurred without <emphasis>mupA</emphasis> (<link linkend="ch0094s000000li0117">117</link>). More recently, HLR to mupirocin has been attributed to a different allele, <emphasis>mupB.</emphasis> The predicted MupB protein shares limited homology with MupA, but expression of <emphasis>mupB</emphasis> from a plasmid is sufficient to confer HLR to a naive <emphasis>S. aureus</emphasis> strain (<link linkend="ch0094s000000li0118">118</link>). It has been shown that elimination of <emphasis>S. aureus</emphasis> colonizing strains with mupirocin HLR is not possible (<link linkend="ch0094s000000li0119">119</link>); whether colonizing strains with low-level resistance can be eliminated with mupirocin is debatable (<link linkend="ch0094s000000li0120">120</link>).</para>
      <para id="ch0094s000000p0094">Based on data from a multilaboratory study (<link linkend="ch0094s000000li0117">117</link>), CLSI included methods for prediction of mupirocin HLR by use of disk diffusion or a single-well broth microdilution screening test. For disk diffusion testing, the standard disk diffusion procedure is used with a 200-μg mupirocin disk. The test plate is incubated at 35°C for 24 h; the absence of a zone of inhibition is indicative of mupirocin HLR, whereas any zone indicates the absence of HLR. For the broth microdilution procedure, a single well containing 0.1 ml of 256-μg/ml mupirocin is inoculated using a standard inoculum and incubated at 35°C for 24 h. Growth in the well indicates high-level mupirocin resistance; no growth indicates the absence of HLR.</para>
      <para id="ch0094s000000p0095">EUCAST mupirocin breakpoints, designed for nasal decolonization only, are ≤1 mg/liter as susceptible and &gt;256 mg/liter as resistant. By disk diffusion, using a 200-μg mupirocin disk, these breakpoints are ≥30 mm and &lt;18 mm. Isolates that fall in the intermediate range can still be treated with mupirocin for short-term suppression, such as preoperatively, but long-term eradication rates are low.</para>
      <sect2 id="ch0094s0013s0001">
        <title>PHENOTYPIC DETECTION OF RESISTANCE AMONG GRAM-NEGATIVE ORGANISMS</title>
        <anchor id="ch0094s000013a0002"/>
        <anchor id="ch0094s000000a0067"/>
        <para id="ch0094s000000p0096">Antimicrobial resistance among Gram-negative bacilli, and especially resistance to β-lactam agents, is a serious public health concern worldwide. Even more alarming is increasing resistance to agents of last resort, such as the carbapenems, and emerging resistance to novel β-lactam combination agents (e.g., ceftazidime-avibactam), resulting in MDR and extensively drug-resistant (XDR) organisms (<link linkend="ch0094s000000li0121">121</link>, <link linkend="ch0094s000000li0122">122</link>). Preserving effective antibiotic agents for treatment and preventing the spread of these organisms are increasingly recognized as high priorities throughout the continuum of patient care, and reliable detection of resistance in this group of organisms is essential for guiding therapeutic decisions and/or infection control interventions (<link linkend="ch0094s000000li0123">123</link>, <link linkend="ch0094s000000li0124">124</link>). Various phenotypic tests are described that can be used for the detection of β-lactam, fluoroquinolone, and colistin resistance mechanisms among Gram-negative bacilli from both cultured growth or directly from clinical specimens.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0094s0014">
      <title>Detection of β-Lactam Resistance</title>
      <anchor id="ch0094s000014a0001"/>
      <anchor id="ch0094s000000a0068"/>
      <para id="ch0094s000000p0097">β-Lactam resistance among Gram-negative bacilli is not a straightforward issue. Resistance occurs through multiple mechanisms, can be intrinsic or acquired, can be induced from low- to high-level expression, and can spread both through clonal expansion and through horizontal transmission of resistance genes. β-Lactamase producers are of particular concern, because β-lactamase production is the predominant mechanism mediating resistance, and the localization of the β-lactamase genes on or associated with mobile genetic elements (plasmids, transposons, insertion elements) allows ease of transmission of these genes between Gram-negative species (<link linkend="ch0094s000000li0125">125</link>).</para>
      <para id="ch0094s000000p0098">In the clinical laboratory, phenotypic β-lactamase tests can be used for two purposes. The first is to detect an underlying mechanism of resistance that may help guide therapy, and the second is to detect a mechanism of resistance that is epidemiologically important. These purposes are not mutually exclusive. Identification of a β-lactamase in the health care setting can be an infection control concern. However, the use of a special test for enzyme detection does not always mean that the β-lactamase test should be used to predict treatment outcomes. For example, a β-lactamase-positive result for a<emphasis>Neisseria gonorrhoeae</emphasis> isolate means that the isolate is resistant to penicillin and that penicillin would not be an appropriate treatment choice (<link linkend="ch0094s000000li0001">1</link>). A list of Gram-negative organisms for which β-lactamase tests are useful for treatment purposes is given in <link linkend="ch0094s000000a0069">Table 3</link> (see the penicillinase row).</para>
      <table id="ch0094s000000t0005"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0094s000000a0069"/><link linkend="ch0094s000000a0016">TABLE 3</link></phrase></emphasis> Phenotypic tests for the detection of β-lactamase-producing Gram-negative bacilli from cultured isolates<emphasis><anchor id="ch0094s000000a0070"/><link linkend="ch0094s000000a0073">a</link></emphasis>
</title>
        
        <tgroup cols="7">
          <tbody>
            <row>
              <entry><phrase role="left">β-Lactamase</phrase>
              </entry>
              <entry><phrase role="center">Hydrolysis profile<superscript><emphasis><anchor id="ch0094s000000a0071"/><link linkend="ch0094s000000a0074">b</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">Inhibitors</phrase>
              </entry>
              <entry><phrase role="center">Methods for detection</phrase>
              </entry>
              <entry><phrase role="center">Organisms to test</phrase>
              </entry>
              <entry><phrase role="center">Reporting</phrase>
              </entry>
              <entry><phrase role="center">Comments</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Penicillinase</phrase>
              </entry>
              <entry><phrase role="left">Penicillinase-labile penicillins, including amoxicillin, ampicillin, azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin</phrase>
              </entry>
              <entry><para id="ch0094s000000p0099"><phrase role="left">Traditional BLIs: clavulanic acid, sulbactam, tazobactam</phrase>
                </para>
                <para id="ch0094s000000p0100"><phrase role="left">New BLIs: avibactam, vaborbactam, relebactam</phrase>
                </para>
              </entry>
              <entry><phrase role="left">Direct β-lactamase tests include chromogenic cephalosporin, acidimetric, and iodometric tests</phrase>
              </entry>
              <entry><para id="ch0094s000000p0101"><phrase role="left">CLSI: <emphasis>Haemophilus influenzae</emphasis>, HACEK group,<superscript><emphasis><anchor id="ch0094s000000a0072"/><link linkend="ch0094s000000a0075">c</link></emphasis></superscript> <emphasis>Moraxella catarrhalis, Neisseria gonorrhoeae, Pasteurella</emphasis> spp.</phrase>
                </para>
                <para id="ch0094s000000p0102"><phrase role="left">EUCAST: <emphasis>Kingella kingae, M. catarrhalis</emphasis>, and <emphasis>N. gonorrhoeae</emphasis></phrase>
                </para>
              </entry>
              <entry><phrase role="left">β-Lactamase-positive isolates should be reported as resistant to the penicillinase-labile penicillins.</phrase>
              </entry>
              <entry><phrase role="left">A negative reaction is inconclusive, as other mechanisms of resistance may be present, and conventional ASTs must be performed to confirm susceptibility.</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Class A ESBL, i.e., CTX-M, TEM (non-TEM-1 or -2), SHV (non-SHV-1)</phrase>
              </entry>
              <entry><para id="ch0094s000000p0103"><phrase role="left">Penicillins, cephalosporins, and monobactams</phrase>
                </para>
                <para id="ch0094s000000p0104"><phrase role="left">Do not hydrolyze cephamycins or carbapenems.</phrase>
                </para>
              </entry>
              <entry><para id="ch0094s000000p0105"><phrase role="left">Traditional BLIs: clavulanic acid, sulbactam, and tazobactam</phrase>
                </para>
                <para id="ch0094s000000p0106"><phrase role="left">New BLIs: avibactam, vaborbactam, and relebactam</phrase>
                </para>
              </entry>
              <entry><para id="ch0094s000000p0107"><phrase role="left">Cephalosporin ± clavulanic acid-based tests: BMD, DD, gradient diffusion, DDST</phrase>
                </para>
                <para id="ch0094s000000p0108"><phrase role="left">Colorimetric methods: rapid ESBL NPD, Rapid ESBL Screen, β Lacta test</phrase>
                </para>
                <para id="ch0094s000000p0109"><phrase role="left">Lateral-flow assays for CTX-M</phrase>
                </para>
              </entry>
              <entry><para id="ch0094s000000p0110"><phrase role="left">CLSI: <emphasis>Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli</emphasis>, and <emphasis>Proteus mirabilis</emphasis></phrase>
                </para>
                <para id="ch0094s000000p0111"><phrase role="left">EUCAST – testing is differentiated by whether the organisms have an inducible chromosomal AmpC β-lactamase</phrase>
                </para>
                <para id="ch0094s000000p0112"><phrase role="left">Group 1: CLSI organisms, <emphasis>Raoultella</emphasis> spp., <emphasis>Salmonella</emphasis> spp., and <emphasis>Shigella</emphasis> spp.</phrase>
                </para>
                <para id="ch0094s000000p0113"><phrase role="left">Group 2: <emphasis>Enterobacterales</emphasis> with inducible chromosomal AmpC β-lactamase</phrase>
                </para>
              </entry>
              <entry><phrase role="left">Report MICs of the cephalosporins as tested as long as CLSI 2010 or later cephalosporin breakpoints are implemented.</phrase>
              </entry>
              <entry><phrase role="left">Many laboratories still perform testing, as the ESBL screening and confirmatory tests are built into automated Gram-negative AST panels.</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">AmpC β-lactamase, chromosomal or plasmid-mediated</phrase>
              </entry>
              <entry><para id="ch0094s000000p0114"><phrase role="left">Penicillins, cephalosporins (excluding 4th generation), cephamycins, and monobactams</phrase>
                </para>
                <para id="ch0094s000000p0115"><phrase role="left">Does not hydrolyze cefepime or carbapenems</phrase>
                </para>
              </entry>
              <entry><para id="ch0094s000000p0116"><phrase role="left">Poorly inhibited by traditional BLIs, especially clavulanic acid</phrase>
                </para>
                <para id="ch0094s000000p0117"><phrase role="left">Boronic acid and cloxacillin</phrase>
                </para>
                <para id="ch0094s000000p0118"><phrase role="left">New BLIs: avibactam, vaborbactam, relebactam</phrase>
                </para>
              </entry>
              <entry><phrase role="left">Cefoxitin or a third-generation cephalosporin ± cloxacillin or boronic acid</phrase>
              </entry>
              <entry><para id="ch0094s000000p0119"><phrase role="left">CLSI does not endorse any methods for detection of AmpC β-lactamase.</phrase>
                </para>
                <para id="ch0094s000000p0120"><phrase role="left">EUCAST: <emphasis>E. coli K. pneumoniae, P. mirabilis, Salmonella</emphasis> spp., <emphasis>Shigella</emphasis> spp.</phrase>
                </para>
              </entry>
              <entry><para id="ch0094s000000p0121"><phrase role="left">Report MICs of the cephalosporins as tested</phrase>
                </para>
                <para id="ch0094s000000p0122"><phrase role="left">Testing is for epidemiologic and infection control purposes only</phrase>
                </para>
              </entry>
              <entry><phrase role="left">Detection of AmpC β-lactamases does not distinguish between chromosomal and plasmid-mediated methods.</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Class A carbapenemases, i.e., KPC, SME, GES</phrase>
              </entry>
              <entry><phrase role="left">Hydrolyze penicillins, cephalosporins, monobactams, and to various degrees the carbapenems</phrase>
              </entry>
              <entry><para id="ch0094s000000p0123"><phrase role="left">Boronic acid ± clavulanic acid</phrase>
                </para>
                <para id="ch0094s000000p0124"><phrase role="left">New BLIs: avibactam, vaborbactam, and relebactam</phrase>
                </para>
              </entry>
              <entry><phrase role="left">Colorimetric Carba NP assay and derivatives, mCIM, MALDI-TOF MS assays, UV spectrometry, LC-MS/MS, BYG Carba test</phrase>
              </entry>
              <entry><para id="ch0094s000000p0125"><phrase role="left">Carbapenem-resistant <emphasis>Enterobacterales</emphasis> and <emphasis>Pseudomonas aeruginosa</emphasis></phrase>
                </para>
                <para id="ch0094s000000p0126"><phrase role="left">Methods are less reliable for testing carbapenem-resistant <emphasis>Acinetobacter baumannii</emphasis></phrase>
                </para>
              </entry>
              <entry><phrase role="left">Report MICs to the carbapenems as tested as long as CLSI 2010 or later carbapenem breakpoints are implemented</phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><phrase role="left">Class B metallo-β-lactamases, i.e., NDM, VIM, IMP</phrase>
              </entry>
              <entry><para id="ch0094s000000p0127"><phrase role="left">Hydrolyze penicillins, cephalosporins, and to various degrees the carbapenems</phrase>
                </para>
                <para id="ch0094s000000p0128"><phrase role="left">Do not hydrolyze monobactams.</phrase>
                </para>
              </entry>
              <entry><phrase role="left">Divalent cation chelators: dipicolinic acid, EDTA</phrase>
              </entry>
              <entry><phrase role="left">Inhibitor based methods using EDTA such as BMD, DD, gradient diffusion, and the eCIM</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry><phrase role="left">MBL producers tend to have high-level resistance to all β-lactam agents tested except monobactams (in the absence of other mechanisms).</phrase>
              </entry>
            </row>
            <row>
              <entry><para id="ch0094s000000p0129"><phrase role="left">Class D OXA-type β-lactamase</phrase>
                </para>
                <para id="ch0094s000000p0130"><phrase role="left">OXA-48-like enzymes are increasingly reported among the <emphasis>Enterobacterales</emphasis></phrase>
                </para>
                <para id="ch0094s000000p0131"><phrase role="left">OXA-23, OXA-24/40, OXA-51, OXA-58, and OXA-143 among <emphasis>A. baumannii</emphasis></phrase>
                </para>
              </entry>
              <entry><para id="ch0094s000000p0132"><phrase role="left">Hydrolyze penicillins, monobactams, and to various degrees the carbapenems</phrase>
                </para>
                <para id="ch0094s000000p0133"><phrase role="left">Spares third-generation cephalosporins</phrase>
                </para>
              </entry>
              <entry><para id="ch0094s000000p0134"><phrase role="left">No good inhibitors of class D enzymes</phrase>
                </para>
                <para id="ch0094s000000p0135"><phrase role="left">New BLIs: avibactam demonstrates activity against OXA-48-like enzymes</phrase>
                </para>
              </entry>
              <entry><phrase role="left">No inhibition by other inhibitors (i.e., boronic acid, cloxacillin, EDTA) used to identify other classes of β-lactamase and high-level temocillin resistance</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry><phrase role="left">OXA-like enzymes may be difficult to detect in the absence of other mechanisms of resistance, as they may appear susceptible to 3rd-generation cephalosporins with only slightly elevated MICs of carbapenems.</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0073"/><link linkend="ch0094s000000a0070">a</link></emphasis></superscript>BLIs, β-lactamase inhibitors; BMD, broth macrodilution; DD, disk diffusion; DDST, double-disk synergy test.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0074"/><link linkend="ch0094s000000a0071">b</link></emphasis></superscript>Hydrolysis profiles may vary slightly by enzyme type within each group.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0075"/><link linkend="ch0094s000000a0072">c</link></emphasis></superscript>HACEK group: <emphasis>Aggregatibacter</emphasis> spp. (formerly <emphasis>Haemophilus aphrophilus, H. segnis</emphasis>, and <emphasis>Actinobacillus actinomycetemcomitans</emphasis>), <emphasis>Cardiobacterium</emphasis> spp., <emphasis>Eikenella corrodens</emphasis>, and <emphasis>Kingella</emphasis> spp.</para>
      <para id="ch0094s000000p0136">In contrast, the supplemental CLSI tests for detection of ESBLs and carbapenemase producers are useful for detecting resistance mechanisms with epidemiological and infection control significance, but with implementation of the 2010 revised CLSI cephalosporin and carbapenem breakpoints, these tests are not recommended for prediction of cephalosporin and carbapenem treatment outcomes (<link linkend="ch0094s000000li0001">1</link>). Instead, it is recommended that laboratories use the results of routine susceptibility testing and apply current interpretive criteria. On the other hand, the Infectious Disease Society of America (IDSA) Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections promotes therapeutic options when the mechanism mediating resistance is known (<link linkend="ch0094s000000li0123">123</link>, <link linkend="ch0094s000000li0124">124</link>). For example, cefepime can be considered as therapy for <emphasis>Enterobacterales</emphasis> with third-generation-cephalosporin resistance mediated by AmpC production, whereas carbapenems should be considered for ESBL producers. Based on this guidance, mechanism-based testing can be helpful in therapeutic decision making and can supplement reporting of conventional AST results that apply current interpretive criteria. <link linkend="ch0094s000000a0069">Table 3</link> summarizes the various supplemental phenotypic tests for the detection of β-lactamase-producing Gram-negative bacilli from cultured isolates discussed in this chapter.</para>
      <anchor id="ch0094s000000a0076"/>
      <beginpage pagenum="1469"/>
      <anchor id="ch0094s000000a0077"/>
      <beginpage pagenum="1470"/>
      <anchor id="ch0094s000000a0078"/>
      <beginpage pagenum="1471"/>
      <sect2 id="ch0094s0014s0001">
        <title>Detection of Penicillinases in Aerobic and Anaerobic Gram-Negative Organisms</title>
        <anchor id="ch0094s000014a0002"/>
        <anchor id="ch0094s000000a0079"/>
        <para id="ch0094s000000p0137">Penicillinases provide resistance to penicillinase-labile penicillins, including amoxicillin, ampicillin, azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin. In the direct β-lactamase test, a positive reaction indicates that the isolate is resistant to these agents, but a negative reaction is inconclusive, because other mechanisms of β-lactam resistance are possible. For example, most ampicillin-resistant<emphasis>Haemophilus influenzae</emphasis> isolates produce β-lactamases which can be detected by direct β-lactamase tests; however, strains that are ampicillin resistant but β-lactamase negative are observed with increasing frequency (<link linkend="ch0094s000000li0126">126</link>–<link linkend="ch0094s000000li0128">128</link>). These β-lactamase-negative, ampicillin-resistant (BLNAR) isolates can be detected only by conventional AST methods (see <ulink url="ch0092#ch0092s0001">chapter 74</ulink>).</para>
        <para id="ch0094s000000p0138">The use of direct β-lactamase tests is endorsed by CLSI to predict susceptibility to penicillinase-labile penicillins to provide clinically relevant information earlier than traditional AST methods for the following aerobic Gram-negative organisms:<emphasis>H. influenzae</emphasis>, HACEK group (<emphasis>Aggregatibacter</emphasis> spp. [formerly <emphasis>Haemophilus aphrophilus, H. segnis</emphasis>, and <emphasis>Actinobacillus actinomycetemcomitans</emphasis>], <emphasis>Cardiobacterium</emphasis> spp., <emphasis>Eikenella corrodens</emphasis>, and <emphasis>Kingella</emphasis> spp.), <emphasis>Moraxella catarrhalis, N. gonorrhoeae</emphasis>, and <emphasis>Pasteurella</emphasis> species (<link linkend="ch0094s000000a0069">Table 3</link>, penicillinase row). With the emergence of <emphasis>bla</emphasis><subscript>ROB-1</subscript> β-lactamase-producing penicillin-resistant and ciprofloxacin-resistant (chromosomal mutation in the <emphasis>gyrA</emphasis> gene) <emphasis>Neisseria meningitidis</emphasis> serogroup Y isolates in the United States in 2019 and 2020, the CDC suggests that a direct chromogenic β-lactamase test can be considered to rapidly identify penicillin resistance mediated by the <emphasis>bla</emphasis><subscript>ROB-1</subscript> β-lactamase (<link linkend="ch0094s000000li0129">129</link>).</para>
        <para id="ch0094s000000p0139">EUCAST guidelines describe β-lactamase testing for<emphasis>Kingella kingae, M. catarrhalis</emphasis> and <emphasis>N. gonorrhoeae</emphasis> (<link linkend="ch0094s000000li0009">9</link>). For <emphasis>H. influenzae</emphasis>, EUCAST suggests screening for β-lactam resistance using a benzylpenicillin (penicillin G) 1-unit disk screening test. If the zone is ≥12 mm, the β-lactam agents with EUCAST established clinical breakpoints are reported as susceptible, whereas if the zone is &lt;12 mm, a test for β-lactamase production must be performed. If the isolate is β-lactamase positive, it is reported as ampicillin, amoxicillin, and piperacillin resistant. For other β-lactam agents or if the isolate is β-lactamase negative, specific β-lactam agents intended for use must be tested by a routine method (<link linkend="ch0094s000000li0009">9</link>).</para>
        <para id="ch0094s000000p0140">β-Lactamase testing with anaerobic Gram-negative bacilli other than<emphasis>Bacteroides</emphasis> or <emphasis>Parabacteroides</emphasis> species may also be performed based on CLSI guidelines (<link linkend="ch0094s000000li0001">1</link>). It is not necessary to test <emphasis>Bacteroides</emphasis> or <emphasis>Parabacteroides</emphasis> species, because they characteristically produce β-lactamases and should be considered penicillin resistant. As with aerobes, resistance to β-lactam drugs among anaerobic bacteria is not always mediated by β-lactamase production (e.g., in some strains of <emphasis>Parabacteroides distasonis</emphasis> and <emphasis>Bacteroides fragilis</emphasis>) (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0130">130</link>).</para>
      </sect2>
      <sect2 id="ch0094s0014s0002">
        <title>Detection of ESBL-Producing Enterobacterales</title>
        <anchor id="ch0094s000014a0003"/>
        <anchor id="ch0094s000000a0080"/>
        <para id="ch0094s000000p0141">ESBLs are enzymes that are capable of hydrolyzing most penicillins, monobactams, and cephalosporins (narrow- and expanded-spectrum cephalosporins) but not cephamycins or carbapenems (<link linkend="ch0094s000000li0131">131</link>, <link linkend="ch0094s000000li0132">132</link>). Traditional β-lactamases inhibitors (BLIs), such as clavulanic acid, tazobactam, and sulbactam, and newer inhibitors, such as avibactam, vaborbactam, and relebactam, inhibit their activity (<link linkend="ch0094s000000li0005">5</link>). The most common ESBLs are CTX-M, SHV and TEM Ambler class A variants, and they are associated with a variety of <emphasis>in vitro</emphasis> antimicrobial susceptibility profiles (<link linkend="ch0094s000000li0133">133</link>) (<ulink url="https://www.ncbi.nlm.nih.gov/pathogens/submit-beta-lactamase/">https://www.ncbi.nlm.nih.gov/pathogens/submit-beta-lactamase/</ulink>). Although all ESBLs hydrolyze extended-spectrum cephalosporins, the activity against specific third-generation cephalosporins varies by enzyme type. For example, some of the TEM and SHV ESBLs demonstrate greater activity for ceftazidime than for ceftriaxone, whereas the CTX-M enzymes demonstrate greater activity for ceftriaxone than for ceftazidime (<link linkend="ch0094s000000li0133">133</link>). Because ESBLs do not hydrolyze the carbapenems, carbapenems have been the treatment of choice for severe infections with ESBL-producing isolates (<link linkend="ch0094s000000li0134">134</link>, <link linkend="ch0094s000000li0135">135</link>). ESBLs are discussed in further detail in <ulink url="ch0090#ch0090s0001">chapter 72</ulink>.</para>
        <para id="ch0094s000000p0142">Over a decade ago, CLSI and EUCAST revised their recommendations for when to perform ESBL screening and confirmation tests. These revised recommendations were made as the interpretive criteria or breakpoints for cephalosporins and aztreonam were lowered and also because of the limitations of ESBL tests, as described in further detail below (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0009">9</link>). The new breakpoints, based upon pharmacokinetic/pharmacodynamics (PK-PD) data and limited clinical outcome data, are meant to more accurately predict treatment outcomes by using the most commonly used dosages for the cephalosporins. When the current breakpoints are used, ESBL screening and confirmatory tests can be performed for infection control and epidemiological purposes or may be considered to guide therapy rather than for changing interpretive criteria (e.g., changing a cephalosporin report from susceptible to resistant).</para>
        <para id="ch0094s000000p0143">CLSI guidelines describe screening criteria and confirmatory tests for ESBL detection in<emphasis>K. pneumoniae, K. oxytoca, E. coli</emphasis>, and <emphasis>P. mirabilis</emphasis> (<link linkend="ch0094s000000li0001">1</link>); EUCAST guidelines also include <emphasis>Raoultella</emphasis> spp., <emphasis>Salmonella</emphasis> spp. and <emphasis>Shigella</emphasis> spp. (defined as group 1 organisms by EUCAST) (<link linkend="ch0094s000000li0005">5</link>). Although ESBLs do occur in bacteria other than these species, the phenotypic ESBL confirmatory test can produce a false-negative result in the presence of an AmpC-type enzyme, as they are not inhibited by clavulanic acid (<link linkend="ch0094s000000li0136">136</link>), so validation of the ESBL test in bacteria with inducible chromosomally encoded AmpC enzyme (e.g., <emphasis>Enterobacter cloacae</emphasis> complex, <emphasis>Klebsiella</emphasis> [formerly <emphasis>Enterobacter</emphasis>] <emphasis>aerogenes</emphasis> and <emphasis>Citrobacter freundii</emphasis> complex) is difficult. That said, EUCAST has established a confirmatory method for ESBL production among <emphasis>Enterobacterales</emphasis> with inducible chromosomal AmpC, as described below.</para>
        <anchor id="ch0094s000000a0081"/>
        <beginpage pagenum="1472"/>
        <para id="ch0094s000000p0144">The CLSI screening test for putative ESBL producers is based on the MIC (or disk diffusion) cutoffs for one or more cephalosporins and/or aztreonam with a MIC of ≥2 μg/ml for the following agents: aztreonam, cefotaxime, ceftazidime, ceftriaxone, and/or cefpodoxime (cefpodoxime MIC of ≥8 μg/ml for<emphasis>P. mirabilis</emphasis>) (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0009">9</link>). ESBL-producing clinical isolates may demonstrate elevated MICs of one or more of the screening drugs due to the different levels of expression and hydrolytic activities of the enzymes. Thus, the sensitivity of the screening test increases when more than one screening drug is used (<link linkend="ch0094s000000li0133">133</link>). If they are screening test positive, putative ESBL producers need to be confirmed by an ESBL confirmation test.</para>
        <para id="ch0094s000000p0145">ESBLs are inhibited by clavulanic acid, and this property is exploited in laboratory tests to confirm ESBL production (<link linkend="ch0094s000000a0069">Table 3</link>). These tests are based on enhanced drug activity when cephalosporins (usually ceftazidime, cefotaxime, or cefepime) are tested with clavulanic acid compared to its activity when tested alone. Both a disk diffusion test and a broth microdilution MIC test have been described for confirmation of ESBL production in <emphasis>Enterobacterales</emphasis> lacking inducible AmpC enzymes by CLSI and EUCAST (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0005">5</link>). For broth microdilution, cefotaxime and ceftazidime are tested with and without 4 μg of clavulanic acid per ml. A decrease in the MIC of ≥3 doubling dilutions for the agents tested in combination with clavulanic acid compared to the values obtained for the agents tested alone indicates the presence of an ESBL. For disk diffusion testing, the same agents incorporated into disks with and without 10 μg of clavulanic acid are tested. An increase in the zone diameter of ≥5 mm for either of the disks with clavulanic acid indicates the presence of an ESBL (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0009">9</link>). EUCAST also describes a gradient MIC test method (e.g., Etest or MIC test strip [MTS, Liofilchem, Italy]) similar to the BMD method and a double-disk synergy test (DDST) where cephalosporin disks are placed next to a disk containing clavulanic acid (such as amoxicillin-clavulanic acid). A positive DDST is indicated by augmentation of the zone around the cephalosporin disk in the direction of the disk containing clavulanic acid (i.e., the presence of synergy).</para>
        <para id="ch0094s000000p0146">For inducible chromosomal AmpC-producing<emphasis>Enterobacterales</emphasis> (defined as group 2 organisms), EUCAST recommends using cefepime with and without clavulanic acid as an option for detection of ESBL production, as cefepime is stable to AmpC hydrolysis (<link linkend="ch0094s000000li0005">5</link>). Most laboratories rely on commercial automated AST systems to identify ESBL producers, based on built-in ESBL screening and confirmation tests on routine testing cards. For the most part, these systems overcall the presence of an ESBL, and some lack FDA claims for <emphasis>P. mirabilis</emphasis> due to poor performance (<link linkend="ch0094s000000li0137">137</link>–<link linkend="ch0094s000000li0140">140</link>). Thus, laboratories that report out the presence of an ESBL producer using the ESBL test on an automated system may consider performing additional confirmatory testing for ESBL results.</para>
        <para id="ch0094s000000p0147">There are multiple explanations for a screening-positive, confirmatory-test-negative result for an isolate. The isolate may be ESBL negative but demonstrate reduced susceptibility to the screening agents because of decreased porin production, hyperproduction of a broad-spectrum β-lactamase, such as TEM-1 or SHV-1, or production of another cephalosporin-hydrolyzing enzyme, such as an AmpC-type enzyme, which is not inhibited by clavulanic acid. Alternatively, the isolate may be ESBL positive but produce an additional β-lactamase, such as the AmpC-type enzymes, which can interfere with ESBL inhibition by clavulanic acid (<link linkend="ch0094s000000li0136">136</link>, <link linkend="ch0094s000000li0141">141</link>). The addition of an AmpC inhibitor (i.e., cloxacillin) appears to improve the sensitivity of ESBL detection among strains that also produce an AmpC enzyme (<link linkend="ch0094s000000li0142">142</link>). In one version of such a test, the same disk diffusion method and interpretive criteria used for ESBL detection are performed on MHA containing cloxacillin to inhibit AmpC enzymes, thereby improving detection of ESBLs in the presence of both types of resistance (<link linkend="ch0094s000000li0143">143</link>).</para>
        <para id="ch0094s000000p0148">In contrast to traditional phenotypic ESBL screening and confirmation tests, rapid phenotypic methods have been developed with same-day results for the detection of ESBL producers, including colorimetric hydrolysis-based assays, lateral-flow immunoassays, or a combination thereof. Three rapid colorimetric methods have been developed to detect ESBL-producing<emphasis>Enterobacterales</emphasis>: the Rapid ESBL NDP, the Rapid ESBL Screen (Rosco-Diagnostica A/S, Taastrup, Denmark), and the β Lacta test (Bio-Rad, Marnes-La-Coquette, France).</para>
        <para id="ch0094s000000p0149">The Rapid ESBL NDP specifically detects ESBL producers by monitoring cefotaxime hydrolysis in the presence and absence of tazobactam with a pH indicator, phenol red. If an isolate is an ESBL producer, the carboxyl-acid formation from hydrolysis of cefotaxime alone will result in a color change from red to orange/yellow, whereas the tube containing tazobactam will inhibit the activity of the ESBL and no color change will be apparent (i.e., it remains red) (<link linkend="ch0094s000000li0144">144</link>). This method has been applied to cultured isolates with results available within 20 min, with a sensitivity of 93 to 95% and specificity of 100% (<link linkend="ch0094s000000li0144">144</link>, <link linkend="ch0094s000000li0145">145</link>). The method has also been adapted for use directly on urine (<link linkend="ch0094s000000li0146">146</link>) and positive blood cultures (<link linkend="ch0094s000000li0144">144</link>, <link linkend="ch0094s000000li0147">147</link>). A commercial version of the Rapid ESBL NDP test, the Rapid ESBL Screen, has also been developed utilizing lyophilized reagents in dissolvable tablet format (i.e., Diatabs), but its performance characteristics have been reported to be inferior to those of the Rapid ESBL NDP, with a sensitivity of 92% and specificity of 83% after 2 h of incubation (<link linkend="ch0094s000000li0145">145</link>).</para>
        <para id="ch0094s000000p0150">The β Lacta test is a rapid method based on the cleavage of the yellow chromogenic cephalosporin (HMRZ-86) by ESBL, AmpC β-lactamase, and most carbapenemase producers (without distinction of mechanism), producing a red product within 15 min. The method has a reported sensitivity of 88 to 95% and specificity of 71 to 95% for detection of ESBL producers from cultured isolates (<link linkend="ch0094s000000li0145">145</link>, <link linkend="ch0094s000000li0148">148</link>, <link linkend="ch0094s000000li0149">149</link>) and has also been adapted for use directly from urine (<link linkend="ch0094s000000li0150">150</link>, <link linkend="ch0094s000000li0151">151</link>), bronchial aspirates (<link linkend="ch0094s000000li0152">152</link>), and positive blood cultures (<link linkend="ch0094s000000li0153">153</link>). The sensitivity of the assay is variable for AmpC producers, and the specificity differs by study, as it does not differentiate between ESBL, AmpC and carbapenemase producers (<link linkend="ch0094s000000li0145">145</link>, <link linkend="ch0094s000000li0148">148</link>, <link linkend="ch0094s000000li0149">149</link>).</para>
        <para id="ch0094s000000p0151">A lateral-flow immunoassay (LFA) was developed to detect and differentiate the five groups of CTX-M enzymes (i.e., groups 1, 2, 8, 9, 25) (NG-Test CTX-M Multi assay; NG Biotech, Guipry, France) from colonies and from positive blood cultures within 15 min with excellent sensitivity and specificity (≥98%) (<link linkend="ch0094s000000li0154">154</link>, <link linkend="ch0094s000000li0155">155</link>). False-positive results due to OXY-1-type β-lactamases among <emphasis>K. oxytoca</emphasis> isolates have been observed (<link linkend="ch0094s000000li0156">156</link>). The LFIA-CTX assay was recently developed and combines a cefotaxime hydrolysis test with an LFA using monoclonal antibodies against nonhydrolyzed cefotaxime to detect the presence of β-lactamases, including ESBLs (<link linkend="ch0094s000000li0157">157</link>). Gonzalez et al. compared the performance of two lateral flow assays, the NG-Test CTX-M Multi assay and the LFIA-CTX assay, among CTX-M-producing Gram-negative isolates and found similar performance characteristics (<link linkend="ch0094s000000li0158">158</link>).</para>
      </sect2>
      <sect2 id="ch0094s0014s0003">
        <title>Detection of Colonization with ESBL-Producing Gram-Negative Organisms</title>
        <anchor id="ch0094s000014a0004"/>
        <anchor id="ch0094s000000a0082"/>
        <para id="ch0094s000000p0152">Methods utilizing broth enrichment and direct selective culture (MacConkey agar or Drigalski agar) supplemented with a third-generation cephalosporin have been described for surveillance cultures to detect colonization with ESBL-producing Gram-negative organisms (<link linkend="ch0094s000000li0159">159</link>). Furthermore, various chromogenic media have been described that allow presumptive identification based on chromogenic substrates and selection with incorporation of a third-generation cephalosporin. Cefpodoxime is a common cephalosporin used for selection of ESBL producers in chromogenic media, due to increased sensitivity over other cephalosporins (<link linkend="ch0094s000000li0159">159</link>–<link linkend="ch0094s000000li0161">161</link>). The increased sensitivity for detection of ESBL producers is at the expense of specificity, as AmpC and K1 β-lactamase producers may also grow and be detected on these media (<link linkend="ch0094s000000li0161">161</link>). The sensitivity and specificity of the various media for detection of colonization from rectal specimens vary by study (<link linkend="ch0094s000000li0162">162</link>, <link linkend="ch0094s000000li0163">163</link>). A study evaluating 2,337 rectal swabs (354 positive for ESBL) from intensive-care-unit (ICU) patients comparing the CHROMagar ESBL (CHROMagar, France), ChromID ESBL (bioMérieux, France), Brilliance ESBL (Thermo Diagnostics, USA), and BD Drigalski with cefotaxime observed a sensitivity and specificity ranging from 96 to 98% and from 58 to 72%, respectively. The specificity was affected by recovery of both AmpC producers and nonfermenters, predominantly <emphasis>Pseudomonas aeruginosa</emphasis>, which is intrinsically cefotaxime resistant (<link linkend="ch0094s000000li0163">163</link>).</para>
        <anchor id="ch0094s000000a0083"/>
        <beginpage pagenum="1473"/>
      </sect2>
      <sect2 id="ch0094s0014s0004">
        <title>Detection of AmpC β-Lactamases among Enterobacterales</title>
        <anchor id="ch0094s000014a0005"/>
        <anchor id="ch0094s000000a0084"/>
        <para id="ch0094s000000p0153">AmpC β-lactamases are Ambler class C β-lactamases, containing serine residues at their catalytic active site. AmpC β-lactamases can be expressed constitutively or induced in response to β-lactam exposure. High-level expression of AmpC β-lactamase enzymes confers resistance to penicillins, cephalosporins (but generally not cefepime), cephamycins, and monobactams but are not effective at hydrolyzing the carbapenems. They are poorly inhibited by traditional BLIs (especially clavulanic acid), whereas boronic acid and cloxacillin are good inhibitors of AmpC β-lactamases. The ability to hydrolyze cephamycins, the inability to hydrolyze cefepime, and the lack of inhibition by clavulanic acid help distinguish putative AmpC producers from putative ESBL producers.</para>
        <para id="ch0094s000000p0154">There are three mechanisms mediating AmpC production among Gram-negative organisms. These mechanisms include chromosomally encoded inducible AmpC production, stable derepression of chromosomal AmpC, and plasmid-mediated AmpC. See<ulink url="ch0090#ch0090s0001">chapter 72</ulink> in this <emphasis>Manual</emphasis> for more details on AmpC β-lactamases.</para>
        <para id="ch0094s000000p0155">Genes encoding inducible AmpC-type β-lactamases occur on the chromosomes of several Gram-negative bacilli,<emphasis>Aeromonas</emphasis> spp., <emphasis>C. freundii</emphasis> complex, <emphasis>E. cloacae</emphasis> complex, <emphasis>Hafnia alvei, K. aerogenes, Morganella morganii, Providencia</emphasis> spp., <emphasis>P. aeruginosa, Serratia marcescens</emphasis>, and <emphasis>Yersinia enterocolitica.</emphasis> AmpC β-lactamase genes may also be located on transmissible plasmids in several bacterial species that lack an inducible chromosomally mediated enzyme, including <emphasis>E. coli, Klebsiella</emphasis> spp., <emphasis>Salmonella</emphasis> spp., and <emphasis>P. mirabilis</emphasis> (<link linkend="ch0094s000000li0164">164</link>). Like plasmids encoding ESBLs, plasmids encoding AmpC-type enzymes often carry resistance determinants for multiple classes of antimicrobial agents, and the combination of an AmpC-type enzyme with porin loss can result in carbapenem resistance (<link linkend="ch0094s000000li0165">165</link>).</para>
        <para id="ch0094s000000p0156">None of the phenotypic tests described below for AmpC detection can differentiate between genes located on the chromosome and those on a plasmid. Detection of an AmpC enzyme in members of the<emphasis>Enterobacterales</emphasis> that do not typically carry a chromosomal enzyme gene is assumed to indicate a plasmid-borne enzyme; in <emphasis>E. coli</emphasis> and <emphasis>Shigella</emphasis> spp., which carry a chromosomally located but typically unexpressed AmpC gene, molecular studies are necessary to distinguish between plasmid and chromosomal genes. Mutations in the promoter and/or attenuator regions of the chromosomal <emphasis>ampC</emphasis> gene in <emphasis>E. coli</emphasis> and <emphasis>Shigella</emphasis> spp. may result in hyperexpression, leading to an AmpC phenotype (<link linkend="ch0094s000000li0166">166</link>). The detection of plasmid-mediated AmpC-type enzymes is helpful for infection control and epidemiological investigations (<link linkend="ch0094s000000li0167">167</link>, <link linkend="ch0094s000000li0168">168</link>), and most large studies evaluating methods for AmpC detection have focused on plasmid-mediated enzymes (<link linkend="ch0094s000000li0169">169</link>).</para>
        <para id="ch0094s000000p0157">Several tests have been proposed for detection of AmpC-mediated resistance. The more promising assays incorporate an inhibitor of AmpC enzymes into one of several confirmatory AmpC assays, described below. Two inhibitors that have been evaluated widely are cloxacillin and boronic acid, although proprietary inhibitors have also been evaluated for this purpose (<link linkend="ch0094s000000li0170">170</link>). It is important to note that the boronic acid inhibitor is not specific for AmpC enzymes; boronic acid affects both class A carbapenemases (e.g., KPC) and class C (e.g., AmpC) enzymes, so additional testing must be performed to differentiate these (<link linkend="ch0094s000000li0171">171</link>, <link linkend="ch0094s000000li0172">172</link>).</para>
        <para id="ch0094s000000p0158">Phenotypic tests for AmpC production are generally performed on isolates that screen positive for potential AmpC production by testing not susceptible to the cephamycins (i.e., cefoxitin or cefotetan). Cefoxitin resistance demonstrates better sensitivity for this purpose, although cefotetan resistance is a more specific predictor of AmpC production (<link linkend="ch0094s000000li0173">173</link>–<link linkend="ch0094s000000li0175">175</link>). It should also be noted that cefoxitin resistance can be mediated by porin mutations (<link linkend="ch0094s000000li0166">166</link>). Others have suggested that a combination of resistance to cefoxitin and resistance to ceftazidime, ceftriaxone, or cefotaxime can improve specificity without decreasing sensitivity (<link linkend="ch0094s000000li0176">176</link>, <link linkend="ch0094s000000li0177">177</link>). Although less specific, susceptibility to cefepime, together with resistance to cefotaxime, ceftriaxone, and/or ceftazidime, may be used if cephamycins are not tested (<link linkend="ch0094s000000li0005">5</link>). EUCAST suggests a cefoxitin MIC of &gt;8 mg/liter combined with a ceftazidime and/or cefotaxime MIC of &gt;1 mg/liter as a screening test for putative AmpC production among <emphasis>E. coli, K. pneumoniae, P. mirabilis, Salmonella</emphasis> spp., and <emphasis>Shigella</emphasis> spp. Isolates that screen as potential AmpC producers can be confirmed with a molecular test (see <ulink url="ch0098#ch0098s0001">chapter 80</ulink>) or one of the phenotypic confirmatory tests described below. EUCAST suggests confirmation testing using a method to demonstrate cloxacillin synergy to detect plasmid-mediated AmpC producers for the organisms listed above, and if such testing is positive for <emphasis>E. coli/Shigella</emphasis> spp., further PCR testing is required to discriminate between plasmid-mediated and hyperproduction of chromosomal AmpC. CLSI does not provide guidance for screening and confirmation of AmpC producers.</para>
        <para id="ch0094s000000p0159">The double-disk synergy test has been evaluated widely for detection of both plasmid- and chromosome-encoded AmpC enzymes. This test involves a paper disk or tablet containing an antibiotic (typically cefoxitin, ceftazidime, or cefotaxime) placed near an AmpC inhibitor (typically cloxacillin or boronic acid) on a lawn of the organism to be tested. The inhibitor inactivates the β-lactamase, resulting in a zone of inhibition around the antibiotic disk that is enlarged and distorted toward the inhibitor disk (<link linkend="ch0094s000000li0178">178</link>). Numerous studies have reported this test to have good sensitivity (range of 85 to 96%), although its specificity is much less reliable (<link linkend="ch0094s000000li0177">177</link>, <link linkend="ch0094s000000li0179">179</link>, <link linkend="ch0094s000000li0180">180</link>). Ruppé et al. (<link linkend="ch0094s000000li0178">178</link>) developed a modification of this approach that can be used to detect the AAC-1 β-lactamase, which is inhibited by oxacillin. Essentially, the double-disk synergy test is set up in duplicate with ceftazidime and cefotaxime, using cloxacillin as an inhibitor for one set and cefoxitin as the inhibitor for the other. Organisms producing an AAC-1 enzyme will demonstrate inhibition in both assays, while those producing other AmpC β-lactamases will demonstrate inhibition only with cloxacillin (<link linkend="ch0094s000000li0178">178</link>).</para>
        <anchor id="ch0094s000000a0085"/>
        <beginpage pagenum="1474"/>
        <para id="ch0094s000000p0160">Another test incorporates a disk containing both a test drug (typically cefoxitin, but also cefotaxime or ceftazidime) and an AmpC inhibitor (cloxacillin or boronic acid) in a standard disk diffusion assay similar to the ESBL confirmatory test. The zone diameter of the test drug alone is compared to that obtained in the presence of the inhibitor; an increase in zone size (typically of ≥4 mm) is interpreted as positive (<link linkend="ch0094s000000li0179">179</link>, <link linkend="ch0094s000000li0181">181</link>). Numerous studies have evaluated different combinations of β-lactams and inhibitors with this assay, and each has concluded that it demonstrates good sensitivity and specificity for confirmation of both plasmid- and chromosome-encoded AmpC enzymes (<link linkend="ch0094s000000li0173">173</link>–<link linkend="ch0094s000000li0175">175</link>, <link linkend="ch0094s000000li0179">179</link>, <link linkend="ch0094s000000li0181">181</link>). In one study evaluating the cloxacillin and boronic acid inhibitors, each compound performed well, but the best assay performance was observed when both compounds were combined with cefoxitin (<link linkend="ch0094s000000li0181">181</link>).</para>
        <para id="ch0094s000000p0161">At least three commercial manufacturers have developed test systems based on the methods described herein. Rosco NeoSensitabs (sensitivity, 96%; specificity, 92% [179]) and Mast AmpC detection (sensitivity, ≥96%; specificity, ≥98% [182]) tests both incorporate several disks or tablets into panels that can be used to decipher various β-lactam resistance mechanisms. These systems have generally performed well in a limited number of published studies (<link linkend="ch0094s000000li0173">173</link>, <link linkend="ch0094s000000li0179">179</link>). bioMérieux also produces an Etest AmpC assay (Etest AmpC) that follows a similar logic, with a reported sensitivity of 84 to 93% and specificity of 70 to 100% (<link linkend="ch0094s000000li0173">173</link>, <link linkend="ch0094s000000li0182">182</link>). Etest AmpC uses a double-ended strip containing a gradient of cefotetan on one end and a gradient of cefotetan plus cloxacillin on the other; the MIC for cefotetan alone is compared to the MIC with the inhibitor, and a ratio of ≥8 is considered positive, as is a deformation of the ellipse or formation of a phantom zone (<ulink url="http://www.ilexmedical.com/files/E-test-Package-Insert/Product_supplement.pdf">http://www.ilexmedical.com/files/E-test-Package-Insert/Product_supplement.pdf</ulink>).</para>
      </sect2>
      <sect2 id="ch0094s0014s0005">
        <title>Detection of Carbapenemases among Gram-Negative Bacilli</title>
        <anchor id="ch0094s000014a0006"/>
        <anchor id="ch0094s000000a0086"/>
        <para id="ch0094s000000p0162">Carbapenems are broad-spectrum β-lactam agents used for empiric treatment of very serious infections and for treatment of infections with MDR organisms. As such, carbapenems are viewed as agents of last resort, and resistance to them is a significant clinical and public health concern. Mechanisms of carbapenem resistance among Gram-negative organisms are heterogeneous but are primarily broken down into two broad categories: carbapenemase-producing (CP) and non-carbapenemase-producing (non-CP) mechanisms. For the latter, carbapenem resistance is mediated by porin mutations or efflux pumps or the combination of these with ESBL and/or AmpC production, depending on the Gram-negative organism. A summary of acronyms used to describe carbapenem resistance mechanisms among Gram-negative bacilli is presented in<anchor id="ch0094s000000a0087"/><link linkend="ch0094s000000a0090">Table 4</link>.</para>
        <para id="ch0094s000000p0163">Carbapenemases are β-lactamases that can hydrolyze carbapenem antimicrobial agents (e.g., ertapenem, doripenem, imipenem, and meropenem) to various degrees. Typically, carbapenemases can also hydrolyze other β-lactam agents, such as the penicillins, traditional β-lactam–β-lactamase inhibitor (BL/BLI) combinations, monobactams (except metallo-β-lactamases [MBLs]), and cephalosporins (expanded-spectrum cephalosporins are not efficiently hydrolyzed by OXA-type β-lactamases), so isolates producing a carbapenemase can be resistant to all β-lactam drugs. The new BL/BLI combinations, such as ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam, have good activity against class A serine carbapenemase producers but not against class B MBL producers (<link linkend="ch0094s000000li0183">183</link>, <link linkend="ch0094s000000li0184">184</link>). Ceftazidime-avibactam also exhibits activity against class D OXA-48-like-producing <emphasis>Enterobacterales</emphasis> (<link linkend="ch0094s000000li0185">185</link>). Cefiderocol is a novel siderophore-conjugated cephalosporin with activity against a broad array of Gram-negative bacilli, including those producing class A, B, and D carbapenemases (<link linkend="ch0094s000000li0186">186</link>). Although carbapenemases can be chromosomally encoded, most are encoded on plasmids that can also contain other resistance determinants, leading to MDR organisms.</para>
        <para id="ch0094s000000p0164">Carbapenemase production is the primary mechanism mediating increased carbapenem resistance among<emphasis>Enterobacterales</emphasis>, and infections with CP carbapenem-resistant Gram-negative organisms (CP-CRO) cause significant morbidity and mortality (<link linkend="ch0094s000000li0187">187</link>–<link linkend="ch0094s000000li0190">190</link>). Thus, it is these features of carbapenemases that make identifying isolates harboring such resistance mechanisms a significant infection control and public health concern. Detection of CP-CRO in the hospital setting may warrant more-intensive infection control strategies than would be employed for non-CP-CRO. Moreover, as more novel antimicrobial agents with activity against CRO become available, the differentiation of CP-CRO from non-CP-CRO is becoming increasingly important for antimicrobial stewardship programs prioritizing the use of these new agents for CP-CRO infections, such as the new BL/BLI combinations discussed above (<link linkend="ch0094s000000li0191">191</link>, <link linkend="ch0094s000000li0192">192</link>).</para>
        <para id="ch0094s000000p0165">Carbapenemases fall within the following three classes of β-lactamases: Ambler class A enzymes, including KPC, SME, IMI, NMC, and some GES enzymes; class B enzymes, also known as the MBLs, with NDM, VIM, and IMP being the most common types; and some class D OXA enzymes (<link linkend="ch0094s000000li0193">193</link>, <link linkend="ch0094s000000li0194">194</link>). These enzymes are described in more detail in <ulink url="ch0090#ch0090s0001">chapter 72</ulink>. Carbapenemases have been identified in many different Gram-negative bacilli, but their emergence and spread among the <emphasis>Enterobacterales</emphasis> represent a significant escalation of their clinical relevance. The KPC enzyme is the most commonly identified carbapenemase in the United States; it usually occurs in <emphasis>Enterobacterales</emphasis> but has also been identified among nonfermenters (<link linkend="ch0094s000000li0194">194</link>, <link linkend="ch0094s000000li0195">195</link>). In the past, MBLs were most often found in <emphasis>P. aeruginosa</emphasis> and <emphasis>Acinetobacter</emphasis> spp. and only occasionally in <emphasis>Enterobacterales</emphasis> (<link linkend="ch0094s000000li0196">196</link>). In contrast to historic MBLs, the NDM mechanism has emerged primarily among <emphasis>Enterobacterales</emphasis>, although it has also been described for <emphasis>Acinetobacter</emphasis> spp., <emphasis>Pseudomonas</emphasis> spp., and <emphasis>Stenotrophomonas maltophilia</emphasis> (<link linkend="ch0094s000000li0197">197</link>–<link linkend="ch0094s000000li0199">199</link>). Its presence was documented in numerous countries across several continents within the first few years of its description (<link linkend="ch0094s000000li0198">198</link>, <link linkend="ch0094s000000li0199">199</link>).</para>
        <para id="ch0094s000000p0166">OXA carbapenemases are most commonly found in<emphasis>Acinetobacter</emphasis> spp., but the OXA-48-like family of carbapenemases is now one of the fastest growing groups in the <emphasis>Enterobacterales</emphasis> in Europe and the United States (<link linkend="ch0094s000000li0200">200</link>, <link linkend="ch0094s000000li0201">201</link>) (<ulink url="https://www.cdc.gov/hai/organisms/cre/trackingcre.html">https://www.cdc.gov/hai/organisms/cre/trackingcre.html</ulink>). OXA-48-like producing <emphasis>Enterobacterales</emphasis> are particularly concerning, as they can easily go unrecognized due to their unusual susceptibility profile. In the absence of other β-lactam resistance mechanisms, OXA-48-like enzymes hydrolyze penicillins at high levels and carbapenems at low levels and spare the expanded-spectrum cephalosporins (<link linkend="ch0094s000000li0201">201</link>). Furthermore, the emergence of dual- and triple-carbapenemase production among isolates is increasingly reported worldwide (<link linkend="ch0094s000000li0202">202</link>).</para>
        <anchor id="ch0094s000000a0088"/>
        <beginpage pagenum="1475"/>
        <anchor id="ch0094s000000a0089"/>
        <beginpage pagenum="1476"/>
        <table id="ch0094s000000t0006"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0094s000000a0090"/><link linkend="ch0094s000000a0087">TABLE 4</link></phrase></emphasis> Acronyms used to describe carbapenem resistance mechanisms among Gram-negative bacilli
</title>
          
          <tgroup cols="6">
            <tbody>
              <row>
                <entry><phrase role="left">Name</phrase>
                </entry>
                <entry><phrase role="center">Acronym(s)</phrase>
                </entry>
                <entry><phrase role="center">Definition</phrase>
                </entry>
                <entry><phrase role="center">Organisms</phrase>
                </entry>
                <entry><phrase role="center">Laboratory identification</phrase>
                </entry>
                <entry><phrase role="center">Mechanisms of carbapenem resistance</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Carbapenem-resistant <emphasis>Enterobacterales</emphasis></phrase>
                </entry>
                <entry><phrase role="left">CRE</phrase>
                </entry>
                <entry><phrase role="left">Encompasses organisms from the order <emphasis>Enterobacterales</emphasis> that are resistant to carbapenems regardless of the mechanism</phrase>
                </entry>
                <entry><phrase role="left"><emphasis>Enterobacterales</emphasis> (e.g., <emphasis>E. coli, K. pneumoniae</emphasis>)</phrase>
                </entry>
                <entry><phrase role="left">“R” result from a carbapenem disk diffusion or MIC test interpreted with current CLSI breakpoints<superscript><emphasis><anchor id="ch0094s000000a0091"/><link linkend="ch0094s000000a0093">a</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="left">Includes all carbapenem resistance mechanisms (e.g., production of an AmpC or ESBL plus altered permeability or carbapenemase production)</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Carbapenemase-producing <emphasis>Enterobacterales</emphasis></phrase>
                </entry>
                <entry><phrase role="left">CPE, CP-CRE</phrase>
                </entry>
                <entry><phrase role="left">Encompasses organisms from the order <emphasis>Enterobacterales</emphasis> that are resistant to carbapenems due to the production of a carbapenemase</phrase>
                </entry>
                <entry><phrase role="left"><emphasis>Enterobacterales</emphasis> (e.g., <emphasis>E. coli, K. pneumoniae</emphasis>)</phrase>
                </entry>
                <entry><phrase role="left">Positive result from a carbapenemase test<superscript><emphasis><anchor id="ch0094s000000a0092"/><link linkend="ch0094s000000a0094">b</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="left">Production of a carbapenemase (i.e., KPC, NDM, OXA-48-like)</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Non-carbapenemase-producing carbapenem-resistant <emphasis>Enterobacterales</emphasis></phrase>
                </entry>
                <entry><phrase role="left">Non-CP-CRE</phrase>
                </entry>
                <entry><phrase role="left">Encompasses organisms from the order <emphasis>Enterobacterales</emphasis> that are resistant to carbapenems due to mechanisms other than carbapenemase-production (excludes carbapenemase-producers).</phrase>
                </entry>
                <entry><phrase role="left"><emphasis>Enterobacterales</emphasis> (e.g., <emphasis>E. coli, K. pneumoniae</emphasis>)</phrase>
                </entry>
                <entry><phrase role="left">Negative result for a carbapenemase test</phrase>
                </entry>
                <entry><phrase role="left">Production of an AmpC or ESBL with altered permeability due to porin mutations or efflux pumps</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Carbapenem-resistant organism</phrase>
                </entry>
                <entry><phrase role="left">CRO</phrase>
                </entry>
                <entry><phrase role="left">Encompasses all Gram-negative bacilli including the <emphasis>Enterobacterales</emphasis> that are resistant to carbapenems regardless of the mechanism.</phrase>
                </entry>
                <entry><phrase role="left">All Gram-negative bacilli including the <emphasis>Enterobacterales</emphasis>, the non-glucose-fermenting Gram-negative bacilli (e.g., <emphasis>Pseudomonas</emphasis> and <emphasis>Acinetobacter</emphasis> spp.) and others (e.g., <emphasis>Aeromonas</emphasis> spp.)</phrase>
                </entry>
                <entry><phrase role="left">“R” result from a carbapenem disk diffusion or MIC test interpreted with current CLSI breakpoints<superscript><emphasis><link linkend="ch0094s000000a0093">a</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="left">Includes all carbapenem resistance mechanisms</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Carbapenemase-producing organism</phrase>
                </entry>
                <entry><phrase role="left">CPO, CP-CRO</phrase>
                </entry>
                <entry><phrase role="left">Encompasses all Gram-negative bacilli including the <emphasis>Enterobacterales</emphasis> that are resistant to carbapenems due to the production of a carbapenemase enzyme.</phrase>
                </entry>
                <entry><phrase role="left">All Gram-negative bacilli including the <emphasis>Enterobacterales</emphasis>, the non-glucose-fermenting Gram-negative bacilli (e.g., <emphasis>Pseudomonas</emphasis> and <emphasis>Acinetobacter</emphasis> spp.), and others (e.g., <emphasis>Aeromonas</emphasis> spp.)</phrase>
                </entry>
                <entry><phrase role="left">Positive result from a carbapenemase test<superscript><emphasis><link linkend="ch0094s000000a0094">b</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="left">Production of a carbapenemase (e.g., KPC, NDM, OXA type, VIM, IMP)</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Non-carbapenemase-producing carbapenem-resistant Gram-negative organism</phrase>
                </entry>
                <entry><phrase role="left">Non-CP-CRO</phrase>
                </entry>
                <entry><phrase role="left">Encompasses all Gram-negative bacilli, including the <emphasis>Enterobacterales</emphasis>, that are resistant to carbapenems due to mechanisms other than carbapenemase production (excludes carbapenemase producers).</phrase>
                </entry>
                <entry><phrase role="left">All Gram-negative bacilli, including the <emphasis>Enterobacterales</emphasis>, the non-glucose-fermenting Gram-negative bacilli (e.g., <emphasis>Pseudomonas</emphasis> and <emphasis>Acinetobacter</emphasis> spp.), and others (e.g., <emphasis>Aeromonas</emphasis> spp.)</phrase>
                </entry>
                <entry><phrase role="left">Negative result for a carbapenemase test</phrase>
                </entry>
                <entry><phrase role="left">Includes non-carbapenemase-mediated carbapenem resistance mechanisms, including decreased permeability due to porin mutations, over expression of efflux pumps, production of an AmpC or ESBL, and altered permeability and changes in penicillin binding proteins (rare).</phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0093"/><link linkend="ch0094s000000a0091">a</link></emphasis></superscript>“R” (resistant) to ertapenem (<emphasis>Enterobacterales</emphasis> only), doripenem, imipenem, and/or meropenem.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0094s000000a0094"/><link linkend="ch0094s000000a0092">b</link></emphasis></superscript>Carbapenemase tests include phenotypic (as described in this chapter) and molecular methods (see <ulink url="ch0098#ch0098s0001">chapter 80</ulink>). Molecular assays for carbapenemase can only rule in or out the carbapenemases associated with the gene targets.</para>
        <para id="ch0094s000000p0167">In January 2010, CLSI lowered the carbapenem breakpoints, resulting in the removal of the recommendation for routine testing for the detection of carbapenemase producers among isolates with elevated carbapenem MICs, and no longer required the modification of interpretive criteria according to the presence of a carbapenemase producer. Laboratories may choose to detect carbapenemase producers for therapeutic management, infection control, or epidemiologic purposes, but it is no longer required for routine care provided that the 2010 carbapenem breakpoints have been implemented. Many different phenotypic methods for the detection of carbapenemase producers among carbapenem-resistant Gram-negative organisms have been developed. The modified Hodge test (MHT) (<anchor id="ch0094s000000a0095"/><link linkend="ch0094s000000a0097">Fig. 1A</link>) was one of the first methods described and was retired as a CLSI-endorsed method in 2018, as several newer methods with improved performance characteristics have been described and endorsed by CLSI and EUCAST, such as the Carba NP (<link linkend="ch0094s000000a0097">Fig. 1B</link>) and the modified carbapenem-inactivation method (mCIM) (<link linkend="ch0094s000000a0097">Fig. 1F</link> and <link linkend="ch0094s000000a0097">G</link>) (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0005">5</link>). Although the MHT was easy to perform, it was subjective, lacked sensitivity for detection of MBLs, and lacked specificity, as many ESBL and AmpC producers with porin mutations would produce false-positive results (see previous versions of this <emphasis>Manual</emphasis> for further description of the MHT) (<link linkend="ch0094s000000li0201">201</link>, <link linkend="ch0094s000000li0203">203</link>, <link linkend="ch0094s000000li0204">204</link>).</para>
        <para id="ch0094s000000p0168">The Carba NP (NP: Nordmann and Poirel) was endorsed by both EUCAST (2013) and CLSI (2015) for detection of carbapenemase production among<emphasis>Enterobacterales, P. aeruginosa</emphasis>, and <emphasis>Acinetobacter</emphasis> spp. (<link linkend="ch0094s000000li0205">205</link>). The method relies on a phenol red pH indicator to detect hydrolysis of the imipenem β-lactam ring by a carbapenemase, resulting in a color change from red to orange/yellow upon acid production (<link linkend="ch0094s000000li0004">4</link>). Several studies have demonstrated excellent sensitivity and specificity for detection of many different carbapenemase enzymes in both <emphasis>Enterobacterales</emphasis> and <emphasis>P. aeruginosa</emphasis> (<link linkend="ch0094s000000li0206">206</link>–<link linkend="ch0094s000000li0208">208</link>), although this test performs less well for the GES and OXA-48 families of carbapenemases and mucoid isolates (<link linkend="ch0094s000000li0209">209</link>). The Carba NP test is inexpensive, quick (30 min to 2 h), allowing same-day results, and relatively easy to perform (<link linkend="ch0094s000000li0004">4</link>, <link linkend="ch0094s000000li0208">208</link>, <link linkend="ch0094s000000li0209">209</link>). The major disadvantage of the method is the need to prepare reagents in-house, with the imipenem-based solution having a shelf life of 3 days, which may become wasteful if carbapenem resistance is infrequently encountered and adds complexity to testing. Also, interpretation of the assay may be subjective, especially the interpretation of minor color changes. A few studies demonstrated that the Carba NP does not perform well among <emphasis>Acinetobacter baumannii</emphasis> isolates, and therefore, CLSI removed its endorsement of the Carba NP for use with <emphasis>A. baumannii</emphasis> in 2018 (<link linkend="ch0094s000000li0206">206</link>, <link linkend="ch0094s000000li0210">210</link>). An amended version of the Carba NP, CarbAcineto NP, demonstrates good performance (94.7% sensitivity and 100% specificity) for detection of carbapenemases among <emphasis>A. baumannii</emphasis> isolates through modified lysis and increased inoculum (<link linkend="ch0094s000000li0211">211</link>).</para>
        <anchor id="ch0094s000000a0096"/>
        <beginpage pagenum="1477"/>
        <figure id="ch0094s000000f0001"><title><phrase role="figureLabel"><anchor id="ch0094s000000a0097"/><link linkend="ch0094s000000a0095">FIGURE 1</link></phrase> (A) Modified Hodge test. (Section 1) <emphasis>Klebsiella pneumoniae</emphasis> ATCC BAA-1705, positive result; (section 2) <emphasis>K. pneumoniae</emphasis> ATCC BAA-1706, negative result; (section 3) clinical isolate, positive result. (B) CLSI Carba NP positive result. Tube A, no imipenem added (red); tube B, imipenem added (yellow). (C) RAPIDEC CARBA NP (bioMérieux, Inc.) positive result. Well d, no imipenem added (red); well e, imipenem added (yellow). (D) Neo-Rapid Carba Screen (Rosco Diagnostica), positive result. Tube 1a, no imipenem added (red); tube 1b, imipenem added (yellow) (E) Rapid CARB Blue Screen (Rosco Diagnostica). Tube a, no imipenem added (blue); tube b, imipenem added (yellow). (F) mCIM, positive result. (G) mCIM, negative result. (H) mCIM and eCIM positive for a serine carbapenemase producer, as there is no inhibition of carbapenemase activity in the presence of EDTA. (I) mCIM and eCIM positive for a metallo-β-lactamase producer, as there is inhibition of carbapenemase activity in the presence of EDTA. (J) CARBA 5 (NG Biotech) lateral-flow immunoassay results for the different carbapenemases detected. Panel D is from reference <link linkend="ch0094s000000li0214">214</link>, reprinted with permission of the publisher.</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0094f01.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <para id="ch0094s000000p0169">Many different derivatives of the original Carba NP method have since been described, including different inocula, different extraction regents, modifications to the starting pH, different pH indicators, and different reading times (<link linkend="ch0094s000000li0208">208</link>, <link linkend="ch0094s000000li0212">212</link>, <link linkend="ch0094s000000li0213">213</link>). In addition, there are presently three different commercial assays available, the FDA-cleared RAPIDEC CARBA NP for use with <emphasis>Enterobacterales</emphasis> and <emphasis>P. aeruginosa</emphasis> (<link linkend="ch0094s000000a0097">Fig. 1C</link>), the research-use-only (RUO) Neo-Rapid Carb Screen (Rosco Diagnostica, Taastrup, Denmark) (<link linkend="ch0094s000000a0097">Fig. 1D</link>), and the RUO Rapid Carb Blue Screen (Rosco Diagnostica, Taastrup, Denmark) (<link linkend="ch0094s000000a0097">Fig. 1E</link>). The commercial methods simplify testing through use of lyophilized reagents. The performance characteristics of the commercial methods are comparable to those of the manual Carba NP methods (<link linkend="ch0094s000000li0206">206</link>, <link linkend="ch0094s000000li0207">207</link>, <link linkend="ch0094s000000li0214">214</link>).</para>
        <para id="ch0094s000000p0170">The mCIM was endorsed by CLSI first for use with the<emphasis>Enterobacterales</emphasis> in 2016 and then for use with <emphasis>P. aeruginosa</emphasis> in 2017. The mCIM is based on the principle that when a meropenem disk is incubated in a broth solution with a carbapenemase-producing organism for 4 h, the carbapenem in the disk is degraded by the carbapenemase, whereas if the Gram-negative organism is a non-CP-CRO, the meropenem retains its antimicrobial activity after the broth incubation step. To assess the activity of the meropenem disk after incubation with the organisms of interest, the meropenem disk is removed from the broth and placed on an MHA plate that is preinoculated with a lawn of a carbapenem-susceptible indicator strain (<emphasis>E. coli</emphasis> ATCC 25922). After overnight incubation, the zone of inhibition is measured to determine whether the meropenem has been hydrolyzed (a 6- to 15-mm zone diameter indicates that the organism is a carbapenemase producer) (<link linkend="ch0094s000000a0097">Fig. 1F</link>) or if it is still active (≥19 mm indicates that the organism is not a carbapenemase producer) (<link linkend="ch0094s000000a0097">Fig. 1G</link>). The method is a modification of the original CIM described by van der Zwaluw et al. in 2015 (<link linkend="ch0094s000000li0215">215</link>). While this initial report documented excellent sensitivity and specificity for a variety of carbapenemases, more recent data demonstrated that the CIM has limited detection of both NDM and OXA-48-like enzymes (<link linkend="ch0094s000000li0207">207</link>). Nonetheless, the method is straightforward to perform and interpret and is performed using readily available, low-cost materials (i.e., disks and MHA), making it easy for most laboratories to implement.</para>
        <para id="ch0094s000000p0171">Modifications to the original CIM were made by CLSI to overcome shortcomings of the assay, by use of a 1-μl inoculum for the<emphasis>Enterobacterales</emphasis> (as opposed to 10 μl), use of tryptic soy broth (TSB) instead of water for incubation of the meropenem disk with the organism suspension, use of an extended incubation of 4 h versus 2 h in the original procedure, and changes in the interpretation of the zone diameter readings. The modifications made by CLSI to the CIM allow improved detection of both NDM and OXA-48-like producers, and the overall sensitivity and specificity for detection of carbapenemase production among <emphasis>Enterobacterales</emphasis> and <emphasis>P. aeruginosa</emphasis> have been reported to be &gt;95% (<link linkend="ch0094s000000li0206">206</link>, <link linkend="ch0094s000000li0207">207</link>, <link linkend="ch0094s000000li0216">216</link>). The major limitations of the mCIM are that overnight incubation is required and that results are available only after 24 h. Some investigators have implemented shorter incubation periods of the disk with the carbapenem-susceptible indicator strain (6 h) to report results more rapidly (<link linkend="ch0094s000000li0215">215</link>). Alternatively, simplified approaches with direct inoculation of the test organism on the surface of the carbapenem disk, removing the TSB incubation step, have been developed (<link linkend="ch0094s000000li0217">217</link>, <link linkend="ch0094s000000li0218">218</link>). The mCIM does not have good performance characteristics for use with <emphasis>A. baumannii</emphasis> isolates, with 71 to 80% sensitivity and 53 to 70% specificity (<link linkend="ch0094s000000li0206">206</link>, <link linkend="ch0094s000000li0210">210</link>). As such, CLSI does not recommend its use with <emphasis>A. baumannii.</emphasis> A modification to the mCIM using 0.5 M Tris-HCl buffer for extraction (CIMTris) detected carbapenemase production in <emphasis>Acinetobacter</emphasis> and <emphasis>Pseudomonas</emphasis> species with a sensitivity of 98% and specificity of 93% (<link linkend="ch0094s000000li0219">219</link>).</para>
        <para id="ch0094s000000p0172">The mCIM was further developed to allow differentiation of MBLs from serine carbapenemases by the addition of EDTA, a divalent cation chelator and inhibitor of MBLs. The EDTA CIM (eCIM) is performed in parallel with the mCIM, because interpretation of the eCIM requires evaluation of an mCIM for the test isolate. A ≥5-mm zone diameter difference for the indicator strain by the eCIM compared to the mCIM indicates that the isolate produces an MBL. If there is a ≤4-mm difference, the test isolate produces a serine carbapenemase that is not efficiently inhibited by EDTA (<link linkend="ch0094s000000a0097">Fig. 1H</link>). Interpretation of the eCIM is possible only in the context of a positive mCIM (<link linkend="ch0094s000000a0097">Fig. 1I</link>). Recent evaluation of the eCIM demonstrated sensitivity of &gt;95% and specificity of &gt;92% for differentiation of MBLs from serine carbapenemases among <emphasis>Enterobacterales</emphasis> isolates investigated by CLSI (<link linkend="ch0094s000000li0220">220</link>). Of note, if both a serine carbapenemase and an MBL are coproduced by one organism, differentiation between enzymes will not be possible and a false-negative eCIM result may occur. This is a limitation of most inhibitor-based assays. Furthermore, some OXA-type enzymes have also been shown to be inhibited by EDTA, because divalent cations are required to stabilize the more active dimeric form of the enzyme. In the presence of EDTA, the OXA-type enzyme is converted to the less-active monomeric form, resulting in reduction in carbapenemase activity and potentially false-positive MBL results (<link linkend="ch0094s000000li0221">221</link>, <link linkend="ch0094s000000li0222">222</link>). Differentiation of MBLs from serine carbapenemases can be clinically useful with the introduction of novel BL/BLI combinations, such as ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam, that have activity against serine carbapenemases but not against MBL producers. Thus, the detection of an MBL producer can rule out the use of these novel BL/BLI combinations if a specific MIC or disk test is not available for these agents. However, detection of a serine carbapenemase does not guarantee the activity of these antimicrobials, as not all serine carbapenemase producers are susceptible to these agents (<link linkend="ch0094s000000li0185">185</link>, <link linkend="ch0094s000000li0223">223</link>, <link linkend="ch0094s000000li0224">224</link>).</para>
        <para id="ch0094s000000p0173">Similar to the eCIM, multiple different inhibitor-based assays have been described for detection and differentiation of the Ambler classes of carbapenemases (<link linkend="ch0094s000000a0069">Table 3</link>). These assays test a carbapenem (mostly meropenem) with and without one or more known inhibitors to differentiate the activity of one carbapenemase class from the other. Class A enzymes are inhibited by boronic acid, which also inhibits AmpC enzymes. Thus, to differentiate carbapenem resistance mediated by class A carbapenemases from AmpC (chromosomal or plasmid-mediated) plus porin loss (non-CP carbapenem-resistant <emphasis>Enterobacteriaceae</emphasis> [non-CP-CRE]), a specific AmpC inhibitor, cloxacillin, may be added for specificity. Class B enzymes are inhibited by divalent cation chelators such as EDTA, 2-mercaptopropionic acid, and dipicolinic acid. There is no currently available inhibitor for class D carbapenemases. Thus, if carbapenem resistance is not inhibited by any of the above combinations (through a process of elimination), then it is either an ESBL plus porin loss or a class D OXA-48-like enzyme. High-level temocillin resistance, defined as a MIC of &gt;32 μg/ml or a zone diameter of &lt;11 mm with a 30-μg disk, has been suggested as a phenotypic marker for OXA-48-like enzymes (<link linkend="ch0094s000000li0225">225</link>). However, it is not specific, because other resistance mechanisms may confer this phenotype. Thus, EUCAST suggests use of temocillin in conjunction with inhibitor-based assays to differentiate carbapenem resistance mediated by OXA-48-like enzymes (HLR) from ESBL plus porin loss (negative for HLR).</para>
        <anchor id="ch0094s000000a0098"/>
        <beginpage pagenum="1478"/>
        <para id="ch0094s000000p0174">EUCAST endorses an inhibitor-based approach as described above using combination disk tests with and without inhibitors, similar to the CLSI ESBL confirmation test (<link linkend="ch0094s000000li0225">225</link>). Several different test formats have been described for inhibitor-based assays, and essentially every phenotypic carbapenemase assay described herein has been converted into an inhibitor-based format. These tests for detection of specific carbapenemases are generally convenient and easy to perform, and some have very favorable performance characteristics. However, significant disadvantages of the tests are that multiple tests would need to be performed routinely to detect carbapenemases of different classes, and detection of OXA carbapenemases occurs through a process of elimination as described above (<link linkend="ch0094s000000li0201">201</link>). To simplify the manual interpretation of these algorithms, the BD Phoenix CPO Detect test was designed to be incorporated into automated AST panels with computer assisted algorithm-based detection (<link linkend="ch0094s000000li0226">226</link>). Similar to ESBL tests on automated systems, the test consists of nine wells on the BD Phoenix AST panel, each containing a β-lactam antibiotic, alone and in combination with various β-lactamase inhibitors for detection and classification of carbapenemases. Several studies have demonstrated high sensitivity for carbapenemase detection with low specificity and poor accuracy of carbapenemase classification (<link linkend="ch0094s000000li0227">227</link>). Thus, confirmation of positive results using alternative methods, especially for nonfermentative Gram-negative bacilli, is advised.</para>
        <para id="ch0094s000000p0175">As MALDI-TOF MS has become an important method in clinical microbiology laboratories for identification of microorganisms, the method has further been exploited for detection of β-lactamase activity using hydrolysis-based studies. These studies incubate either the supernatant from cell extracts or the whole organism from culture plates with a carbapenem for a defined period of time and analyze the supernatant by MALDI-TOF MS to identify peaks corresponding to the intact carbapenem (negative; non-CP-CRO) or a metabolite of the carbapenem indicating carbapenem hydrolysis (positive; carbapenemase-producing organism [CPO]) (<link linkend="ch0094s000000li0228">228</link>). Overall, the method has demonstrated good sensitivity and specificity in several studies (<link linkend="ch0094s000000li0228">228</link>–<link linkend="ch0094s000000li0230">230</link>). The addition of NH<subscript>4</subscript>HCO<subscript>3</subscript> and of ZnSO<subscript>4</subscript> provides improved detection of OXA-48-like and MBL producers, respectively (<link linkend="ch0094s000000li0229">229</link>, <link linkend="ch0094s000000li0230">230</link>). Furthermore, the method has been adapted to be performed directly from positive blood cultures (<link linkend="ch0094s000000li0231">231</link>). This approach has been described as inexpensive and rapid but requires the settings of the MALDI-TOF MS instrument to be altered, because the system is optimized for bacterial identification (<emphasis>m</emphasis>/<emphasis>z</emphasis> range of 2,000 to 20,000) rather than detection of drug metabolites (lower <emphasis>m</emphasis>/<emphasis>z</emphasis> range of 160 to 600).</para>
        <para id="ch0094s000000p0176">Hydrolysis-based studies applying UV spectrometry and liquid chromatography-tandem mass spectrometry (LC-MS/MS) have been described (<link linkend="ch0094s000000li0232">232</link>, <link linkend="ch0094s000000li0233">233</link>). A novel hydrolysis method using electrochemical currents, the BYG (Bogaerts-Yunus-Glupczynski) Carba test, detects variations of conductivity of an electrosensing-polymer (polyaniline)-coated electrode that is highly sensitive to pH and redox activity occurring during imipenem hydrolysis by carbapenemases (<link linkend="ch0094s000000li0234">234</link>). A multicenter trial testing 1,181 CRE isolates observed an overall sensitivity of 96%, specificity of 99%, positive predictive value of 99%, and negative predictive value of 98% for the BYG Carba test (<link linkend="ch0094s000000li0235">235</link>). The BYG Carba test appears to be a rapid (30 min), objective, sensitive, and specific method for detection of CP-CRE (<link linkend="ch0094s000000li0234">234</link>).</para>
        <para id="ch0094s000000p0177">Other methods utilizing mass spectrometry for detection of carbapenemases include a peak identification method by MALDI-TOF MS that detects a protein marker associated with a carbapenemase-bearing plasmid using the standard bacterial identification method. So far, this method has been established only for the<emphasis>bla</emphasis><subscript>KPC</subscript>-bearing plasmid pKpQIL, which was responsible for the carbapenemase-producing-<emphasis>Enterobacterales</emphasis> (CPE) outbreak that occurred at the NIH Clinical Center in 2011 (<link linkend="ch0094s000000li0236">236</link>, <link linkend="ch0094s000000li0237">237</link>). The principal advantage of the method is the ability to simultaneously identify the organism and detect putative carbapenemase producers by identifying a specific peak on the standard chromatogram. Furthermore, an LC-MS/MS peptide marker approach for detecting KPC-, NDM-, OXA-48-like-, and VIM-producing isolates using tryptic-digested fragments of the carbapenemase proteins in clinical isolates looks like a promising new method (<link linkend="ch0094s000000li0100">100</link>, <link linkend="ch0094s000000li0238">238</link>).</para>
        <para id="ch0094s000000p0178">Rapid and simple immunochromatographic lateral-flow assays for detection of carbapenemase enzymes have also been developed. These tests use colloidal gold nanoparticles bound to nitrocellulose membrane sensitized with monoclonal antibodies for the detection of specific carbapenemases, including KPC, NDM, OXA-48-like, VIM, and IMP, individually or in a multiplex format (K-SeT tests; Coris BioConcept, NDM LFIA, or RESIST-5 O.O.K.N.V.) (<link linkend="ch0094s000000li0239">239</link>). Recently, the NG-Test Carba 5 LFA targeting the five main carbapenemase families (i.e., KPC, NDM, VIM, IMP, and OXA-48-like carbapenemases) was FDA cleared (<link linkend="ch0094s000000a0097">Fig. 1J</link>) (<link linkend="ch0094s000000li0240">240</link>). A multicenter study demonstrated an overall positive percent agreement (PPA) and negative percent agreement (NPA) of 100% for the NG-Test Carba 5 compared to a composite reference standard for testing cultured isolates of <emphasis>Enterobacterales</emphasis> and <emphasis>P. aeruginosa</emphasis> recovered on both blood and MacConkey agars (<link linkend="ch0094s000000li0241">241</link>). Importantly, the Carba5 has demonstrated accurate detection of isolates producing multiple carbapenemases (e.g., NDM-type and OXA-48-like carbapenemases), and cross-reactivity was not observed with nontargeted carbapenemases (e.g., GES and SME). Additional studies have demonstrated use of LFAs for accurate detection of carbapenemases from positive blood culture broths and directly from rectal swabs (<link linkend="ch0094s000000li0242">242</link>–<link linkend="ch0094s000000li0244">244</link>).</para>
      </sect2>
      <sect2 id="ch0094s0014s0006">
        <title>Detection of Colonization with Carbapenem-Resistant Organisms</title>
        <anchor id="ch0094s000014a0007"/>
        <anchor id="ch0094s000000a0099"/>
        <para id="ch0094s000000p0179">Gastrointestinal colonization of MDR Gram-negative organisms, such as ESBL-producing organisms and CRO, is an important reservoir for transmission of these critical pathogens in the hospital setting (<link linkend="ch0094s000000li0188">188</link>). Therefore, many hospitals have opted to screen high-risk patients (i.e., patients from or hospitalized in areas where such organisms are endemic; intensive care unit, transplant, and oncology patients; or patients with significant exposure to the health care setting) for colonization with these MDR Gram-negative organisms to implement infection control interventions to reduce their spread. Both culture-based methods and nucleic acid amplification tests (NAATs) have been developed. NAAT methods are described in further detail in <ulink url="ch0098#ch0098s0001">chapter 80</ulink>.</para>
        <para id="ch0094s000000p0180">An ideal culture-based method for MDR organisms needs to be rapid, accurate, able to detect low-level resistance (organisms with elevated but low MICs) and a low organism burden, especially in fecal specimens (<link linkend="ch0094s000000li0125">125</link>, <link linkend="ch0094s000000li0245">245</link>). Culture-based methods are convenient, readily available, low-cost alternatives that include broth-enrichment methods, direct selective culture, and chromogenic media. The major limitation of these methods is the longer turnaround time, with some methods taking up to 3 to 4 days, which may not be optimal for infection control practices. Furthermore, many of the selective culture-based methods have less-than-ideal specificity, and extra time and resources are spent ruling out putative results requiring confirmation of identification (ID) and AST, as described in more depth below. These methods generally do not differentiate resistance mechanisms, because an antimicrobial (either a third-generation cephalosporin or a carbapenem) is used as part of selection; therefore, if the detection of specific mechanisms of resistance is desired, such as ESBL or carbapenemase production, further testing of recovered isolates by genotypic or phenotypic methods will be required.</para>
        <anchor id="ch0094s000000a0100"/>
        <beginpage pagenum="1479"/>
        <para id="ch0094s000000p0181">One of the first described methods for detection of CRO among fecal specimens was the CDC broth enrichment method (<link linkend="ch0094s000000li0246">246</link>). Disadvantages of the CDC method include many false-positive broths due to overgrowth of enterococci from the rectal swab and the long turnaround time of up to 4 days to identify CP-CRO. Furthermore, it has been shown that although the broth enrichment was designed to increase sensitivity of detection of CRO, it may in fact hinder the recovery of organisms with low carbapenem MICs or a low inoculum of a CRO in the presence of high inocula of competing organisms, negating the need for the broth enrichment step (<link linkend="ch0094s000000li0125">125</link>). The reported sensitivity ranges from 40 to 80% and specificity from 68 to 80% (<link linkend="ch0094s000000li0125">125</link>, <link linkend="ch0094s000000li0245">245</link>).</para>
        <para id="ch0094s000000p0182">Another method using standard laboratory supplies for detection of CRO from fecal specimens, without the need for broth enrichment, is the direct MacConkey plate method (<link linkend="ch0094s000000li0247">247</link>, <link linkend="ch0094s000000li0248">248</link>). This method involves direct inoculation of a MacConkey plate with the fecal specimen and placement of a carbapenem disk at the juncture of quadrants 1 and 2 and a second disk at the juncture of quadrants 2 and 3. Growth of a Gram-negative bacillus after overnight incubation within a predefined zone diameter, such as 27 mm for ertapenem, is further identified, and ASTs are performed (<link linkend="ch0094s000000li0248">248</link>). The sensitivity and specificity of the method using ertapenem disks has been reported at 95% and 91%, respectively, for detection of CRO from rectal swabs (<link linkend="ch0094s000000li0248">248</link>). Due to the lack of detection of a CPE resulting from overgrowth of meropenem-susceptible <emphasis>P. aeruginosa</emphasis>, the authors suggest utilizing an ertapenem disk in the first quadrant to be able to detect mono-ertapenem-resistant CRE and a meropenem disk in the second quadrant to suppress meropenem-susceptible nonfermenters, because they may mask the detection of some CRE (<link linkend="ch0094s000000li0125">125</link>). Negative results are available within 24 h by the direct MacConkey plate method. Positive results require ID and AST to confirm the presence of a putative CRO and, if applicable, detection of carbapenemase production by genotypic or phenotypic means to detect CP-CRO in up to 3 days, depending on the method and workflow (<link linkend="ch0094s000000li0249">249</link>). A study found that reducing the zone diameter that qualified organisms for further workup to ≤25 mm for both ertapenem and meropenem balanced sensitivity and specificity for CRO detection while reducing the burden on the laboratory by decreasing confirmatory workload (<link linkend="ch0094s000000li0250">250</link>).</para>
        <para id="ch0094s000000p0183">Chromogenic media utilizing a carbapenem antibiotic for selection have turnaround times similar to that of the direct MacConkey plate method and have been widely adopted for screening for CRO from rectal specimens due to ease of use. The advantage of chromogenic media over the direct MacConkey plate method would be the putative identification of the organisms based on the chromogens present in the media. Various commercial media are available with various sensitivities (range, 42 to 96%) and specificities (59 to 88%) for detection of different carbapenemase classes using well-characterized isolates. There are few studies evaluating the performance characteristics using perirectal/rectal swabs, and for the most part, these studies have been limited to detection of KPC producers, with good sensitivity (75 to 97%) and specificity (82 to 99%) (<link linkend="ch0094s000000li0245">245</link>). Some of these media are specific for detection of KPC producers and have decreased sensitivity for other carbapenemase classes, especially OXA-48-like enzymes.</para>
        <para id="ch0094s000000p0184">Furthermore, most chromogenic media perform poorly for detection of class D OXA enzymes, and this issue has been specifically addressed by a medium for detection of OXA-48 producers, the chromID OXA-48 medium. A biplate of chromID CARBA (bioMérieux, France) and chromID OXA-48 is available to try to cover the full spectrum of carbapenemases that may be encountered clinically. Similarly, Supercarba agar is a specialized medium that can be made in-house that utilizes ertapenem and cloxacillin in a zinc-supplemented Drigalski lactose agar with a shelf life of 7 days (<link linkend="ch0094s000000li0004">4</link>). A few studies challenging the media with well-characterized isolates have reported a sensitivity of &gt;95% and specificity of 60% (<link linkend="ch0094s000000li0004">4</link>, <link linkend="ch0094s000000li0251">251</link>). Alternatively, some have evaluated chromogenic media utilizing a third-generation cephalosporin for selection (i.e., ESBL chromogenic media; described above) to also detect CRO. The main disadvantage of this is decreased specificity due to detection of expanded-spectrum-cephalosporin-resistant Gram-negative bacilli and the potential to miss OXA-like producers that do not efficiently hydrolyze expanded-spectrum cephalosporins. For more information on the various chromogenic media and a summary of the various studies evaluating the performance characteristics, the excellent review by Viau et al. is recommended (<link linkend="ch0094s000000li0245">245</link>).</para>
      </sect2>
      <sect2 id="ch0094s0014s0007">
        <title>Cefazolin as a Surrogate for Oral Cephalosporins in Urinary Isolates of E. coli, Klebsiella spp., and P. mirabilis</title>
        <anchor id="ch0094s000014a0008"/>
        <anchor id="ch0094s000000a0101"/>
        <para id="ch0094s000000p0185">Oral cephalosporins are an option for empiric treatment of uncomplicated urinary tract infections.<emphasis>Enterobacterales</emphasis> with chromosomal, inducible <emphasis>ampC</emphasis> β-lactamases (<emphasis>Enterobacter</emphasis> spp., <emphasis>Citrobacter</emphasis> spp., and <emphasis>Serratia</emphasis> spp.) are strongly induced by β-lactam antibiotics, leading to increased expression and resistance to first-generation cephalosporins. <emphasis>Enterobacterales</emphasis> lacking a chromosomally encoded inducible <emphasis>ampC</emphasis> β-lactamase, such as <emphasis>E. coli, K. pneumoniae</emphasis>, and <emphasis>P. mirabilis</emphasis>, retain activity against first-generation cephalosporins. Due to the lack of CLSI interpretative criteria for some oral cephalosporins, such as cephalexin (common in clinical use), and lack of representation of many oral cephalosporins on available automated susceptibility testing systems, surrogate testing is required for <emphasis>Enterobacterales</emphasis> that lack inducible <emphasis>ampC</emphasis> to predict susceptibilities with these agents when following CLSI guidelines.</para>
        <para id="ch0094s000000p0186">Previously, cephalothin was recommended as the surrogate agent by FDA and CLSI based on older data (<link linkend="ch0094s000000li0252">252</link>, <link linkend="ch0094s000000li0253">253</link>), but recent studies have demonstrated that cephalothin provided unacceptably low categorical agreement and high major error rates when predicting certain oral cephalosporins (<link linkend="ch0094s000000li0254">254</link>, <link linkend="ch0094s000000li0255">255</link>). As such, the recommendation was reevaluated by CLSI, and a cefazolin MIC of ≤16 μg/ml was found to be an excellent predictor (97.1 to 100% accuracy) of susceptibility to many of the oral cephalosporins (specifically, cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime, cephalexin, and loracarbef) for the treatment of uncomplicated urinary tract infection caused by <emphasis>E. coli, K. pneumoniae</emphasis>, and <emphasis>P. mirabilis</emphasis> (<link linkend="ch0094s000000li0256">256</link>). The results from the CLSI Ad Hoc Oral Cephalosporin Working Group formed the basis of the current CLSI recommendations, where cephalothin was removed and urinary breakpoints were set for cefazolin to act as a surrogate for predicting results to the specified oral cephalosporins. Of note, some isolates that may test resistant to cefazolin may be found to be susceptible to more potent oral agents (cefpodoxime, cefuroxime, and cefdinir) and may be tested individually when being considered for treatment (<link linkend="ch0094s000000li0001">1</link>). A few recent studies confirmed the findings of the CLSI Working Group that cefazolin is a better surrogate than cephalothin (<link linkend="ch0094s000000li0257">257</link>, <link linkend="ch0094s000000li0258">258</link>). However, the study by Bookstaver et al. found cefazolin to predict cefpodoxime susceptibility compared to cefuroxime (categorical agreement, 84%; major error rate, 1.1%; very major error rate, 18.2%), although a small number of cefpodoxime-resistant isolates were tested (<emphasis>n</emphasis> = 11) (<link linkend="ch0094s000000li0257">257</link>). In contrast, EUCAST established urinary breakpoints for the oral cephalosporins cefadroxil, cephalexin, cefixime, cefpodoxime, ceftibuten, and cefuroxime (<link linkend="ch0094s000000li0009">9</link>).</para>
        <anchor id="ch0094s000000a0102"/>
        <beginpage pagenum="1480"/>
      </sect2>
    </sect1>
    <sect1 id="ch0094s0015">
      <title>Detection of Non-β-Lactam Resistance among Gram-Negative Bacilli</title>
      <anchor id="ch0094s000015a0001"/>
      <anchor id="ch0094s000000a0103"/>
      <sect2 id="ch0094s0015s0001">
        <title>Pefloxacin as a Surrogate for Fluoroquinolone Susceptibility in Salmonella enterica</title>
        <anchor id="ch0094s000015a0002"/>
        <anchor id="ch0094s000000a0104"/>
        <para id="ch0094s000000p0187">Fluoroquinolones are an important option for treatment of salmonellosis when therapy is indicated, especially in the case of typhoid fever. Methods for detection of fluoroquinolone resistance among<emphasis>Salmonella</emphasis> have evolved in recent years due to emerging mechanisms of resistance. Initially, nalidixic acid, a nonfluorinated quinolone, was used as a surrogate agent to detect <emphasis>Salmonella enterica</emphasis> with fluoroquinolone resistance due to chromosomal target site mutations (most common mechanisms of resistance) in the quinolone resistance-determining region of <emphasis>gyrA</emphasis> and <emphasis>parC</emphasis> and less frequently among <emphasis>gyrB</emphasis> and <emphasis>parE</emphasis> (<link linkend="ch0094s000000li0259">259</link>, <link linkend="ch0094s000000li0260">260</link>). However, with the discovery of plasmid-mediated quinolone resistance, including mechanisms of target site protection (<emphasis>qnr</emphasis> variants), efflux pumps (<emphasis>oqxAB</emphasis> and <emphasis>qepA</emphasis>), and enzymatic alteration of ciprofloxacin/norfloxacin by acetylation [<emphasis>aac(6</emphasis>′<emphasis>)Ib-cr</emphasis>] (<link linkend="ch0094s000000li0261">261</link>, <link linkend="ch0094s000000li0262">262</link>), the utility of nalidixic acid was diminished, because plasmid-mediated quinolone resistance determinants provide elevated fluoroquinolone MICs without conferring resistance to nalidixic acid. Furthermore, <emphasis>Salmonella</emphasis> isolates with low-level fluoroquinolone resistance with MICs that were considered susceptible (0.125 to 1 μg/ml) prior to 2014 were found to have a greater likelihood of treatment failure and a greater ease of developing higher-level resistance after exposure to fluoroquinolones (<link linkend="ch0094s000000li0259">259</link>).</para>
        <para id="ch0094s000000p0188">To overcome this issue and in support of PK-PD studies (<link linkend="ch0094s000000li0263">263</link>, <link linkend="ch0094s000000li0264">264</link>), CLSI revised the ciprofloxacin, levofloxacin, and ofloxacin MIC breakpoints in 2014 to better reflect the wild-type distribution of <emphasis>Salmonella</emphasis> MICs for these agents. Independently, EUCAST and FDA also revised and lowered the breakpoints for ciprofloxacin for <emphasis>S. enterica</emphasis> and <emphasis>Salmonella enterica</emphasis> serovar Typhi, respectively. Additionally, CLSI and FDA (<emphasis>S.</emphasis> Typhi only) established ciprofloxacin disk diffusion breakpoints. A limitation of lowering the breakpoints was that most automated susceptibility systems do not cover doubling dilutions that go low enough to apply the new breakpoints. Therefore, clinical laboratories are required to validate and apply other methods for AST, many of which do not have the capability of MIC-based testing. A recent study demonstrated that Etest is a viable option (<link linkend="ch0094s000000li0265">265</link>). Consequently, EUCAST and CLSI evaluated the use of multiple surrogate disk tests to differentiate fluoroquinolone-susceptible from nonsusceptible MICs in <emphasis>Salmonella</emphasis> spp. (<link linkend="ch0094s000000li0260">260</link>, <link linkend="ch0094s000000li0266">266</link>). Both studies found pefloxacin disks to provide good separation of the two populations compared to other disk diffusion substrates, including nalidixic acid and ciprofloxacin itself. As a result, pefloxacin surrogate testing was approved and implemented by EUCAST (2014) and CLSI (2016).</para>
        <para id="ch0094s000000p0189">One important limitation of pefloxacin surrogate testing is that it does not detect the presence of<emphasis>aac(6</emphasis>′<emphasis>)Ib-cr</emphasis>, as the mechanism of resistance is specific to ciprofloxacin and norfloxacin (<link linkend="ch0094s000000li0260">260</link>). In addition, pefloxacin disks are not available in the United States, but they may be a practical alternative in resource-limited settings. CLSI encourages the use of MIC-based testing for fluoroquinolones in <emphasis>Salmonella</emphasis> over ciprofloxacin disk diffusion and pefloxacin surrogate testing. Methodologically, those that elect to use pefloxacin disks should be aware of differences among disk manufacturers and the presence of inner colonies suggesting resistance (<link linkend="ch0094s000000li0260">260</link>). Due to the poor performance of nalidixic acid to detect plasmid-mediated quinolone resistance mechanisms among <emphasis>Salmonella</emphasis> spp., it was removed as a surrogate from the CLSI guidelines in 2017.</para>
      </sect2>
      <sect2 id="ch0094s0015s0002">
        <title>Surveillance Cultures for Fluoroquinolone-Resistant Gram-Negative Bacilli</title>
        <anchor id="ch0094s000015a0003"/>
        <anchor id="ch0094s000000a0105"/>
        <para id="ch0094s000000p0190">Prostate cancer is prevalent in industrialized countries and is most commonly diagnosed by transrectal prostate biopsy (TPB) (<link linkend="ch0094s000000li0267">267</link>). Fluoroquinolone-resistant Gram-negative bacterial infections after TPB are increasing and are mostly due to gastrointestinal colonization with fluoroquinolone-resistant <emphasis>E. coli</emphasis> (<link linkend="ch0094s000000li0267">267</link>, <link linkend="ch0094s000000li0268">268</link>). Rectal swab surveillance cultures for fluoroquinolone-resistant Gram-negative bacilli are performed for patients prior to transrectal prostate biopsy to determine if ciprofloxacin is appropriate as prophylaxis to prevent infectious complications following the procedure. Surveillance culture methods include selective broth enrichment (BHI broth supplemented with 10 μg/ml of ciprofloxacin) followed by subculture of turbid broths to MacConkey agar containing 10 μg/ml of ciprofloxacin (<link linkend="ch0094s000000li0269">269</link>). Recently, the fluoroquinolone breakpoints for the <emphasis>Enterobacterales</emphasis> and <emphasis>P. aeruginosa</emphasis> were lowered by CLSI and EUCAST (<link linkend="ch0094s000000li0001">1</link>, <link linkend="ch0094s000000li0009">9</link>). The implications of the breakpoint changes based on selective culture methods for surveillance of fluoroquinolone-resistant Gram-negative bacilli are not known at this time.</para>
      </sect2>
      <sect2 id="ch0094s0015s0003">
        <title>Tests for Detecting Colistin Resistance among Gram-Negative Bacilli</title>
        <anchor id="ch0094s000015a0004"/>
        <anchor id="ch0094s000000a0106"/>
        <para id="ch0094s000000p0191">The polymyxins colistin (polymyxin E) and polymyxin B are considered salvage therapy for treatment of MDR Gram-negative infections. They are large polycationic antimicrobial peptides that bind to the negatively charged cell wall of Gram-negative bacteria, causing disruption of the outer membrane and leading to leakage of intracellular contents and eventually to cell death (<link linkend="ch0094s000000li0270">270</link>). Although colistin and polymyxin B are similar molecules with the same mechanism of action, they differ considerably in the PK-PD parameters of their clinical formulations, requiring establishment of clinical breakpoints for each agent individually (<link linkend="ch0094s000000li0271">271</link>). The clinical use of polymyxins has been fraught with problems, including issues with AST methods and the lack of robust clinical outcome studies.</para>
        <para id="ch0094s000000p0192">Until recently, colistin resistance among Gram-negative bacilli was mediated by chromosomal mutations in the two-component regulatory system for synthesis of lipid A, resulting in a decrease in the net negative charge of the lipopolysaccharide (<link linkend="ch0094s000000li0270">270</link>). This change in the lipopolysaccharide results in reduction of binding of the positively charged agents, leading to resistance. However, plasmid-mediated colistin resistance was discovered in China in 2015 and has since been reported on every continent (<link linkend="ch0094s000000li0272">272</link>). The new resistance determinant was named <emphasis>mcr1</emphasis> and is a plasmid-encoded phosphoethanolamine transferase, which adds a phosphoethanolamine group to lipid A, decreasing the negative charge (<link linkend="ch0094s000000li0005">5</link>). To date (March, 2023), ten slightly different variants of the <emphasis>mcr-1</emphasis> gene (<emphasis>mcr-1</emphasis> to <emphasis>mcr-10</emphasis>) have been identified in different bacteria isolated from animals, foods, farms, humans, and the environment (<link linkend="ch0094s000000li0273">273</link>). MCR enzymes require zinc for activity, and so phenotypic inhibition tests using divalent chelators such as EDTA or dipicolinic acid (similar to MBL tests) have been described (<link linkend="ch0094s000000li0274">274</link>–<link linkend="ch0094s000000li0276">276</link>). In addition to inhibitor-based tests, lateral-flow assays for the detection of MCR-1 with cross-reactivity with MCR-2 have been described with good performance characteristics (<link linkend="ch0094s000000li0276">276</link>, <link linkend="ch0094s000000li0277">277</link>).</para>
        <anchor id="ch0094s000000a0107"/>
        <beginpage pagenum="1481"/>
        <para id="ch0094s000000p0193">To establish standardized breakpoints and address the challenges with colistin AST, CLSI and EUCAST formed a joint working group (polymyxin B was not studied). In 2016, clinical breakpoints for colistin were set for<emphasis>Acinetobacter</emphasis> spp. and <emphasis>P. aeruginosa</emphasis> spp. (susceptible, 2 μg/ml, and resistant, 4 μg/ml). For many years, CLSI did not have breakpoints for the <emphasis>Enterobacterales</emphasis> due to the lack of clinical and PK-PD data needed to establish breakpoints. However, CLSI recognized that there was a clinical need for guidance on how best to use these antimicrobial agents, especially in areas of the world where newer agents were not available. In 2019, colistin breakpoints were introduced for the <emphasis>Enterobacterales</emphasis> and revised for <emphasis>P. aeruginosa</emphasis> and <emphasis>Acinetobacter</emphasis> species. The breakpoints for these organisms included intermediate (≤2 μg/ml) and resistant (≥4 μg/ml) categories but no susceptible category. The rationale was based primarily on the absence of existing clinical and PK-PD evidence demonstrating that any colistin or polymyxin B MIC predicts clinical efficacy, which indicates that organisms should not be labeled as “susceptible” (<link linkend="ch0094s000000li0278">278</link>). Furthermore, colistin and polymyxin B were deemed equivalent agents, so MICs obtained from testing colistin predict polymyxin B results, and vice versa (<link linkend="ch0094s000000li0001">1</link>).</para>
        <para id="ch0094s000000p0194">AST methods for colistin are problematic due to the physiochemical properties of the drug. The large polycationic peptide has difficulty diffusing through agar, so agar diffusion methods, such as disk diffusion and gradient diffusion, are not recommended due to unacceptably high error rates. In addition, the positively charged agent interacts with the negatively charged polystyrene microtiter plates, resulting in variability in MIC results with low concentrations of the drug. The use of surfactants (polysorbate 80) has been evaluated, but may result in artificially low MICs. Thus, the EUCAST and CLSI joint working group has recommended broth microdilution, without surfactant, as the reference method for testing colistin. Due to the lack of FDA breakpoints, commercial methods developed in the United States are labeled as research use only because the FDA requires that manufacturers use only FDA breakpoints for interpretation of results in a 510K submission for FDA clearance. Thus, without FDA breakpoints, no FDA cleared methods will be available for susceptibility testing of colistin.</para>
        <para id="ch0094s000000p0195">The availability of BMD in clinical laboratories is scarce; thus, simplified methods for identifying colistin resistance among Gram-negative bacteria are required. One such method is the polymyxin NP test, which is a rapid colorimetric assay, similar to the Carba NP test, that detects glucose metabolism in the presence of a pH indicator with a set concentration of colistin (3.75 μg/ml/well). Results are available in 2 h, and use is limited to the<emphasis>Enterobacterales</emphasis> due to the requirement for glucose metabolism. The sensitivity and specificity of the assay have been reported to be 99.3% and 95.4%, respectively (<link linkend="ch0094s000000li0279">279</link>). Resazurin-based assays have since been developed for non-lactose-fermenting Gram-negative bacilli, including <emphasis>P. aeruginosa</emphasis> and <emphasis>A. baumannii</emphasis>, applying a similar concept (<link linkend="ch0094s000000li0280">280</link>). These methods will have limitations similar to those of the Carba NP test, with the requirement of preparing specialized reagents and the subjective nature of interpretation (relying on a color change for interpretation). Moreover, several selective agars have been described for the detection of colistin-resistant Gram-negative bacilli (with both acquired and intrinsic resistance to colistin) from cultured isolates or fecal specimens for surveillance culture purposes (<link linkend="ch0094s000000li0281">281</link>, <link linkend="ch0094s000000li0282">282</link>).</para>
        <para id="ch0094s000000p0196">In 2020, CLSI endorsed two new methods for the determination of colistin MICs for<emphasis>Enterobacterales</emphasis> and <emphasis>P. aeruginosa</emphasis>: (i) the colistin agar test and (ii) the colistin broth-disk elution method. The colistin agar test is a modified agar dilution test that uses a different inoculum and approach to interpreting results than standard agar dilution testing. Mueller-Hinton agar plates containing 0, 1, 2, and 4 μg/ml are prepared and inoculated with a pipette or 10 μl loop of a 1:10 dilution of a 0.5 McFarland turbidity standard of the test organism. The plates are incubated overnight, and the MIC is read at the lowest colistin agar plate concentration that completely inhibits growth of the test isolate. The broth-disk elution method is a simple historical method that was described in 1972 for anaerobic susceptibility testing (<link linkend="ch0094s000000li0283">283</link>). The method adapted for colistin testing requires the use of four 10-ml CA-MHB broths per isolate with 0, 1, 2, and 4 colistin (10 μg) disks added to the broths for a final concentration of 0 (growth control), 1, 2 and 4 μg/ml/tube to determine a MIC (<link linkend="ch0094s000000li0284">284</link>). A multicenter study evaluated these methods using a large cohort of <emphasis>Enterobacterales, P. aeruginosa</emphasis>, and <emphasis>Acinetobacter</emphasis> sp. isolates compared to reference broth microdilution for determining colistin MICs. The methods demonstrated a high degree of categorical agreement (&gt;98%) and essential agreement (&gt;94%) for the <emphasis>Enterobacterales</emphasis> and <emphasis>P. aeruginosa.</emphasis> However, the method was not recommended for <emphasis>Acinetobacter</emphasis> species due to high error rates and the large number of isolates excluded from analysis due to the absence of a reference MIC. Based on these data, the CLSI AST subcommittee endorsed the colistin agar test and colistin broth disk elution method for colistin testing of <emphasis>Enterobacterales</emphasis> and <emphasis>P. aerugin</emphasis><emphasis>osa</emphasis> (<link linkend="ch0094s000000li0285">285</link>).</para>
      </sect2>
      <sect2 id="ch0094s0015s0004">
        <title>CONCLUSION</title>
        <anchor id="ch0094s000015a0005"/>
        <anchor id="ch0094s000000a0108"/>
        <para id="ch0094s000000p0197">Many special phenotypic tests exists to detect antimicrobial resistance among Gram-positive and Gram-negative organisms, as described in this chapter. Generally, these methods have been viewed as less rapid but inexpensive alternatives to molecular tests. Recently, newer technologies and methodologies have been changing this paradigm, providing phenotypic results within time frames that are similar to those achieved with molecular options, increasing their value and uptake into clinical practice. Thus, these special phenotypic tests will continue to play a critical role in our response to the global public health threat that antimicrobial resistance poses.</para>
        <anchor id="ch0094s000000a0109"/>
        <beginpage pagenum="1482"/>
      </sect2>
      <sect2 id="ch0094s0015s0005">
        <title>REFERENCES</title>
        <anchor id="ch0094s000015a0006"/>
        <anchor id="ch0094s000000a0110"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0094s000000li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2022. <citetitle><emphasis>Performance Standards for Antimicrobial Susceptibility Testing; Informational Supplement. M100S</emphasis></citetitle>, 32nd ed. CLSI, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0094s000000li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Ellington MJ, Ekelund O, Aarestrup FM, Canton R, Doumith M, Giske C, Grundman H, Hasman H, Holden MTG, Hopkins KL, Iredell J, Kahlmeter G, Köser CU, MacGowan A, Mevius D, Mulvey M, Naas T, Peto T, Rolain JM, Samuelsen Ø, Woodford N.</emphasis> 2017. The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">23:</emphasis>2–22.</para>
          </listitem>
          <listitem id="ch0094s000000li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Glupczynski Y, Jousset A, Evrard S, Bonnin RA, Huang TD, Dortet L, Bogaerts P, Naas T.</emphasis> 2017. Prospective evaluation of the OKN K-SeT assay, a new multiplex immunochromatographic test for the rapid detection of OXA-48-like, KPC and NDM carbapenemases. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">72:</emphasis>1955–1960.</para>
          </listitem>
          <listitem id="ch0094s000000li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Nordmann P, Poirel L, Dortet L.</emphasis> 2012. Rapid detection of carbapenemase-producing <citetitle><emphasis>Enterobacteriaceae. Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">18:</emphasis>1503–1507.</para>
          </listitem>
          <listitem id="ch0094s000000li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">EUCAST.</emphasis> 2017. EUCAST guidelines for detection of resistance mechanisms and specific resistance of clinical and/or epidemiological importance. <ulink url="http://www.eucast.org/resistance_mechanisms/">http://www.eucast.org/resistance_mechanisms/</ulink></para>
          </listitem>
          <listitem id="ch0094s000000li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">McHardy IH, Veltman J, Hindler J, Bruxvoort K, Carvalho MM, Humphries RM.</emphasis> 2017. Clinical and microbiological aspects of β-lactam resistance in <citetitle><emphasis>Staphylococcus lugdunensis. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>585–595.</para>
          </listitem>
          <listitem id="ch0094s000000li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Resman F, Thegerström J, Månsson F, Ahl J, Tham J, Riesbeck K.</emphasis> 2016. The prevalence, population structure and screening test specificity of penicillin-susceptible <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> bacteremia isolates in Malmö, Sweden. <citetitle><emphasis>J Infect</emphasis></citetitle> <emphasis role="strong">73:</emphasis>129–135.</para>
          </listitem>
          <listitem id="ch0094s000000li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Chabot MR, Stefan MS, Friderici J, Schimmel J, Larioza J.</emphasis> 2015. Reappearance and treatment of penicillin-susceptible <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> in a tertiary medical centre. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">70:</emphasis>3353–3356.</para>
          </listitem>
          <listitem id="ch0094s000000li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">EUCAST.</emphasis> 2022. European Commitee on Antimicrobial Susceptibility Testing breakpoint tables for interpretation of MICs and zone diameters. version 12.0. <ulink url="https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf">https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf</ulink></para>
          </listitem>
          <listitem id="ch0094s000000li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Kaase M, Lenga S, Friedrich S, Szabados F, Sakinc T, Kleine B, Gatermann SG.</emphasis> 2008. Comparison of phenotypic methods for penicillinase detection in <citetitle><emphasis>Staphylococcus aureus. Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">14:</emphasis>614–616.</para>
          </listitem>
          <listitem id="ch0094s000000li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Miller WR, Seas C, Carvajal LP, Diaz L, Echeverri AM, Ferro C, Rios R, Porras P, Luna C, Gotuzzo E, Munita JM, Nannini E, Carcamo C, Reyes J, Arias CA.</emphasis> 2018. The cefazolin inoculum effect is associated with increased mortality in methicillin-susceptible <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> bacteremia. <citetitle><emphasis>Open Forum Infect Dis</emphasis></citetitle> <emphasis role="strong">5:</emphasis>ofy123.</para>
          </listitem>
          <listitem id="ch0094s000000li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Dingle TC, Gamage D, Gomez-Villegas S, Hanson BM, Reyes J, Abbott A, Burnham CD, Dien Bard J, Fritz S, Miller WR, Westblade LF, Zimmer B, Arias CA, Butler-Wu S, CLSI Cefazolin High Inoculum Ad-Hoc Working Group.</emphasis> 2022. Prevalence and characterization of the cefazolin inoculum effect in North American methicillin-susceptible <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> isolates. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">60:</emphasis>e02495-21.</para>
          </listitem>
          <listitem id="ch0094s000000li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Metzidie E, Manolis EN, Pournaras S, Sofianou D, Tsakris A.</emphasis> 2006. Spread of an unusual penicillin- and imipenem-resistant but ampicillin-susceptible phenotype among <citetitle><emphasis>Enterococcus faecalis</emphasis></citetitle> clinical isolates. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">57:</emphasis>158–160.</para>
          </listitem>
          <listitem id="ch0094s000000li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Weinstein MP, Mirrett S, Kannangara S, Monahan J, Harrell LJ, Wilson AC, Reller LB.</emphasis> 2004. Multicenter evaluation of use of penicillin and ampicillin as surrogates for in vitro testing of susceptibility of enterococci to imipenem. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>3747–3751.</para>
          </listitem>
          <listitem id="ch0094s000000li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Murray BE, Mederski-Samaroj B.</emphasis> 1983. Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in <citetitle><emphasis>Streptococcus faecalis. J Clin Invest</emphasis></citetitle> <emphasis role="strong">72:</emphasis>1168–1171.</para>
          </listitem>
          <listitem id="ch0094s000000li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Handwerger S, Perlman DC, Altarac D, McAuliffe V.</emphasis> 1992. Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">14:</emphasis>655–661.</para>
          </listitem>
          <listitem id="ch0094s000000li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Murray BE, Singh KV, Markowitz SM, Lopardo HA, Patterson JE, Zervos MJ, Rubeglio E, Eliopoulos GM, Rice LB, Goldstein FW, Jenkins SG, Caputo GM, Nasnas R, Moore LS, Wong ES, Weinstock G.</emphasis> 1991. Evidence for clonal spread of a single strain of beta-lactamase-producing <citetitle><emphasis>Enterococcus</emphasis></citetitle> (<citetitle><emphasis>Streptococcus</emphasis></citetitle>) <citetitle><emphasis>faecalis</emphasis></citetitle> to six hospitals in five states. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">163:</emphasis>780–785.</para>
          </listitem>
          <listitem id="ch0094s000000li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Coudron PE, Markowitz SM, Wong ES.</emphasis> 1992. Isolation of a beta-lactamase-producing, aminoglycoside-resistant strain of <citetitle><emphasis>Enterococcus faecium. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">36:</emphasis>1125–1126.</para>
          </listitem>
          <listitem id="ch0094s000000li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Sarti M, Campanile F, Sabia C, Santagati M, Gargiulo R, Stefani S.</emphasis> 2012. Polyclonal diffusion of beta-lactamase-producing <citetitle><emphasis>Enterococcus faecium. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>169–172.</para>
          </listitem>
          <listitem id="ch0094s000000li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2017. <citetitle><emphasis>Performance Standards for Antimicrobial Susceptibility Testing. Twenty-seventh Informational Supplement. M100S</emphasis></citetitle>, 27th ed. CLSI, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0094s000000li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Swenson JM, Hill BC, Thornsberry C.</emphasis> 1986. Screening pneumococci for penicillin resistance. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">24:</emphasis>749–752.</para>
          </listitem>
          <listitem id="ch0094s000000li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Doern GV, Brueggemann AB, Pierce G.</emphasis> 1997. Assessment of the oxacillin disk screening test for determining penicillin resistance in S<citetitle><emphasis>treptococcus pneumoniae. Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">16:</emphasis>311–314.</para>
          </listitem>
          <listitem id="ch0094s000000li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">Saeed K, Marsh P, Ahmad N.</emphasis> 2014. Cryptic resistance in <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle>: a risk for the treatment of skin infection? <citetitle><emphasis>Curr Opin Infect Dis</emphasis></citetitle> <emphasis role="strong">27:</emphasis>130–136.</para>
          </listitem>
          <listitem id="ch0094s000000li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Chambers HF, Archer G, Matsuhashi M.</emphasis> 1989. Low-level methicillin resistance in strains of <citetitle><emphasis>Staphylococcus aureus. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">33:</emphasis>424–428</para>
          </listitem>
          <listitem id="ch0094s000000li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Hartman BJ, Tomasz A.</emphasis> 1986. Expression of methicillin resistance in heterogeneous strains of <citetitle><emphasis>Staphylococcus aureus. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">29:</emphasis>85–92.</para>
          </listitem>
          <listitem id="ch0094s000000li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Tomasz A, Nachman S, Leaf H.</emphasis> 1991. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">35:</emphasis>124–129.</para>
          </listitem>
          <listitem id="ch0094s000000li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Swenson JM, Brasso WB, Ferraro MJ, Hardy DJ, Knapp CC, Lonsway D, McAllister S, Reller LB, Sader HS, Shortridge D, Skov R, Weinstein MP, Zimmer BL, Patel JB.</emphasis> 2009. Correlation of cefoxitin MICs with the presence of <citetitle><emphasis>mecA</emphasis></citetitle> in <citetitle><emphasis>Staphylococcus</emphasis></citetitle> spp. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>1902–1905.</para>
          </listitem>
          <listitem id="ch0094s000000li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Swenson JM, Tenover FC, Cefoxitin Disk Study Group.</emphasis> 2005. Results of disk diffusion testing with cefoxitin correlate with presence of <citetitle><emphasis>mecA</emphasis></citetitle> in <citetitle><emphasis>Staphylococcus</emphasis></citetitle> spp. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>3818–3823.</para>
          </listitem>
          <listitem id="ch0094s000000li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Humphries RM, Magnano P, Burnham CA, Dien Bard J, Dingle TC, Callan K, Westblade LF.</emphasis> 2020. Evaluation of surrogate tests for the presence of <citetitle><emphasis>mecA</emphasis></citetitle>-mediated methicillin resistance in <citetitle><emphasis>Staphylococcus capitis</emphasis></citetitle>, <citetitle><emphasis>Staphylococcus haemolyticus</emphasis></citetitle>, <citetitle><emphasis>Staphylococcus hominis</emphasis></citetitle>, and <citetitle><emphasis>Staphylococcus warneri. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e02290-20.</para>
          </listitem>
          <listitem id="ch0094s000000li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Huse HK, Miller SA, Chandrasekaran S, Hindler JA, Lawhon SD, Bemis DA, Westblade LF, Humphries RM.</emphasis> 2018. Evaluation of oxacillin and cefoxitin disk diffusion and MIC breakpoints established by the Clinical and Laboratory Standards Institute for detection of <citetitle><emphasis>mecA</emphasis></citetitle>-mediated oxacillin resistance in <citetitle><emphasis>Staphylococcus schleiferi. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>e01653-17.</para>
          </listitem>
          <listitem id="ch0094s000000li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Wu MT, Burnham CA, Westblade LF, Dien Bard J, Lawhon SD, Wallace MA, Stanley T, Burd E, Hindler J, Humphries RM.</emphasis> 2016. Evaluation of oxacillin and cefoxitin disk and MIC breakpoints for prediction of methicillin resistance in human and veterinary isolates of <citetitle><emphasis>Staphylococcus intermedius</emphasis></citetitle> group. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>535–542.</para>
          </listitem>
          <listitem id="ch0094s000000li0032" role="bibliographyEntry">
            <anchor id="ch0094s000000a0111"/>
            <para>32.<emphasis role="strong">Swenson JM, Lonsway D, McAllister S, Thompson A, Jevitt L, Zhu W, Patel JB.</emphasis> 2007. Detection of <citetitle><emphasis>mecA</emphasis></citetitle>-mediated resistance using reference and commercial testing methods in a collection of <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> expressing borderline oxacillin MICs. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">58:</emphasis>33–39.</para>
          </listitem>
          <listitem id="ch0094s000000li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Naccache SN, Callan K, Burnham CA, Wallace MA, Westblade LF, Dien Bard J, Staphylococcus Ad Hoc Working Group of the CLSI Antimicrobial Susceptibility Testing Subcommittee.</emphasis> 2019. Evaluation of oxacillin and cefoxitin disk diffusion and microbroth dilution methods for detecting <citetitle><emphasis>mecA</emphasis></citetitle>-mediated β-lactam resistance in contemporary <citetitle><emphasis>Staphylococcus epidermidis</emphasis></citetitle> isolates. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>e00961-19.</para>
          </listitem>
          <listitem id="ch0094s000000li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Paterson GK, Harrison EM, Craven EF, Petersen A, Larsen AR, Ellington MJ, Török ME, Peacock SJ, Parkhill J, Zadoks RN, Holmes MA.</emphasis> 2013. Incidence and characterisation of methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> (MRSA) from nasal colonisation in participants attending a cattle veterinary conference in the UK. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e68463.</para>
          </listitem>
          <listitem id="ch0094s000000li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Paterson GK, Harrison EM, Holmes MA.</emphasis> 2014. The emergence of <citetitle><emphasis>mecC</emphasis></citetitle> methicillin-resistant <citetitle><emphasis>Staphylococcus aureus. Trends Microbiol</emphasis></citetitle> <emphasis role="strong">22:</emphasis>42–47.</para>
          </listitem>
          <listitem id="ch0094s000000li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Paterson GK, Morgan FJ, Harrison EM, Cartwright EJ, Török ME, Zadoks RN, Parkhill J, Peacock SJ, Holmes MA.</emphasis> 2014. Prevalence and characterization of human <citetitle><emphasis>mecC</emphasis></citetitle> methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> isolates in England. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">69:</emphasis>907–910.</para>
          </listitem>
          <listitem id="ch0094s000000li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Lakhundi S, Zhang K.</emphasis> 2018. Methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle>: molecular characterization, evolution, and epidemiology. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">31:</emphasis>e00020-18.</para>
          </listitem>
          <listitem id="ch0094s000000li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Kriegeskorte A, Idelevich EA, Schlattmann A, Layer F, Strommenger B, Denis O, Paterson GK, Holmes MA, Werner G, Becker K.</emphasis> 2017. Comparison of different phenotypic approaches to screen and detect <citetitle><emphasis>mecC</emphasis></citetitle>-harboring methicillin-resistant <citetitle><emphasis>Staphylococcus aureus. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>e00826-17.</para>
          </listitem>
          <listitem id="ch0094s000000li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Hryniewicz MM, Garbacz K.</emphasis> 2017. Borderline oxacillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> (BORSA)—a more common problem than expected? <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">66:</emphasis>1367–1373.</para>
          </listitem>
          <listitem id="ch0094s000000li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Nomura R, Nakaminami H, Takasao K, Muramatsu S, Kato Y, Wajima T, Noguchi N.</emphasis> 2020. A class A β-lactamase produced by borderline oxacillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> hydrolyses oxacillin. <citetitle><emphasis>J Glob Antimicrob Resist</emphasis></citetitle> <emphasis role="strong">22:</emphasis>244–247.</para>
          </listitem>
          <listitem id="ch0094s000000li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Swenson JM, Williams PP, Killgore G, O’Hara CM, Tenover FC.</emphasis> 2001. Performance of eight methods, including two new rapid methods, for detection of oxacillin resistance in a challenge set of <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> organisms. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>3785–3788.</para>
          </listitem>
          <listitem id="ch0094s000000li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Cauwelier B, Gordts B, Descheemaecker P, Van Landuyt H.</emphasis> 2004. Evaluation of a disk diffusion method with cefoxitin (30 microg) for detection of methicillin-resistant <citetitle><emphasis>Staphylococcus aureus. Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">23:</emphasis>389–392.</para>
          </listitem>
          <listitem id="ch0094s000000li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Felten A, Grandry B, Lagrange PH, Casin I.</emphasis> 2002. Evaluation of three techniques for detection of low-level methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> (MRSA): a disk diffusion method with cefoxitin and moxalactam, the Vitek 2 system, and the MRSA-screen latex agglutination test. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>2766–2771.</para>
          </listitem>
          <listitem id="ch0094s000000li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Resende CA, Figueiredo AM.</emphasis> 1997. Discrimination of methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> from borderline-resistant and susceptible isolates by different methods. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>145–149.</para>
          </listitem>
          <listitem id="ch0094s000000li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Hindler JA, Inderlied CB.</emphasis> 1985. Effect of the source of Mueller-Hinton agar and resistance frequency on the detection of methicillin-resistant <citetitle><emphasis>Staphylococcus aureus. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">21:</emphasis>205–210.</para>
          </listitem>
          <listitem id="ch0094s000000li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Hindler JA, Warner NL.</emphasis> 1987. Effect of source of Mueller-Hinton agar on detection of oxacillin resistance in <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> using a screening methodology. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">25:</emphasis>734–735.</para>
          </listitem>
          <listitem id="ch0094s000000li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Ho PL, Law YH, Liu MC, Lau A, Tong MK, Chow KH, Wu AK, Tse CW, Cheng VC, Que TL.</emphasis> 2021. Improved detection of <citetitle><emphasis>mecA</emphasis></citetitle>-mediated β-lactam resistance in <citetitle><emphasis>Staphylococcus lugdunensis</emphasis></citetitle> using a new oxacillin salt agar screen. <citetitle><emphasis>Front Microbiol</emphasis></citetitle> <emphasis role="strong">12:</emphasis>704552.</para>
          </listitem>
          <listitem id="ch0094s000000li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Flayhart D, Lema C, Borek A, Carroll KC.</emphasis> 2004. Comparison of the BBL CHROMagar Staph aureus agar medium to conventional media for detection of <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> in respiratory samples. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>3566–3569.</para>
          </listitem>
          <listitem id="ch0094s000000li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Hernandez DR, Newton DW, Ledeboer NA, Buchan B, Young C, Clark AE, Connoly J, Wolk DM.</emphasis> 2016. Multicenter evaluation of MRSASelect II chromogenic agar for identification of methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> from wound and nasal specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>305–311.</para>
          </listitem>
          <listitem id="ch0094s000000li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Wolk DM, Marx JL, Dominguez L, Driscoll D, Schifman RB.</emphasis> 2009. Comparison of MRSASelect Agar, CHROMagar methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> (MRSA) medium, and Xpert MRSA PCR for detection of MRSA in nares: diagnostic accuracy for surveillance samples with various bacterial densities. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>3933–3936.</para>
          </listitem>
          <listitem id="ch0094s000000li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Peterson JF, Dionisio AA, Riebe KM, Hall GS, Wilson DA, Whittier S, Dipersio JR, Ledeboer NA.</emphasis> 2010. Alternative use for spectra MRSA chromogenic agar in detection of methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> from positive blood cultures. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>2265–2267.</para>
          </listitem>
          <listitem id="ch0094s000000li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Perez LR, Antunes AL, Bonfanti JW, Pinto JB, Roesch EW, Rodrigues D, Dias CA.</emphasis> 2012. Detection of methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> in clinical specimens from cystic fibrosis patients by use of chromogenic selective agar. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>2506–2508.</para>
          </listitem>
          <listitem id="ch0094s000000li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">van Loo IHM, van Dijk S, Verbakel-Schelle I, Buiting AGM.</emphasis> 2007. Evaluation of a chromogenic agar (MRSASelect) for the detection of meticillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> with clinical samples in The Netherlands. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>491–494.</para>
          </listitem>
          <listitem id="ch0094s000000li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Dupieux C, Kolenda C, Larsen AR, Pichon B, Holmes M, Bes M, Teale C, Dickson E, Hill R, Skov R, Kearns A, Laurent F.</emphasis> 2017. Variable performance of four commercial chromogenic media for detection of methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> isolates harbouring mecC. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">50:</emphasis>263–265.</para>
          </listitem>
          <listitem id="ch0094s000000li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Harrington AT, Mahlen SD, Clarridge JE III.</emphasis> 2010. Significantly larger numbers of methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> bacteria are recovered from polymicrobial respiratory and wound sites by use of chromogenic primary media than by use of conventional culture. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>1350–1353.</para>
          </listitem>
          <listitem id="ch0094s000000li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Wendt C, Havill NL, Chapin KC, Boyce JM, Dickenson R, Eigner U, Schütt S, Fahr AM.</emphasis> 2010. Evaluation of a new selective medium, BD BBL CHROMagar MRSA II, for detection of methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> in different specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>2223–2227.</para>
          </listitem>
          <listitem id="ch0094s000000li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Pape J, Wadlin J, Nachamkin I.</emphasis> 2006. Use of BBL CHROMagar MRSA medium for identification of methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> directly from blood cultures. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>2575–2576.</para>
          </listitem>
          <listitem id="ch0094s000000li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Riedel S, Dam L, Stamper PD, Shah SA, Carroll KC.</emphasis> 2010. Evaluation of Bio-Rad MRSASelect agar for detection of methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> directly from blood cultures. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>2285–2288.</para>
          </listitem>
          <listitem id="ch0094s000000li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Dupieux C, Bouchiat C, Larsen AR, Pichon B, Holmes M, Teale C, Edwards G, Hill R, Decousser JW, Trouillet-Assant S, Petersen A, Skov R, Kearns A, Laurent F.</emphasis> 2017. Detection of <citetitle><emphasis>mecC</emphasis></citetitle>-positive <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle>: what to expect from immunological tests targeting PBP2a? <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>1961–1963.</para>
          </listitem>
          <listitem id="ch0094s000000li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Dupieux C, Trouillet-Assant S, Tasse J, Freydière AM, Raulin O, Roure-Sobas C, Salord H, Tigaud S, Laurent F.</emphasis> 2016. Evaluation of a commercial immunochromatographic assay for rapid routine identification of PBP2a-positive <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> and coagulase-negative staphylococci. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">86:</emphasis>262–264.</para>
          </listitem>
          <listitem id="ch0094s000000li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Leclercq R, Courvalin P.</emphasis> 1997. Resistance to glycopeptides in enterococci. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">24:</emphasis>545–554.</para>
          </listitem>
          <listitem id="ch0094s000000li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Boyd DA, Conly J, Dedier H, Peters G, Robertson L, Slater E, Mulvey MR.</emphasis> 2000. Molecular characterization of the <citetitle><emphasis>vanD</emphasis></citetitle> gene cluster and a novel insertion element in a vancomycin-resistant enterococcus isolated in Canada. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>2392–2394..</para>
          </listitem>
          <listitem id="ch0094s000000li0063" role="bibliographyEntry">
            <anchor id="ch0094s000000a0112"/>
            <para>63.<emphasis role="strong">Finks J, Wells E, Dyke TL, Husain N, Plizga L, Heddurshetti R, Wilkins M, Rudrik J, Hageman J, Patel J, Miller C.</emphasis> 2009. Vancomycin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle>, Michigan, USA, 2007. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>943–945.</para>
          </listitem>
          <listitem id="ch0094s000000li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">McKessar SJ, Berry AM, Bell JM, Turnidge JD, Paton JC.</emphasis> 2000. Genetic characterization of <citetitle><emphasis>vanG</emphasis></citetitle>, a novel vancomycin resistance locus of <citetitle><emphasis>Enterococcus faecalis. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">44:</emphasis>3224–3228.</para>
          </listitem>
          <listitem id="ch0094s000000li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Lebreton F, Depardieu F, Bourdon N, Fines-Guyon M, Berger P, Camiade S, Leclercq R, Courvalin P, Cattoir V.</emphasis> 2011. d-Ala-d-Ser VanN-type transferable vancomycin resistance in <citetitle><emphasis>Enterococcus faecium. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">55:</emphasis>4606–4612.</para>
          </listitem>
          <listitem id="ch0094s000000li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Xu X, Lin D, Yan G, Ye X, Wu S, Guo Y, Zhu D, Hu F, Zhang Y, Wang F, Jacoby GA, Wang M.</emphasis> 2010. <citetitle><emphasis>vanM</emphasis></citetitle>, a new glycopeptide resistance gene cluster found in <citetitle><emphasis>Enterococcus faecium. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>4643–4647.</para>
          </listitem>
          <listitem id="ch0094s000000li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Downing MA, Xiong J, Eshaghi A, McGeer A, Patel SN, Johnstone J.</emphasis> 2015. Vancomycin-variable enterococcal bacteremia. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>3951–3953.</para>
          </listitem>
          <listitem id="ch0094s000000li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Carroll KC, Borek AP, Burger C, Glanz B, Bhally H, Henciak S, Flayhart DC.</emphasis> 2006. Evaluation of the BD Phoenix automated microbiology system for identification and antimicrobial susceptibility testing of staphylococci and enterococci. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>2072–2077.</para>
          </listitem>
          <listitem id="ch0094s000000li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Abele-Horn M, Hommers L, Trabold R, Frosch M.</emphasis> 2006. Validation of VITEK 2 version 4.01 software for detection, identification, and classification of glycopeptide-resistant enterococci. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>71–76.</para>
          </listitem>
          <listitem id="ch0094s000000li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Bobenchik AM, Hindler JA, Giltner CL, Saeki S, Humphries RM.</emphasis> 2014. Performance of Vitek 2 for antimicrobial susceptibility testing of <citetitle><emphasis>Staphylococcus</emphasis></citetitle> spp. and <citetitle><emphasis>Enterococcus</emphasis></citetitle> spp. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>392–397.</para>
          </listitem>
          <listitem id="ch0094s000000li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Fahr AM, Eigner U, Armbrust M, Caganic A, Dettori G, Chezzi C, Bertoncini L, Benecchi M, Menozzi MG.</emphasis> 2003. Two-center collaborative evaluation of the performance of the BD Phoenix automated microbiology system for identification and antimicrobial susceptibility testing of <citetitle><emphasis>Enterococcus</emphasis></citetitle> spp. and <citetitle><emphasis>Staphylococcus</emphasis></citetitle> spp. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>1135–1142.</para>
          </listitem>
          <listitem id="ch0094s000000li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Willey BM, Kreiswirth BN, Simor AE, Willaims G, Scriver SR, Phillips A, Low DE.</emphasis> 1992. Detection of vancomycin resistance in <citetitle><emphasis>Enterococcus</emphasis></citetitle> species. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">30:</emphasis>1621–1624.</para>
          </listitem>
          <listitem id="ch0094s000000li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Swenson JM, Clark NC, Ferraro MJ, Sahm DF, Doern G, Pfaller MA, Reller LB, Weinstein MP, Zabransky RJ, Tenover FC.</emphasis> 1994. Development of a standardized screening method for detection of vancomycin-resistant enterococci. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">32:</emphasis>1700–1704.</para>
          </listitem>
          <listitem id="ch0094s000000li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Reid KC, Cockerill FR III, Patel R.</emphasis> 2001. Clinical and epidemiological features of <citetitle><emphasis>Enterococcus casseliflavus/flavescens</emphasis></citetitle> and <citetitle><emphasis>Enterococcus gallinarum</emphasis></citetitle> bacteremia: a report of 20 cases. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">32:</emphasis>1540–1546.</para>
          </listitem>
          <listitem id="ch0094s000000li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Jenkins SG, Raskoshina L, Schuetz AN.</emphasis> 2011. Comparison of performance of the novel chromogenic spectra VRE agar to that of bile esculin azide and <citetitle><emphasis>Campylobacter</emphasis></citetitle> agars for detection of vancomycin-resistant enterococci in fecal samples. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>3947–3949.</para>
          </listitem>
          <listitem id="ch0094s000000li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Grabsch EA, Ghaly-Derias S, Gao W, Howden BP.</emphasis> 2008. Comparative study of selective chromogenic (chromID VRE) and bile esculin agars for isolation and identification of <citetitle><emphasis>vanB</emphasis></citetitle>-containing vancomycin-resistant enterococci from feces and rectal swabs. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>4034–4036.</para>
          </listitem>
          <listitem id="ch0094s000000li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Gouliouris T, Blane B, Brodrick HJ, Raven KE, Ambridge KE, Kidney AD, Hadjirin NF, Török ME, Limmathurotsakul D, Peacock SJ.</emphasis> 2016. Comparison of two chromogenic media for the detection of vancomycin-resistant enterococcal carriage by nursing home residents. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">85:</emphasis>409–412.</para>
          </listitem>
          <listitem id="ch0094s000000li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Asir K, Wilkinson K, Perry JD, Reed RH, Gould FK.</emphasis> 2009. Evaluation of chromogenic media for the isolation of vancomycin-resistant enterococci from stool samples. <citetitle><emphasis>Lett Appl Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>230–233.</para>
          </listitem>
          <listitem id="ch0094s000000li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Delmas J, Robin F, Schweitzer C, Lesens O, Bonnet R.</emphasis> 2007. Evaluation of a new chromogenic medium, ChromID VRE, for detection of vancomycin-resistant enterococci in stool samples and rectal swabs. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>2731–2733.</para>
          </listitem>
          <listitem id="ch0094s000000li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Suwantarat N, Roberts A, Prestridge J, Seeley R, Speser S, Harmon C, Zhang C, Henciak S, Stamper PD, Ross T, Carroll KC.</emphasis> 2014. Comparison of five chromogenic media for recovery of vancomycin-resistant enterococci from fecal samples. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>4039–4042.</para>
          </listitem>
          <listitem id="ch0094s000000li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Tenover FC, Moellering RC Jr.</emphasis> 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for <citetitle><emphasis>Staphylococcus aureus. Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">44:</emphasis>1208–1215. .</para>
          </listitem>
          <listitem id="ch0094s000000li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Cong Y, Yang S, Rao X.</emphasis> 2019. Vancomycin resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> infections: a review of case updating and clinical features. <citetitle><emphasis>J Adv Res</emphasis></citetitle> <emphasis role="strong">21:</emphasis>169–176.</para>
          </listitem>
          <listitem id="ch0094s000000li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML.</emphasis> 2010. Reduced vancomycin susceptibility in <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle>, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">23:</emphasis>99–139.</para>
          </listitem>
          <listitem id="ch0094s000000li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Howden BP, Peleg AY, Stinear TP.</emphasis> 2014. The evolution of vancomycin intermediate <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> (VISA) and heterogenous-VISA. <citetitle><emphasis>Infect Genet Evol</emphasis></citetitle> <emphasis role="strong">21:</emphasis>575–582.</para>
          </listitem>
          <listitem id="ch0094s000000li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, O’Hara CM, McAllister SK, Clark NC, Hiramatsu K.</emphasis> 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>1020–1027.</para>
          </listitem>
          <listitem id="ch0094s000000li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Nunes AP, Schuenck RP, Bastos CC, Magnanini MM, Long JB, Iorio NL, Santos KR.</emphasis> 2007. Heterogeneous resistance to vancomycin and teicoplanin among <citetitle><emphasis>Staphylococcus</emphasis></citetitle> spp. isolated from bacteremia. <citetitle><emphasis>Braz J Infect Dis</emphasis></citetitle> <emphasis role="strong">11:</emphasis>345–350.</para>
          </listitem>
          <listitem id="ch0094s000000li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Nunes AP, Teixeira LM, Iorio NL, Bastos CC, de Sousa Fonseca L, Souto-Padrón T, dos Santos KR.</emphasis> 2006. Heterogeneous resistance to vancomycin in <citetitle><emphasis>Staphylococcus epidermidis</emphasis></citetitle>, <citetitle><emphasis>Staphylococcus haemolyticus</emphasis></citetitle> and <citetitle><emphasis>Staphylococcus warneri</emphasis></citetitle> clinical strains: characterisation of glycopeptide susceptibility profiles and cell wall thickening. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">27:</emphasis>307–315.</para>
          </listitem>
          <listitem id="ch0094s000000li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Swenson JM, Anderson KF, Lonsway DR, Thompson A, McAllister SK, Limbago BM, Carey RB, Tenover FC, Patel JB.</emphasis> 2009. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate <citetitle><emphasis>Staphylococcus aureus. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>2013–2017.</para>
          </listitem>
          <listitem id="ch0094s000000li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Prakash V, Lewis JS II, Jorgensen JH.</emphasis> 2008. Vancomycin MICs for methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> isolates differ based upon the susceptibility test method used. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">52:</emphasis>4528.</para>
          </listitem>
          <listitem id="ch0094s000000li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I.</emphasis> 1997. Dissemination in Japanese hospitals of strains of <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> heterogeneously resistant to vancomycin. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">350:</emphasis>1670–1673.</para>
          </listitem>
          <listitem id="ch0094s000000li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Walsh TR, Bolmström A, Qwärnström A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D.</emphasis> 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>2439–2444.</para>
          </listitem>
          <listitem id="ch0094s000000li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Wootton M, MacGowan AP, Walsh TR, Howe RA.</emphasis> 2007. A multicenter study evaluating the current strategies for isolating <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> strains with reduced susceptibility to glycopeptides. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>329–332.</para>
          </listitem>
          <listitem id="ch0094s000000li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Riederer K, Shemes S, Chase P, Musta A, Mar A, Khatib R.</emphasis> 2011. Detection of intermediately vancomycin-susceptible and heterogeneous <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> isolates: comparison of Etest and agar screening methods. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>2147–2150.</para>
          </listitem>
          <listitem id="ch0094s000000li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">van Hal SJ, Wehrhahn MC, Barbagiannakos T, Mercer J, Chen D, Paterson DL, Gosbell IB.</emphasis> 2011. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> in bloodstream isolates. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>1489–1494.</para>
          </listitem>
          <listitem id="ch0094s000000li0095" role="bibliographyEntry">
            <anchor id="ch0094s000000a0113"/>
            <para>95.<emphasis role="strong">Yusof A, Engelhardt A, Karlsson A, Bylund L, Vidh P, Mills K, Wootton M, Walsh TR.</emphasis> 2008. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> (GISA), in particular, heterogeneous GISA. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>3042–3047.</para>
          </listitem>
          <listitem id="ch0094s000000li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Arias CA, Murray BE.</emphasis> 2008. Emergence and management of drug-resistant enterococcal infections. <citetitle><emphasis>Expert Rev Anti Infect Ther</emphasis></citetitle> <emphasis role="strong">6:</emphasis>637–655.</para>
          </listitem>
          <listitem id="ch0094s000000li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Murray BE.</emphasis> 1990. The life and times of the <citetitle><emphasis>Enterococcus. Clin Microbiol Re</emphasis></citetitle><citetitle><emphasis>v</emphasis></citetitle> <emphasis role="strong">3:</emphasis>46–65.</para>
          </listitem>
          <listitem id="ch0094s000000li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Moellering RC Jr, Korzeniowski OM, Sande MA, Wennersten CB.</emphasis> 1979. Species-specific resistance to antimocrobial synergism in <citetitle><emphasis>Streptococcus faecium</emphasis></citetitle> and <citetitle><emphasis>Streptococcus faecali</emphasis></citetitle>s. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">140:</emphasis>203–208.</para>
          </listitem>
          <listitem id="ch0094s000000li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Chow JW.</emphasis> 2000. Aminoglycoside resistance in enterococci. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">31:</emphasis>586–589.</para>
          </listitem>
          <listitem id="ch0094s000000li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Foudraine DE, Dekker LJM, Strepis N, Bexkens ML, Klaassen CHW, Luider TM, Goessens WHF.</emphasis> 2019. Accurate detection of the four most prevalent carbapenemases in <citetitle><emphasis>E. coli</emphasis></citetitle> and <citetitle><emphasis>K. pneumoniae</emphasis></citetitle> by high-resolution mass spectrometry. <citetitle><emphasis>Front Microbiol</emphasis></citetitle> <emphasis role="strong">10:</emphasis>2760.</para>
          </listitem>
          <listitem id="ch0094s000000li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Hindler JA, Wong-Beringer A, Charlton CL, Miller SA, Kelesidis T, Carvalho M, Sakoulas G, Nonejuie P, Pogliano J, Nizet V, Humphries R.</emphasis> 2015. <citetitle><emphasis>In vitro</emphasis></citetitle> activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>4279–4288.</para>
          </listitem>
          <listitem id="ch0094s000000li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Fines M, Perichon B, Reynolds P, Sahm DF, Courvalin P.</emphasis> 1999. VanE, a new type of acquired glycopeptide resistance in <citetitle><emphasis>Enterococcus faecalis</emphasis></citetitle> BM4405. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">43:</emphasis>2161–2164.</para>
          </listitem>
          <listitem id="ch0094s000000li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Sahm DF, Boonlayangoor S, Schulz JE.</emphasis> 1991. Detection of high-level aminoglycoside resistance in enterococci other than <citetitle><emphasis>Enterococcus faecalis. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">29:</emphasis>2595–2598.</para>
          </listitem>
          <listitem id="ch0094s000000li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Swenson JM, Ferraro MJ, Sahm DF, Clark NC, Culver DH, Tenover FC, National Committee for Clinical Laboratory Standards Study Group on Enterococci.</emphasis> 1995. Multilaboratory evaluation of screening methods for detection of high-level aminoglycoside resistance in enterococci. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>3008–3018.</para>
          </listitem>
          <listitem id="ch0094s000000li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2015. <citetitle><emphasis>Performance Standards for Antimicrobial Disk Susceptibility Tests</emphasis></citetitle>, 12th ed. <citetitle><emphasis>Approved Standard M02-A12.</emphasis></citetitle> CLSI, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0094s000000li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Sahm DF, Torres C.</emphasis> 1988. High-content aminoglycoside disks for determining aminoglycoside-penicillin synergy against Enterococcus faecalis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">26:</emphasis>257–260.</para>
          </listitem>
          <listitem id="ch0094s000000li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Leclercq R.</emphasis> 2002. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">34:</emphasis>482–492.</para>
          </listitem>
          <listitem id="ch0094s000000li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Lewis JS II, Jorgensen JH.</emphasis> 2005. Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">40:</emphasis>280–285.</para>
          </listitem>
          <listitem id="ch0094s000000li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Lewis JS II, Lepak AJ, Thompson GR III, Craig WA, Andes DR, Sabol-Dzintars KE, Jorgensen JH.</emphasis> 2014. Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">58:</emphasis>1327–1331.</para>
          </listitem>
          <listitem id="ch0094s000000li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC).</emphasis> 2010. Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. <citetitle><emphasis>MMWR Recomm Rep</emphasis></citetitle> <emphasis role="strong">59</emphasis>(RR-10)<emphasis role="strong">:</emphasis>1–36.</para>
          </listitem>
          <listitem id="ch0094s000000li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH.</emphasis> 2003. Practical disk diffusion method for detection of inducible clindamycin resistance in <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> and coagulase-negative staphylococci. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>4740–4744.</para>
          </listitem>
          <listitem id="ch0094s000000li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Raney PM, Tenover FC, Carey RB, McGowan JE Jr, Patel JB.</emphasis> 2006. Investigation of inducible clindamycin and telithromycin resistance in isolates of beta-hemolytic streptococci. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">55:</emphasis>213–218.</para>
          </listitem>
          <listitem id="ch0094s000000li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Jorgensen JH, Crawford SA, McElmeel ML, Fiebelkorn KR.</emphasis> 2004. Detection of inducible clindamycin resistance of staphylococci in conjunction with performance of automated broth susceptibility testing. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1800–1802.</para>
          </listitem>
          <listitem id="ch0094s000000li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Zelazny AM, Ferraro MJ, Glennen A, Hindler JF, Mann LM, Munro S, Murray PR, Reller LB, Tenover FC, Jorgensen JH.</emphasis> 2005. Selection of strains for quality assessment of the disk induction method for detection of inducible clindamycin resistance in staphylococci: a CLSI collaborative study. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>2613–2615.</para>
          </listitem>
          <listitem id="ch0094s000000li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Cookson BD.</emphasis> 1998. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">41:</emphasis>11–18.</para>
          </listitem>
          <listitem id="ch0094s000000li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Eltringham I.</emphasis> 1997. Mupirocin resistance and methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> (MRSA). <citetitle><emphasis>J Hosp Infe</emphasis></citetitle><citetitle><emphasis>ct</emphasis></citetitle> <emphasis role="strong">35:</emphasis>1–8.</para>
          </listitem>
          <listitem id="ch0094s000000li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Swenson JM, Wong B, Simor AE, Thomson RB, Ferraro MJ, Hardy DJ, Hindler J, Jorgensen J, Reller LB, Traczewski M, McDougal LK, Patel JB.</emphasis> 2010. Multicenter study to determine disk diffusion and broth microdilution criteria for prediction of high- and low-level mupirocin resistance in <citetitle><emphasis>Staphylococcus aureus. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>2469–2475.</para>
          </listitem>
          <listitem id="ch0094s000000li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Seah C, Alexander DC, Louie L, Simor A, Low DE, Longtin J, Melano RG.</emphasis> 2012. MupB, a new high-level mupirocin resistance mechanism in <citetitle><emphasis>Staphylococcus aureus. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>1916–1920.</para>
          </listitem>
          <listitem id="ch0094s000000li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Simor AE, Stuart TL, Louie L, Watt C, Ofner-Agostini M, Gravel D, Mulvey M, Loeb M, McGeer A, Bryce E, Matlow A, Canadian Nosocomial Infection Surveillance Program.</emphasis> 2007. Mupirocin-resistant, methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> strains in Canadian hospitals. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">51:</emphasis>3880–3886.</para>
          </listitem>
          <listitem id="ch0094s000000li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Simor AE, Phillips E, McGeer A, Konvalinka A, Loeb M, Devlin HR, Kiss A.</emphasis> 2007. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant <citetitle><emphasis>Staphylococcus aureus</emphasis></citetitle> colonization. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">44:</emphasis>178–185.</para>
          </listitem>
          <listitem id="ch0094s000000li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL.</emphasis> 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">18:</emphasis>268–281.</para>
          </listitem>
          <listitem id="ch0094s000000li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Papp-Wallace KM, Mack AR, Taracila MA, Bonomo RA.</emphasis> 2020. Resistance to novel β-lactam-β-lactamase inhibitor combinations: the “price of progress”. <citetitle><emphasis>Infect Dis Clin North Am</emphasis></citetitle> <emphasis role="strong">34:</emphasis>773–819.</para>
          </listitem>
          <listitem id="ch0094s000000li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ.</emphasis> 2022. IDSA guidance on the treatment of antimicrobial-resistant Gram-negative infections: version 1.0. <ulink url="https://www.idsociety.org/practice-guideline/amr-guidance/#">https://www.idsociety.org/practice-guideline/amr-guidance/#</ulink>. Accessed July 2022.</para>
          </listitem>
          <listitem id="ch0094s000000li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ.</emphasis> 2022. IDSA guidance on the treatment of antimicrobial-resistant Gram-negative infections: version 2.0. <ulink url="https://www.idsociety.org/practice-guideline/amr-guidance-2.0/">https://www.idsociety.org/practice-guideline/amr-guidance-2.0/</ulink>. Accessed July 2022.</para>
          </listitem>
          <listitem id="ch0094s000000li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Gniadek TJ, Carroll KC, Simner PJ.</emphasis> 2016. Carbapenem-resistant non-glucose-fermenting Gram-negative bacilli: the missing piece to the puzzle. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>1700–1710.</para>
          </listitem>
          <listitem id="ch0094s000000li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Schotte L, Wautier M, Martiny D, Piérard D, Depypere M.</emphasis> 2019. Detection of beta-lactamase-negative ampicillin resistance in <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> in Belgium. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">93:</emphasis>243–249.</para>
          </listitem>
          <listitem id="ch0094s000000li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Blondeau JM, Vaughan D, Laskowski R, Borsos S, Canadian Antimicrobial Study Group.</emphasis> 2001. Susceptibility of Canadian isolates of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle>, <citetitle><emphasis>Moraxella catarrhalis</emphasis></citetitle> and <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle> to oral antimicrobial agents. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">17:</emphasis>457–464.</para>
          </listitem>
          <listitem id="ch0094s000000li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Felmingham D, Grüneberg RN.</emphasis> 2000. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">45:</emphasis>191–203.</para>
          </listitem>
          <listitem id="ch0094s000000li0129" role="bibliographyEntry">
            <anchor id="ch0094s000000a0114"/>
            <para>129.<emphasis role="strong">McNamara LA, Potts C, Blain AE, Retchless AC, Reese N, Swint S, Lonsway D, Karlsson M, Lunquest K, Sweitzer JJ, Wang X, Hariri S, Fox LM, Dhungana N, Gabrio-Brannon R, Kyle J, Martin B, Barnes M, Moore A, Hannagan S, Keating P, Li S, Albertson J, Fleming W, Lurie P, Russell C, Reid K, Sanders K, DeBolt C, Graff N, Lam E, Hanisch B, Taormina G, Antimicrobial-Resistant Neisseria meningitidis Team.</emphasis> 2020. Detection of ciprofloxacin-resistant, β-lactamase-producing <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> serogroup Y isolates - United States, 2019-2020. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">69:</emphasis>735–739.</para>
          </listitem>
          <listitem id="ch0094s000000li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Schuetz AN.</emphasis> 2014. Antimicrobial resistance and susceptibility testing of anaerobic bacteria. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">59:</emphasis>698–705.</para>
          </listitem>
          <listitem id="ch0094s000000li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Bush K.</emphasis> 2001. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">32:</emphasis>1085–1089.</para>
          </listitem>
          <listitem id="ch0094s000000li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Paterson DL, Bonomo RA.</emphasis> 2005. Extended-spectrum beta-lactamases: a clinical update. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">18:</emphasis>657–686.</para>
          </listitem>
          <listitem id="ch0094s000000li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Castanheira M, Simner PJ, Bradford PA.</emphasis> 2021. Extended-spectrum beta-lactamases: an update on their characteristics, epidemiology and detection. JAC Antimicrob Resist 3<emphasis role="strong">:</emphasis>dlab092.</para>
          </listitem>
          <listitem id="ch0094s000000li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J, Athan E, Paul SK, Baker P, Harris-Brown T, Paterson DL.</emphasis> 2015. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible <citetitle><emphasis>Escherichia coli</emphasis></citetitle> and <citetitle><emphasis>Klebsiella</emphasis></citetitle> spp (the MERINO trial): study protocol for a randomised controlled trial. <citetitle><emphasis>Trials</emphasis></citetitle> <emphasis role="strong">16:</emphasis>24.</para>
          </listitem>
          <listitem id="ch0094s000000li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Henderson A, Paterson DL, Chatfield MD, Tambyah PA, Lye DC, De PP</emphasis>, <emphasis role="strong">Lin RTP, Chew K L, Yin M, Lee TH, Yilmaz M, Cakmak R, Alenazi TH, Arabi YM, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj SS, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke DFM, Runnegar NJ, Miyakis S, Walls G, Khamis MAI, Zikri A, Crowe A, Ingram PR, Daneman N, Griffin P, Athan E, Roberts L, Beatson SA, Peleg AY, Cottrell K, Bauer MJ, Tan E, Chaw K, Nimmo GR, Harris-Brown T, Harris PNA, MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN).</emphasis> 2021. Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO Study. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>e3842–e3850.</para>
          </listitem>
          <listitem id="ch0094s000000li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Robberts FJ, Kohner PC, Patel R.</emphasis> 2009. Unreliable extended-spectrum beta-lactamase detection in the presence of plasmid-mediated AmpC in <citetitle><emphasis>Escherichia coli</emphasis></citetitle> clinical isolates. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>358–361.</para>
          </listitem>
          <listitem id="ch0094s000000li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Bobenchik AM, Deak E, Hindler JA, Charlton CL, Humphries RM.</emphasis> 2015. Performance of Vitek 2 for antimicrobial susceptibility testing of <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>816–823.</para>
          </listitem>
          <listitem id="ch0094s000000li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">El-Jade MR, Parcina M, Schmithausen RM, Stein C, Meilaender A, Hoerauf A, Molitor E, Bekeredjian-Ding I.</emphasis> 2016. ESBL detection: comparison of a commercially available chromogenic test for third generation cephalosporine resistance and automated susceptibility testing in <citetitle><emphasis>Enterobactericeae. PLoS One</emphasis></citetitle> <emphasis role="strong">11</emphasis><emphasis role="strong">:</emphasis>e0160203.</para>
          </listitem>
          <listitem id="ch0094s000000li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">Espinar MJ, Rocha R, Ribeiro M, Gonçalves Rodrigues A, Pina-Vaz C.</emphasis> 2011. Extended-spectrum β-lactamases of <citetitle><emphasis>Escherichia coli</emphasis></citetitle> and <citetitle><emphasis>Klebsiella pneumoniae</emphasis></citetitle> screened by the VITEK 2 system. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">60:</emphasis>756–760.</para>
          </listitem>
          <listitem id="ch0094s000000li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Fisher MA, Stamper PD, Hujer KM, Love Z, Croft A, Cohen S, Bonomo RA, Carroll KC, Petti CA.</emphasis> 2009. Performance of the Phoenix bacterial identification system compared with disc diffusion methods for identifying extended-spectrum beta-lactamase, AmpC and KPC producers. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>774–778.</para>
          </listitem>
          <listitem id="ch0094s000000li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Patterson JE.</emphasis> 2000. Extended-spectrum beta-lactamases. <citetitle><emphasis>Semin Respir Infect</emphasis></citetitle> <emphasis role="strong">15:</emphasis>299–307.</para>
          </listitem>
          <listitem id="ch0094s000000li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">Willems E, Cartuyvels R, Magerman K, Raymaekers M, Verhaegen J.</emphasis> 2013. Comparison of different phenotypic assays for the detection of extended-spectrum β-lactamase production by inducible AmpC-producing Gram-negative bacilli. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">32:</emphasis>549–555.</para>
          </listitem>
          <listitem id="ch0094s000000li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Garrec H, Drieux-Rouzet L, Golmard JL, Jarlier V, Robert J.</emphasis> 2011. Comparison of nine phenotypic methods for detection of extended-spectrum beta-lactamase production by <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>1048–1057.</para>
          </listitem>
          <listitem id="ch0094s000000li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">Nordmann P, Dortet L, Poirel L.</emphasis> 2012. Rapid detection of extended-spectrum-β-lactamase-producing <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>3016–3022.</para>
          </listitem>
          <listitem id="ch0094s000000li0145" role="bibliographyEntry">
            <para>145.<emphasis role="strong">Poirel L, Fernández J, Nordmann P.</emphasis> 2016. Comparison of three biochemical tests for rapid detection of extended-spectrum-β-lactamase-producing <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>423–427.</para>
          </listitem>
          <listitem id="ch0094s000000li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Dortet L, Poirel L, Nordmann P.</emphasis> 2014. Rapid detection of extended-spectrum-β-lactamase-producing enterobacteriaceae from urine samples by use of the ESBL NDP test. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>3701–3706.</para>
          </listitem>
          <listitem id="ch0094s000000li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">Affolabi D, Sogbo F, Laleye G, Orekan J, Massou F, Kehinde A, Anagonou S.</emphasis> 2017. Rapid detection of extended-spectrum-β-lactamase-producing Enterobacteriaceae in blood cultures using the ESBL NDP test in Cotonou, Benin. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">66:</emphasis>884–887.</para>
          </listitem>
          <listitem id="ch0094s000000li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Morosini MI, García-Castillo M, Tato M, Gijón D, Valverde A, Ruiz-Garbajosa P, Cantón R.</emphasis> 2014. Rapid detection of β-lactamase-hydrolyzing extended-spectrum cephalosporins in <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> by use of the new chromogenic βLacta test. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>1741–1744.</para>
          </listitem>
          <listitem id="ch0094s000000li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Renvoisé A, Decré D, Amarsy-Guerle R, Huang TD, Jost C, Podglajen I, Raskine L, Genel N, Bogaerts P, Jarlier V, Arlet G.</emphasis> 2013. Evaluation of the βLacta test, a rapid test detecting resistance to third-generation cephalosporins in clinical strains of <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>4012–4017.</para>
          </listitem>
          <listitem id="ch0094s000000li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Gallah S, Decré D, Genel N, Arlet G.</emphasis> 2014. The β-Lacta test for direct detection of extended-spectrum-β-lactamase-producing <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> in urine. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>3792–3794.</para>
          </listitem>
          <listitem id="ch0094s000000li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Amzalag J, Mizrahi A, Naouri D, Nguyen JC, Ganansia O, Le Monnier A.</emphasis> 2016. Optimization of the β LACTA test for the detection of extended-spectrum-β-lactamase-producing bacteria directly in urine samples. <citetitle><emphasis>Infect Dis (Lond)</emphasis></citetitle> <emphasis role="strong">48:</emphasis>695–698.</para>
          </listitem>
          <listitem id="ch0094s000000li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Gallah S, Benzarara Y, Tankovic J, Woerther PL, Bensekri H, Mainardi JL, Arlet G, Vimont S, Garnier M.</emphasis> 2017. beta-LACTA(R) test performance for detection of extended-spectrum-beta-lactamase-producing Gram negative bacilli directly on bronchial aspirates samples: a validation study. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">24:</emphasis>402–408.</para>
          </listitem>
          <listitem id="ch0094s000000li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Prod’hom G, Durussel C, Blanc D, Croxatto A, Greub G.</emphasis> 2015. Early detection of extended-spectrum β-lactamase from blood culture positive for an <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> using βLACTA test. <citetitle><emphasis>New Microbes New Infect</emphasis></citetitle> <emphasis role="strong">8:</emphasis>1–3.</para>
          </listitem>
          <listitem id="ch0094s000000li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Bernabeu S, Ratnam KC, Boutal H, Gonzalez C, Vogel A, Devilliers K, Plaisance M, Oueslati S, Malhotra-Kumar S, Dortet L, Fortineau N, Simon S, Volland H, Naas T.</emphasis> 2020. A lateral flow immunoassay for the rapid identification of CTX-M-producing <citetitle><emphasis>Enterobacterales</emphasis></citetitle> from culture plates and positive blood cultures. <citetitle><emphasis>Diagnostics (Basel)</emphasis></citetitle> <emphasis role="strong">10:</emphasis>764.</para>
          </listitem>
          <listitem id="ch0094s000000li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Bianco G, Boattini M, Iannaccone M, Cavallo R, Costa C.</emphasis> 2020. Evaluation of the NG-Test CTX-M MULTI immunochromatographic assay for the rapid detection of CTX-M extended-spectrum-β-lactamase producers from positive blood cultures. <citetitle><emphasis>J Hosp Infect</emphasis></citetitle> <emphasis role="strong">105:</emphasis>341–343.</para>
          </listitem>
          <listitem id="ch0094s000000li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Ortiz de la Rosa JM, Demord A, Poirel L, Greub G, Blanc D, Nordmann P.</emphasis> 2021. False immunological detection of CTX-M enzymes in <citetitle><emphasis>Klebsiella oxytoca. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e00609-21.</para>
          </listitem>
          <listitem id="ch0094s000000li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Moguet C, Gonzalez C, Sallustrau A, Gelhaye S, Naas T, Simon S, Volland H.</emphasis> 2022. Detection of expanded-spectrum cephalosporin hydrolysis by lateral flow immunoassay. <citetitle><emphasis>Microb Biotechnol</emphasis></citetitle> <emphasis role="strong">15:</emphasis>603–612.</para>
          </listitem>
          <listitem id="ch0094s000000li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Gonzalez C, Moguet C, Chalin A, Oueslati S, Dortet L, Simon S, Volland H, Naas T.</emphasis> 2022. Comparison of three expanded-spectrum cephalosporin hydrolysis assays and the NG-Test CTX-M Multi assay that detects all CTX-M-like enzymes. <citetitle><emphasis>Diagnostics (Basel)</emphasis></citetitle> <emphasis role="strong">12:</emphasis>197.</para>
          </listitem>
          <listitem id="ch0094s000000li0159" role="bibliographyEntry">
            <anchor id="ch0094s000000a0115"/>
            <para>159.<emphasis role="strong">Gazin M, Paasch F, Goossens H, Malhotra-Kumar S, Mosar WP, MOSAR WP2 and SATURN WP1 Study Teams.</emphasis> 2012. Current trends in culture-based and molecular detection of extended-spectrum-β-lactamase-harboring and carbapenem-resistant <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>1140–1146.</para>
          </listitem>
          <listitem id="ch0094s000000li0160" role="bibliographyEntry">
            <para>160.<emphasis role="strong">Glupczynski Y, Berhin C, Bauraing C, Bogaerts P.</emphasis> 2007. Evaluation of a new selective chromogenic agar medium for detection of extended-spectrum beta-lactamase-producing <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>501–505.</para>
          </listitem>
          <listitem id="ch0094s000000li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Huang TD, Bogaerts P, Berhin C, Guisset A, Glupczynski Y.</emphasis> 2010. Evaluation of Brilliance ESBL agar, a novel chromogenic medium for detection of extended-spectrum-beta-lactamase-producing <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>2091–2096.</para>
          </listitem>
          <listitem id="ch0094s000000li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">Willems E, Cartuyvels R, Magerman K, Verhaegen J.</emphasis> 2013. Evaluation of 3 different agar media for rapid detection of extended-spectrum β-lactamase-producing <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> from surveillance samples. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">76:</emphasis>16–19.</para>
          </listitem>
          <listitem id="ch0094s000000li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Grohs P, Tillecovidin B, Caumont-Prim A, Carbonnelle E, Day N, Podglajen I, Gutmann L.</emphasis> 2013. Comparison of five media for detection of extended-spectrum beta-lactamase by use of the Wasp instrument for automated specimen processing. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>2713–2716.</para>
          </listitem>
          <listitem id="ch0094s000000li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Philippon A, Arlet G, Jacoby GA.</emphasis> 2002. Plasmid-determined AmpC-type beta-lactamases. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1–11.</para>
          </listitem>
          <listitem id="ch0094s000000li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Stapleton PD, Shannon KP, French GL.</emphasis> 1999. Carbapenem resistance in <citetitle><emphasis>Escherichia coli</emphasis></citetitle> associated with plasmid-determined CMY-4 beta-lactamase production and loss of an outer membrane protein. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">43:</emphasis>1206–1210.</para>
          </listitem>
          <listitem id="ch0094s000000li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Jacoby GA.</emphasis> 2009. AmpC beta-lactamases. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">22:</emphasis>161–182.</para>
          </listitem>
          <listitem id="ch0094s000000li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2008. Outbreak of multidrug-resistant <citetitle><emphasis>Salmonella enterica</emphasis></citetitle> serotype Newport infections associated with consumption of unpasteurized Mexican-style aged cheese—Illinois, March 2006-April 2007. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">57:</emphasis>432–435.</para>
          </listitem>
          <listitem id="ch0094s000000li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Nadjar D, Rouveau M, Verdet C, Donay L, Herrmann J, Lagrange PH, Philippon A, Arlet G.</emphasis> 2000. Outbreak of <citetitle><emphasis>Klebsiella pneumoniae</emphasis></citetitle> producing transferable AmpC-type beta-lactamase (ACC-1) originating from <citetitle><emphasis>Hafnia alvei. FEMS Microbiol Lett</emphasis></citetitle> <emphasis role="strong">187:</emphasis>35–40.</para>
          </listitem>
          <listitem id="ch0094s000000li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Willems E, Verhaegen J, Magerman K, Nys S, Cartuyvels R.</emphasis> 2013. Towards a phenotypic screening strategy for emerging β-lactamases in Gram-negative bacilli. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">41:</emphasis>99–109.</para>
          </listitem>
          <listitem id="ch0094s000000li0170" role="bibliographyEntry">
            <para>170.<emphasis role="strong">Black JA, Thomson KS, Buynak JD, Pitout JD.</emphasis> 2005. Evaluation of beta-lactamase inhibitors in disk tests for detection of plasmid-mediated AmpC beta-lactamases in well-characterized clinical strains of <citetitle><emphasis>Klebsiella</emphasis></citetitle> spp. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>4168–4171.</para>
          </listitem>
          <listitem id="ch0094s000000li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Pasteran F, Mendez T, Guerriero L, Rapoport M, Corso A.</emphasis> 2009. Sensitive screening tests for suspected class A carbapenemase production in species of <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>1631–1639.</para>
          </listitem>
          <listitem id="ch0094s000000li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Tsakris A, Kristo I, Poulou A, Themeli-Digalaki K, Ikonomidis A, Petropoulou D, Pournaras S, Sofianou D.</emphasis> 2009. Evaluation of boronic acid disk tests for differentiating KPC-possessing <citetitle><emphasis>Klebsiella pneumoniae</emphasis></citetitle> isolates in the clinical laboratory. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>362–367.</para>
          </listitem>
          <listitem id="ch0094s000000li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Ingram PR, Inglis TJJ, Vanzetti TR, Henderson BA, Harnett GB, Murray RJ.</emphasis> 2011. Comparison of methods for AmpC β-lactamase detection in <citetitle><emphasis>Enterobacteriaceae. J Med Microbiol</emphasis></citetitle> <emphasis role="strong">60:</emphasis>715–721.</para>
          </listitem>
          <listitem id="ch0094s000000li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Lee W, Jung B, Hong SG, Song W, Jeong SH, Lee K, Kwak HS.</emphasis> 2009. Comparison of 3 phenotypic-detection methods for identifying plasmid-mediated AmpC beta-lactamase-producing <citetitle><emphasis>Escherichia coli</emphasis></citetitle>, <citetitle><emphasis>Klebsiella pneumoniae</emphasis></citetitle>, and <citetitle><emphasis>Proteus mirabilis</emphasis></citetitle> strains. <citetitle><emphasis>Korean J Lab Med</emphasis></citetitle> <emphasis role="strong">29:</emphasis>448–454.</para>
          </listitem>
          <listitem id="ch0094s000000li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">Polsfuss S, Bloemberg GV, Giger J, Meyer V, Böttger EC, Hombach M.</emphasis> 2011. Practical approach for reliable detection of AmpC beta-lactamase-producing <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>2798–2803.</para>
          </listitem>
          <listitem id="ch0094s000000li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Edquist P, Ringman M, Liljequist BO, Wisell KT, Giske CG.</emphasis> 2013. Phenotypic detection of plasmid-acquired AmpC in <citetitle><emphasis>Escherichia coli</emphasis></citetitle>—evaluation of screening criteria and performance of two commercial methods for the phenotypic confirmation of AmpC production. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">32:</emphasis>1205–1210.</para>
          </listitem>
          <listitem id="ch0094s000000li0177" role="bibliographyEntry">
            <para>177.<emphasis role="strong">Gude MJ, Seral C, Sáenz Y, González-Domínguez M, Torres C, Castillo FJ.</emphasis> 2012. Evaluation of four phenotypic methods to detect plasmid-mediated AmpC β-lactamases in clinical isolates. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">31:</emphasis>2037–2043.</para>
          </listitem>
          <listitem id="ch0094s000000li0178" role="bibliographyEntry">
            <para>178.<emphasis role="strong">Ruppé E, Bidet P, Verdet C, Arlet G, Bingen E.</emphasis> 2006. First detection of the Ambler class C 1 AmpC beta-lactamase in <citetitle><emphasis>Citrobacter freundii</emphasis></citetitle> by a new, simple double-disk synergy test. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>4204–4207.</para>
          </listitem>
          <listitem id="ch0094s000000li0179" role="bibliographyEntry">
            <para>179.<emphasis role="strong">Hansen F, Hammerum AM, Skov RL, Giske CG, Sundsfjord A, Samuelsen O.</emphasis> 2012. Evaluation of ROSCO Neo-Sensitabs for phenotypic detection and subgrouping of ESBL-, AmpC- and carbapenemase-producing <citetitle><emphasis>Enterobacteriaceae. APMIS</emphasis></citetitle> <emphasis role="strong">120:</emphasis>724–732.</para>
          </listitem>
          <listitem id="ch0094s000000li0180" role="bibliographyEntry">
            <para>180.<emphasis role="strong">Tsui K, Wong SS, Lin LC, Tsai CR, Chen LC, Huang CH.</emphasis> 2012. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to <citetitle><emphasis>Escherichia coli</emphasis></citetitle> and <citetitle><emphasis>Klebsiella pneumoniae</emphasis></citetitle> producing extended-spectrum and AmpC type β-lactamases. <citetitle><emphasis>J Microbiol Immunol Infect</emphasis></citetitle> <emphasis role="strong">45:</emphasis>193–199.</para>
          </listitem>
          <listitem id="ch0094s000000li0181" role="bibliographyEntry">
            <para>181.<emphasis role="strong">Tan TY, Ng LS, He J, Koh TH, Hsu LY.</emphasis> 2009. Evaluation of screening methods to detect plasmid-mediated AmpC in <citetitle><emphasis>Escherichia coli</emphasis></citetitle>, <citetitle><emphasis>Klebsiella pneumoniae</emphasis></citetitle>, and <citetitle><emphasis>Proteus mirabilis. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">53:</emphasis>146–149.</para>
          </listitem>
          <listitem id="ch0094s000000li0182" role="bibliographyEntry">
            <para>182.<emphasis role="strong">Halstead FD, Vanstone GL, Balakrishnan I.</emphasis> 2012. An evaluation of the Mast D69C AmpC detection disc set for the detection of inducible and derepressed AmpC β-lactamases. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">67:</emphasis>2303–2304.</para>
          </listitem>
          <listitem id="ch0094s000000li0183" role="bibliographyEntry">
            <para>183.<emphasis role="strong">Barber KE, Ortwine JK, Akins RL.</emphasis> 2016. Ceftazidime/avibactam: who says you can’t teach an old drug new tricks? <citetitle><emphasis>J Pharm Pharm Sci</emphasis></citetitle> <emphasis role="strong">19:</emphasis>448–464.</para>
          </listitem>
          <listitem id="ch0094s000000li0184" role="bibliographyEntry">
            <para>184.<emphasis role="strong">Castanheira M, Huband MD, Mendes RE, Flamm RK.</emphasis> 2017. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant <citetitle><emphasis>Enterobacteriaceae. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e00567-17.</para>
          </listitem>
          <listitem id="ch0094s000000li0185" role="bibliographyEntry">
            <para>185.<emphasis role="strong">Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, Nguyen MH.</emphasis> 2017. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant <citetitle><emphasis>Enterobacteriaceae. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e00642-17.</para>
          </listitem>
          <listitem id="ch0094s000000li0186" role="bibliographyEntry">
            <para>186.<emphasis role="strong">Simner PJ, Patel R.</emphasis> 2020. Cefiderocol antimicrobial susceptibility testing considerations: the Achilles’ heel of the Trojan horse? <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e00951-20.</para>
          </listitem>
          <listitem id="ch0094s000000li0187" role="bibliographyEntry">
            <para>187.<emphasis role="strong">Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, Maor Y, Rahav G.</emphasis> 2012. Outcome of carbapenem resistant <citetitle><emphasis>Klebsiella pneumoniae</emphasis></citetitle> bloodstream infections. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">18:</emphasis>54–60.</para>
          </listitem>
          <listitem id="ch0094s000000li0188" role="bibliographyEntry">
            <para>188.<emphasis role="strong">CDC.</emphasis> 2015. Facility guidance for control of carbapenem-resistant <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> (CRE). November 2015 update - CRE tookit. <ulink url="https://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf">https://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf</ulink></para>
          </listitem>
          <listitem id="ch0094s000000li0189" role="bibliographyEntry">
            <para>189.<emphasis role="strong">Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP.</emphasis> 2008. Outcomes of carbapenem-resistant <citetitle><emphasis>Klebsiella pneumoniae</emphasis></citetitle> infection and the impact of antimicrobial and adjunctive therapies. <citetitle><emphasis>Infect Control Hosp Epidemiol</emphasis></citetitle> <emphasis role="strong">29:</emphasis>1099–1106.</para>
          </listitem>
          <listitem id="ch0094s000000li0190" role="bibliographyEntry">
            <para>190.<emphasis role="strong">Tamma PD, Goodman KE, Harris AD, Tekle T, Roberts A, Taiwo A, Simner PJ.</emphasis> 2017. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> bacteremia. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">64:</emphasis>257–264.</para>
          </listitem>
          <listitem id="ch0094s000000li0191" role="bibliographyEntry">
            <para>191.<emphasis role="strong">Fernandes P, Martens E.</emphasis> 2017. Antibiotics in late clinical development. <citetitle><emphasis>Biochem Pharmacol</emphasis></citetitle> <emphasis role="strong">133:</emphasis>152–163.</para>
          </listitem>
          <listitem id="ch0094s000000li0192" role="bibliographyEntry">
            <para>192.<emphasis role="strong">Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, Westblade LF.</emphasis> 2018. Carbapenemase-producing organisms: a global scourge. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">66:</emphasis>1290–1297.</para>
          </listitem>
          <listitem id="ch0094s000000li0193" role="bibliographyEntry">
            <anchor id="ch0094s000000a0116"/>
            <para>193.<emphasis role="strong">Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, Samuelsen Ø, Seifert H, Woodford N, Nordmann P, European Network on Carbapenemases.</emphasis> 2012. Rapid evolution and spread of carbapenemases among <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> in Europe. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">18:</emphasis>413–431.</para>
          </listitem>
          <listitem id="ch0094s000000li0194" role="bibliographyEntry">
            <para>194.<emphasis role="strong">Queenan AM, Bush K.</emphasis> 2007. Carbapenemases: the versatile beta-lactamases. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">20:</emphasis>440–458.</para>
          </listitem>
          <listitem id="ch0094s000000li0195" role="bibliographyEntry">
            <para>195.<emphasis role="strong">Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP, Colombian Nosocomial Resistance Study Group.</emphasis> 2007. First identification of <citetitle><emphasis>Pseudomonas aeruginosa</emphasis></citetitle> isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1553–1555.</para>
          </listitem>
          <listitem id="ch0094s000000li0196" role="bibliographyEntry">
            <para>196.<emphasis role="strong">Walsh TR, Toleman MA, Poirel L, Nordmann P.</emphasis> 2005. Metallo-beta-lactamases: the quiet before the storm? <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">18:</emphasis>306–325.</para>
          </listitem>
          <listitem id="ch0094s000000li0197" role="bibliographyEntry">
            <para>197.<emphasis role="strong">Bushnell G, Mitrani-Gold F, Mundy LM.</emphasis> 2013. Emergence of New Delhi metallo-β-lactamase type 1-producing <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> and non-<citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle>: global case detection and bacterial surveillance. <citetitle><emphasis>Int J Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>e325–e333.</para>
          </listitem>
          <listitem id="ch0094s000000li0198" role="bibliographyEntry">
            <para>198.<emphasis role="strong">Johnson AP, Woodford N.</emphasis> 2013. Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">62:</emphasis>499–513.</para>
          </listitem>
          <listitem id="ch0094s000000li0199" role="bibliographyEntry">
            <para>199.<emphasis role="strong">Nordmann P.</emphasis> 2014. Carbapenemase-producing <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle>: overview of a major public health challenge. <citetitle><emphasis>Med Mal Infect</emphasis></citetitle> <emphasis role="strong">44:</emphasis>51–56.</para>
          </listitem>
          <listitem id="ch0094s000000li0200" role="bibliographyEntry">
            <para>200.<emphasis role="strong">Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL, European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group.</emphasis> 2015. Carbapenemase-producing <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> in Europe: assessment by national experts from 38 countries, May 2015. <citetitle><emphasis>Euro Surveill</emphasis></citetitle> <emphasis role="strong">20</emphasis>.</para>
          </listitem>
          <listitem id="ch0094s000000li0201" role="bibliographyEntry">
            <para>201.<emphasis role="strong">Girlich D, Poirel L, Nordmann P.</emphasis> 2012. Value of the modified Hodge test for detection of emerging carbapenemases in <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>477–479.</para>
          </listitem>
          <listitem id="ch0094s000000li0202" role="bibliographyEntry">
            <para>202.<emphasis role="strong">Bianco G, Boattini M, Comini S, Casale R, Iannaccone M, Cavallo R, Costa C.</emphasis> 2022. Occurrence of multi-carbapenemases producers among carbapenemase-producing <citetitle><emphasis>Enterobacterales</emphasis></citetitle> and <citetitle><emphasis>in vitro</emphasis></citetitle> activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">41:</emphasis>573–580.</para>
          </listitem>
          <listitem id="ch0094s000000li0203" role="bibliographyEntry">
            <para>203.<emphasis role="strong">Carvalhaes CG, Picão RC, Nicoletti AG, Xavier DE, Gales AC.</emphasis> 2010. Cloverleaf test (modified Hodge test) for detecting carbapenemase production in <citetitle><emphasis>Klebsiella pneumoniae</emphasis></citetitle>: be aware of false positive results. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">65:</emphasis>249–251.</para>
          </listitem>
          <listitem id="ch0094s000000li0204" role="bibliographyEntry">
            <para>204.<emphasis role="strong">Mochon AB, Garner OB, Hindler JA, Krogstad P, Ward KW, Lewinski MA, Rasheed JK, Anderson KF, Limbago BM, Humphries RM.</emphasis> 2011. New Delhi metallo-β-lactamase (NDM-1)-producing <citetitle><emphasis>Klebsiella pneumoniae</emphasis></citetitle>: case report and laboratory detection strategies. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>1667–1670.</para>
          </listitem>
          <listitem id="ch0094s000000li0205" role="bibliographyEntry">
            <para>205.<emphasis role="strong">Cunningham SA, Limbago B, Traczewski M, Anderson K, Hackel M, Hindler J, Sahm D, Alyanak E, Lawsin A, Gulvik CA, de Man TJB, Mandrekar JN, Schuetz AN, Jenkins S, Humphries R, Palavecino E, Vasoo S, Patel R.</emphasis> 2017. Multicenter performance assessment of Carba NP test. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>1954–1960.</para>
          </listitem>
          <listitem id="ch0094s000000li0206" role="bibliographyEntry">
            <para>206.<emphasis role="strong">Simner PJ, Opene BNA, Chambers KK, Naumann ME, Carroll KC, Tamma PD.</emphasis> 2017. Carbapenemase detection among carbapenem-resistant glucose-nonfermenting Gram-negative bacilli. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>2858–2864.</para>
          </listitem>
          <listitem id="ch0094s000000li0207" role="bibliographyEntry">
            <para>207.<emphasis role="strong">Tamma PD, Opene BN, Gluck A, Chambers KK, Carroll KC, Simner PJ.</emphasis> 2017. Comparison of 11 phenotypic assays for accurate detection of carbapenemase-producing <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>1046–1055.</para>
          </listitem>
          <listitem id="ch0094s000000li0208" role="bibliographyEntry">
            <para>208.<emphasis role="strong">Vasoo S, Cunningham SA, Kohner PC, Simner PJ, Mandrekar JN, Lolans K, Hayden MK, Patel R.</emphasis> 2013. Comparison of a novel, rapid chromogenic biochemical assay, the Carba NP test, with the modified Hodge test for detection of carbapenemase-producing Gram-negative bacilli. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>3097–3101.</para>
          </listitem>
          <listitem id="ch0094s000000li0209" role="bibliographyEntry">
            <para>209.<emphasis role="strong">Tijet N, Boyd D, Patel SN, Mulvey MR, Melano RG.</emphasis> 2013. Evaluation of the Carba NP test for rapid detection of carbapenemase-producing <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> and <citetitle><emphasis>Pseudomonas aeruginosa. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">57:</emphasis>4578–4580.</para>
          </listitem>
          <listitem id="ch0094s000000li0210" role="bibliographyEntry">
            <para>210.<emphasis role="strong">Simner PJ, Johnson JK, Brasso WB, Anderson K, Lonsway DR, Pierce VM, Bobenchik AM, Lockett ZC, Charnot-Katsikas A, Westblade LF, Yoo BB, Jenkins SG, Limbago BM, Das S, Roe-Carpenter DE.</emphasis> 2017. Multicenter evaluation of the modified carbapenem inactivation method and the Carba NP for detection of carbapenemase-producing <citetitle><emphasis>Pseudomonas aeruginosa</emphasis></citetitle> and <citetitle><emphasis>Acinetobacter baumannii. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>e01369-17.</para>
          </listitem>
          <listitem id="ch0094s000000li0211" role="bibliographyEntry">
            <para>211.<emphasis role="strong">Dortet L, Poirel L, Errera C, Nordmann P.</emphasis> 2014. CarbAcineto NP test for rapid detection of carbapenemase-producing <citetitle><emphasis>Acinetobacter</emphasis></citetitle> spp. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>2359–2364.</para>
          </listitem>
          <listitem id="ch0094s000000li0212" role="bibliographyEntry">
            <para>212.<emphasis role="strong">Bakour S, Garcia V, Loucif L, Brunel JM, Gharout-Sait A, Touati A, Rolain JM.</emphasis> 2015. Rapid identification of carbapenemase-producing <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle>, <citetitle><emphasis>Pseudomonas aeruginosa</emphasis></citetitle> and <citetitle><emphasis>Acinetobacter baumannii</emphasis></citetitle> using a modified Carba NP test. <citetitle><emphasis>New Microbes New Infect</emphasis></citetitle> <emphasis role="strong">7:</emphasis>89–93.</para>
          </listitem>
          <listitem id="ch0094s000000li0213" role="bibliographyEntry">
            <para>213.<emphasis role="strong">Pires J, Novais A, Peixe L.</emphasis> 2013. Blue-carba, an easy biochemical test for detection of diverse carbapenemase producers directly from bacterial cultures. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>4281–4283.</para>
          </listitem>
          <listitem id="ch0094s000000li0214" role="bibliographyEntry">
            <para>214.<emphasis role="strong">Simner PJ, Gilmour MW, DeGagne P, Nichol K, Karlowsky JA.</emphasis> 2015. Evaluation of five chromogenic agar media and the Rosco Rapid Carb screen kit for detection and confirmation of carbapenemase production in Gram-negative bacilli. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>105–112.</para>
          </listitem>
          <listitem id="ch0094s000000li0215" role="bibliographyEntry">
            <para>215.<emphasis role="strong">van der Zwaluw K, de Haan A, Pluister GN, Bootsma HJ, de Neeling AJ, Schouls LM.</emphasis> 2015. The carbapenem inactivation method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in gram-negative rods. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">10</emphasis><emphasis role="strong">:</emphasis>e0123690.</para>
          </listitem>
          <listitem id="ch0094s000000li0216" role="bibliographyEntry">
            <para>216.<emphasis role="strong">Pierce VM, Simner PJ, Lonsway DR, Roe-Carpenter DE, Johnson JK, Brasso WB, Bobenchik AM, Lockett ZC, Charnot-Katsikas A, Ferraro MJ, Thomson RB Jr, Jenkins SG, Limbago BM, Das S.</emphasis> 2017. Modified carbapenem inactivation method for phenotypic detection of carbapenemase production among <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>2321–2333.</para>
          </listitem>
          <listitem id="ch0094s000000li0217" role="bibliographyEntry">
            <para>217.<emphasis role="strong">Jing X, Min X, Zhang X, Gong L, Wu T, Sun R, Chen L, Liu R, Zeng J.</emphasis> 2019. The rapid carbapenemase detection method (rCDM) for rapid and accurate detection of carbapenemase-producing <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> and <citetitle><emphasis>Pseudomonas aeruginosa. Front Cell Infect Microbiol</emphasis></citetitle> <emphasis role="strong">9:</emphasis>371.</para>
          </listitem>
          <listitem id="ch0094s000000li0218" role="bibliographyEntry">
            <para>218.<emphasis role="strong">Jing X, Zhou H, Min X, Zhang X, Yang Q, Du S, Li Y, Yu F, Jia M, Zhan Y, Zeng Y, Yang B, Pan Y, Lu B, Liu R, Zeng J.</emphasis> 2018. The simplified carbapenem inactivation method (sCIM) for simple and accurate detection of carbapenemase-producing Gram-negative bacilli. <citetitle><emphasis>Front Microbiol</emphasis></citetitle> <emphasis role="strong">9:</emphasis>2391.</para>
          </listitem>
          <listitem id="ch0094s000000li0219" role="bibliographyEntry">
            <para>219.<emphasis role="strong">Uechi K, Tada T, Shimada K, Kuwahara-Arai K, Arakaki M, Tome T, Nakasone I, Maeda S, Kirikae T, Fujita J.</emphasis> 2017. A modified carbapenem inactivation method, CIMTris, for carbapenemase production in <citetitle><emphasis>Acinetobacter</emphasis></citetitle> and <citetitle><emphasis>Pseudomonas</emphasis></citetitle> species. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>3405–3410.</para>
          </listitem>
          <listitem id="ch0094s000000li0220" role="bibliographyEntry">
            <para>220.<emphasis role="strong">Sfeir MM, Hayden JA, Fauntleroy KA, Mazur C, Johnson JK, Simner PJ, Das S, Satlin MJ, Jenkins SG, Westblade LF.</emphasis> 2019. EDTA-modified carbapenem inactivation method: a phenotypic method for detecting metallo-β-lactamase-producing <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>e01757-18.</para>
          </listitem>
          <listitem id="ch0094s000000li0221" role="bibliographyEntry">
            <para>221.<emphasis role="strong">Danel F, Paetzel M, Strynadka NC, Page MG.</emphasis> 2001. Effect of divalent metal cations on the dimerization of OXA-10 and -14 class D beta-lactamases from <citetitle><emphasis>Pseudomonas aeruginosa. Biochemistry</emphasis></citetitle> <emphasis role="strong">40:</emphasis>9412–9420.</para>
          </listitem>
          <listitem id="ch0094s000000li0222" role="bibliographyEntry">
            <para>222.<emphasis role="strong">Segal H, Elisha BG.</emphasis> 2005. Use of Etest MBL strips for the detection of carbapenemases in <citetitle><emphasis>Acinetobacter baumannii. J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>598.</para>
          </listitem>
          <listitem id="ch0094s000000li0223" role="bibliographyEntry">
            <para>223.<emphasis role="strong">Papp-Wallace KM, Winkler ML, Taracila MA, Bonomo RA.</emphasis> 2015. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>3710–3717.</para>
          </listitem>
          <listitem id="ch0094s000000li0224" role="bibliographyEntry">
            <anchor id="ch0094s000000a0117"/>
            <para>224.<emphasis role="strong">Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O.</emphasis> 2017. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing <citetitle><emphasis>Klebsiella pneumoniae. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e01694-17.</para>
          </listitem>
          <listitem id="ch0094s000000li0225" role="bibliographyEntry">
            <para>225.<emphasis role="strong">Giske CG, Martinez-Martinez L, Canton R, Stefani S, Skov R, Glupczynski Y, Nordmann P, Wooton M, Miriagou V, Skov Simonsen G, Zemlickova H, Cohen-Stuart J, Gniadkowski M.</emphasis> 2013. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. <ulink url="http://www.amcli.it/wp-content/uploads/2015/10/EUCAST_detection_resistance_mechanisms_V1.pdf">http://www.amcli.it/wp-content/uploads/2015/10/EUCAST_detection_resistance_mechanisms_V1.pdf</ulink>. Accessed August 2022.</para>
          </listitem>
          <listitem id="ch0094s000000li0226" role="bibliographyEntry">
            <para>226.<emphasis role="strong">Thomson G, Turner D, Brasso W, Kircher S, Guillet T, Thomson K.</emphasis> 2017. High-stringency evaluation of the automated BD Phoenix CPO Detect and Rapidec Carba NP tests for detection and classification of carbapenemases. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>3437–3443.</para>
          </listitem>
          <listitem id="ch0094s000000li0227" role="bibliographyEntry">
            <para>227.<emphasis role="strong">Berneking L, Both A, Berinson B, Hoffmann A, Lütgehetmann M, Aepfelbacher M, Rohde H.</emphasis> 2021. Performance of the BD Phoenix CPO detect assay for detection and classification of carbapenemase-producing organisms. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">40:</emphasis>979–985.</para>
          </listitem>
          <listitem id="ch0094s000000li0228" role="bibliographyEntry">
            <para>228.<emphasis role="strong">Mirande C, Canard I, Buffet Croix Blanche S, Charrier JP, van Belkum A, Welker M, Chatellier S.</emphasis> 2015. Rapid detection of carbapenemase activity: benefits and weaknesses of MALDI-TOF MS. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">34:</emphasis>2225–2234.</para>
          </listitem>
          <listitem id="ch0094s000000li0229" role="bibliographyEntry">
            <para>229.<emphasis role="strong">Knox J, Palombo E.</emphasis> 2017. Performance of a MALDI-TOF MS-based imipenem hydrolysis assay incorporating zinc sulfate. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">87:</emphasis>258–260.</para>
          </listitem>
          <listitem id="ch0094s000000li0230" role="bibliographyEntry">
            <para>230.<emphasis role="strong">Papagiannitsis CC, Študentová V, Izdebski R, Oikonomou O, Pfeifer Y, Petinaki E, Hrabák J.</emphasis> 2015. Matrix-assisted laser desorption ionization-time of flight mass spectrometry meropenem hydrolysis assay with NH<subscript>4</subscript>HCO<subscript>3</subscript>, a reliable tool for direct detection of carbapenemase activity. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>1731–1735.</para>
          </listitem>
          <listitem id="ch0094s000000li0231" role="bibliographyEntry">
            <para>231.<emphasis role="strong">Hoyos-Mallecot Y, Riazzo C, Miranda-Casas C, Rojo-Martín MD, Gutiérrez-Fernández J, Navarro-Marí JM.</emphasis> 2014. Rapid detection and identification of strains carrying carbapenemases directly from positive blood cultures using MALDI-TOF MS. <citetitle><emphasis>J Microbiol Methods</emphasis></citetitle> <emphasis role="strong">105:</emphasis>98–101.</para>
          </listitem>
          <listitem id="ch0094s000000li0232" role="bibliographyEntry">
            <para>232.<emphasis role="strong">Lin HR, Hu A, Lai MJ, Chiang CW, Liao CC, Chang KC.</emphasis> 2016. Rapid and sensitive detection of carbapenemase activity in <citetitle><emphasis>Acinetobacter baumannii</emphasis></citetitle> using superficially porous liquid chromatography-tandem mass spectrometry. <citetitle><emphasis>J Microbiol Immunol Infect</emphasis></citetitle> <emphasis role="strong">49:</emphasis>910–917.</para>
          </listitem>
          <listitem id="ch0094s000000li0233" role="bibliographyEntry">
            <para>233.<emphasis role="strong">Peaper DR, Kulkarni MV, Tichy AN, Jarvis M, Murray TS, Hodsdon ME.</emphasis> 2013. Rapid detection of carbapenemase activity through monitoring ertapenem hydrolysis in <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> with LC-MS/MS. <citetitle><emphasis>Bioanalysis</emphasis></citetitle> <emphasis role="strong">5:</emphasis>147–157.</para>
          </listitem>
          <listitem id="ch0094s000000li0234" role="bibliographyEntry">
            <para>234.<emphasis role="strong">Bogaerts P, Yunus S, Massart M, Huang TD, Glupczynski Y.</emphasis> 2016. Evaluation of the BYG Carba test, a new electrochemical assay for rapid laboratory detection of carbapenemase-producing <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>349–358.</para>
          </listitem>
          <listitem id="ch0094s000000li0235" role="bibliographyEntry">
            <para>235.<emphasis role="strong">Bogaerts P, Oueslati S, Meunier D, Nonhoff C, Yunus S, Massart M, Denis O, Woodford N, Hopkins KL, Naas T, Dortet L, Huang TD, Glupczynski Y.</emphasis> 2017. Multicentre evaluation of the BYG Carba v2.0 test, a simplified electrochemical assay for the rapid laboratory detection of carbapenemase-producing <citetitle><emphasis>Enterobacteriaceae. Sci Rep</emphasis></citetitle> <emphasis role="strong">7:</emphasis>9937.</para>
          </listitem>
          <listitem id="ch0094s000000li0236" role="bibliographyEntry">
            <para>236.<emphasis role="strong">Lau AF, Wang H, Weingarten RA, Drake SK, Suffredini AF, Garfield MK, Chen Y, Gucek M, Youn JH, Stock F, Tso H, DeLeo J, Cimino JJ, Frank KM, Dekker JP.</emphasis> 2014. A rapid matrix-assisted laser desorption ionization-time of flight mass spectrometry-based method for single-plasmid tracking in an outbreak of carbapenem-resistant <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>2804–2812.</para>
          </listitem>
          <listitem id="ch0094s000000li0237" role="bibliographyEntry">
            <para>237.<emphasis role="strong">Youn JH, Drake SK, Weingarten RA, Frank KM, Dekker JP, Lau AF.</emphasis> 2015. Clinical performance of a matrix-assisted laser desorption ionization time-of-flight mass spectrometry method for the detection of certain <citetitle><emphasis>bla</emphasis></citetitle><subscript>KPC</subscript>-containing plasmids. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>e01643-15.</para>
          </listitem>
          <listitem id="ch0094s000000li0238" role="bibliographyEntry">
            <para>238.<emphasis role="strong">Wang H, Drake SK, Youn JH, Rosenberg AZ, Chen Y, Gucek M, Suffredini AF, Dekker JP.</emphasis> 2017. Peptide markers for rapid detection of KPC carbapenemase by LC-MS/MS. <citetitle><emphasis>Sci Rep</emphasis></citetitle> <emphasis role="strong">7:</emphasis>2531.</para>
          </listitem>
          <listitem id="ch0094s000000li0239" role="bibliographyEntry">
            <para>239.<emphasis role="strong">Boutal H, Naas T, Devilliers K, Oueslati S, Dortet L, Bernabeu S, Simon S, Volland H.</emphasis> 2017. Development and validation of a lateral flow immunoassay for rapid detection of NDM-producing <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>2018–2029.</para>
          </listitem>
          <listitem id="ch0094s000000li0240" role="bibliographyEntry">
            <para>240.<emphasis role="strong">Boutal H, Vogel A, Bernabeu S, Devilliers K, Creton E, Cotellon G, Plaisance M, Oueslati S, Dortet L, Jousset A, Simon S, Naas T, Volland H.</emphasis> 2018. A multiplex lateral flow immunoassay for the rapid identification of NDM-, KPC-, IMP- and VIM-type and OXA-48-like carbapenemase-producing <citetitle><emphasis>Enterobacteriaceae. J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">73:</emphasis>909–915.</para>
          </listitem>
          <listitem id="ch0094s000000li0241" role="bibliographyEntry">
            <para>241.<emphasis role="strong">Jenkins S, Ledeboer NA, Westblade LF, Burnham CA, Faron ML, Bergman Y, Yee R, Mesich B, Gerstbrein D, Wallace MA, Robertson A, Fauntleroy KA, Klavins AS, Malherbe R, Hsiung A, Simner PJ.</emphasis> 2020. Evaluation of NG-Test Carba 5 for rapid phenotypic detection and differentiation of five common carbapenemase families: results of a multicenter clinical evaluation. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>e00344-20.</para>
          </listitem>
          <listitem id="ch0094s000000li0242" role="bibliographyEntry">
            <para>242.<emphasis role="strong">Bianco G, Boattini M, van Asten SAV, Iannaccone M, Zanotto E, Zaccaria T, Bernards AT, Cavallo R, Costa C.</emphasis> 2020. RESIST-5 O.O.K.N.V. and NG-Test Carba 5 assays for the rapid detection of carbapenemase-producing <citetitle><emphasis>Enterobacterales</emphasis></citetitle> from positive blood cultures: a comparative study. <citetitle><emphasis>J Hosp Infect</emphasis></citetitle> <emphasis role="strong">105:</emphasis>162–166.</para>
          </listitem>
          <listitem id="ch0094s000000li0243" role="bibliographyEntry">
            <para>243.<emphasis role="strong">Takissian J, Bonnin RA, Naas T, Dortet L.</emphasis> 2019. NG-Test Carba 5 for rapid detection of carbapenemase-producing <citetitle><emphasis>Enterobacterales</emphasis></citetitle> from positive blood cultures. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">63:</emphasis>e00011-19.</para>
          </listitem>
          <listitem id="ch0094s000000li0244" role="bibliographyEntry">
            <para>244.<emphasis role="strong">Vasilakopoulou A, Karakosta P, Vourli S, Kalogeropoulou E, Pournaras S.</emphasis> 2021. Detection of KPC, NDM and VIM-producing organisms directly from rectal swabs by a multiplex lateral flow immunoassay. <citetitle><emphasis>Microorganisms</emphasis></citetitle> <emphasis role="strong">9:</emphasis>942.</para>
          </listitem>
          <listitem id="ch0094s000000li0245" role="bibliographyEntry">
            <para>245.<emphasis role="strong">Viau R, Frank KM, Jacobs MR, Wilson B, Kaye K, Donskey CJ, Perez F, Endimiani A, Bonomo RA.</emphasis> 2016. Intestinal carriage of carbapenemase-producing organisms: current status of surveillance methods. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">29:</emphasis>1–27.</para>
          </listitem>
          <listitem id="ch0094s000000li0246" role="bibliographyEntry">
            <para>246.<emphasis role="strong">CDC.</emphasis> 2008. Laboratory protocol for detection of carbapenem-resistant or carbapenemase-producing, <citetitle><emphasis>Klebsiella</emphasis></citetitle> spp. and <citetitle><emphasis>E. coli</emphasis></citetitle> from rectal swabs. <ulink url="https://www.aab.org/images/aab/pdf/2013/Klebsiella_or_Ecoli_Lab_protocol.pdf">https://www.aab.org/images/aab/pdf/2013/Klebsiella_or_Ecoli_Lab_protocol.pdf</ulink>.</para>
          </listitem>
          <listitem id="ch0094s000000li0247" role="bibliographyEntry">
            <para>247.<emphasis role="strong">Blackburn J, Tsimiklis C, Lavergne V, Pilotte J, Grenier S, Gilbert A, Lefebvre B, Domingo MC, Tremblay C, Bourgault AM.</emphasis> 2013. Carbapenem disks on MacConkey agar in screening methods for detection of carbapenem-resistant Gram-negative rods in stools. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>331–333.</para>
          </listitem>
          <listitem id="ch0094s000000li0248" role="bibliographyEntry">
            <para>248.<emphasis role="strong">Lolans K, Calvert K, Won S, Clark J, Hayden MK.</emphasis> 2010. Direct ertapenem disk screening method for identification of KPC-producing <citetitle><emphasis>Klebsiella pneumoniae</emphasis></citetitle> and <citetitle><emphasis>Escherichia coli</emphasis></citetitle> in surveillance swab specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>836–841.</para>
          </listitem>
          <listitem id="ch0094s000000li0249" role="bibliographyEntry">
            <para>249.<emphasis role="strong">Yee R, Fisher S, Bergman Y, Chambers KK, Tamma PD, Carroll KC, Simner PJ.</emphasis> 2021. Combined selective culture and molecular methods for the detection of carbapenem-resistant organisms from fecal specimens. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">40:</emphasis>2315–2321.</para>
          </listitem>
          <listitem id="ch0094s000000li0250" role="bibliographyEntry">
            <para>250.<emphasis role="strong">Workneh M, Wang R, Kazmi AQ, Chambers KK, Opene BNA, Lewis S, Goodman K, Tamma PD, Carroll KC, Milstone AM, Simner PJ.</emphasis> 2019. Evaluation of the direct MacConkey method for identification of carbapenem-resistant Gram-negative organisms from rectal swabs: reevaluating zone diameter cutoffs. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>e01127-19.</para>
          </listitem>
          <listitem id="ch0094s000000li0251" role="bibliographyEntry">
            <para>251.<emphasis role="strong">Girlich D, Poirel L, Nordmann P.</emphasis> 2013. Comparison of the SUPERCARBA, CHROMagar KPC, and Brilliance CRE screening media for detection of <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> with reduced susceptibility to carbapenems. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">75:</emphasis>214–217.</para>
          </listitem>
          <listitem id="ch0094s000000li0252" role="bibliographyEntry">
            <para>252.<emphasis role="strong">Barry AL, Thornsberry C, Jones RN, Fuchs PC, Gavan TL, Gerlach EH.</emphasis> 1978. Reassessment of the “class” concept of disk susceptibility testing. Cephalothin disks versus minimal inhibitory concentrations with eleven cephalosporins. <citetitle><emphasis>Am J Clin Pathol</emphasis></citetitle> <emphasis role="strong">70:</emphasis>909–913.</para>
          </listitem>
          <listitem id="ch0094s000000li0253" role="bibliographyEntry">
            <anchor id="ch0094s000000a0118"/>
            <para>253.<emphasis role="strong">Preston DA, Jones RN, Barry AL, Thornsberry C.</emphasis> 1983. Comparison of the antibacterial spectra of cephalexin and cefaclor with those of cephalothin and newer cephalosporins: reevaluation of the class representative concept of susceptibility testing. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">17:</emphasis>1156–1158.</para>
          </listitem>
          <listitem id="ch0094s000000li0254" role="bibliographyEntry">
            <para>254.<emphasis role="strong">Bookstaver DA, Bland CM, Woodberry MW, Mansell KB.</emphasis> 2014. Correlation of cefpodoxime susceptibility with cephalothin and cefuroxime for urinary tract isolates. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">63:</emphasis>218–221.</para>
          </listitem>
          <listitem id="ch0094s000000li0255" role="bibliographyEntry">
            <para>255.<emphasis role="strong">Nguyen HM, Graber CJ.</emphasis> 2013. Cephalothin susceptibility testing as class representative for oral cephalosporins: is it time to move on? <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">76:</emphasis>483–485.</para>
          </listitem>
          <listitem id="ch0094s000000li0256" role="bibliographyEntry">
            <para>256.<emphasis role="strong">Schuetz AN, Brasso WB, Crandon JL, Hardy DJ, Jenkins SG, Jones RN, Knapp CC, Reller LB, Ad Hoc Oral Cephalosporin Working Group of the Subcommittee on Antimicrobial Susceptibility Testing of the CLSI.</emphasis> 2013. Cefazolin as a class representative for oral cephalosporins and uncomplicated urinary tract infections caused by indicated <citetitle><emphasis>Enterobacteriaceae. Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">77:</emphasis>381–382.</para>
          </listitem>
          <listitem id="ch0094s000000li0257" role="bibliographyEntry">
            <para>257.<emphasis role="strong">Bookstaver DA, Bland CM, Arroyo MA.</emphasis> 2015. Evaluation of cefazolin as a surrogate marker for cefpodoxime susceptibility for urinary tract isolates. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">64:</emphasis>1170–1173.</para>
          </listitem>
          <listitem id="ch0094s000000li0258" role="bibliographyEntry">
            <para>258.<emphasis role="strong">López IA, Montes JC, Álvarez MJ, Mazarrasa CF, Martínez-Martínez L.</emphasis> 2016. Cephalothin is not a reliable surrogate marker for oral cephalosporins in susceptibility testing of <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> causing urinary tract infection. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">86:</emphasis>412–416.</para>
          </listitem>
          <listitem id="ch0094s000000li0259" role="bibliographyEntry">
            <para>259.<emphasis role="strong">Fang FC.</emphasis> 2015. Fluoroquinolone resistance in <citetitle><emphasis>Salmonella</emphasis></citetitle> and the utility of pefloxacin disk diffusion [corrected]. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>3401–3404.</para>
          </listitem>
          <listitem id="ch0094s000000li0260" role="bibliographyEntry">
            <para>260.<emphasis role="strong">Skov R, Matuschek E, Sjölund-Karlsson M, Åhman J, Petersen A, Stegger M, Torpdahl M, Kahlmeter G.</emphasis> 2015. Development of a pefloxacin disk diffusion method for detection of fluoroquinolone-resistant <citetitle><emphasis>Salmonella enterica. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>3411–3417.</para>
          </listitem>
          <listitem id="ch0094s000000li0261" role="bibliographyEntry">
            <para>261.<emphasis role="strong">Rodríguez-Martínez JM, Machuca J, Cano ME, Calvo J, Martínez-Martínez L, Pascual A.</emphasis> 2016. Plasmid-mediated quinolone resistance: two decades on. <citetitle><emphasis>Drug Resist Updat</emphasis></citetitle> <emphasis role="strong">29:</emphasis>13–29.</para>
          </listitem>
          <listitem id="ch0094s000000li0262" role="bibliographyEntry">
            <para>262.<emphasis role="strong">Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A.</emphasis> 2009. Plasmid-mediated quinolone resistance: a multifaceted threat. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">22:</emphasis>664–689.</para>
          </listitem>
          <listitem id="ch0094s000000li0263" role="bibliographyEntry">
            <para>263.<emphasis role="strong">Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, Bhavnani SM, Jones RN, Ambrose PG.</emphasis> 2005. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for <citetitle><emphasis>Salmonella enterica</emphasis></citetitle> serotype typhi. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">49:</emphasis>1775–1781.</para>
          </listitem>
          <listitem id="ch0094s000000li0264" role="bibliographyEntry">
            <para>264.<emphasis role="strong">Crump JA, Barrett TJ, Nelson JT, Angulo FJ.</emphasis> 2003. Reevaluating fluoroquinolone breakpoints for <citetitle><emphasis>Salmonella enterica</emphasis></citetitle> serotype Typhi and for non-Typhi salmonellae. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">37:</emphasis>75–81.</para>
          </listitem>
          <listitem id="ch0094s000000li0265" role="bibliographyEntry">
            <para>265.<emphasis role="strong">Deak E, Hindler JA, Skov R, Sjölund-Karlsson M, Sokovic A, Humphries RM.</emphasis> 2015. Performance of Etest and disk diffusion for detection of ciprofloxacin and levofloxacin resistance in <citetitle><emphasis>Salmonella enterica. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>298–301.</para>
          </listitem>
          <listitem id="ch0094s000000li0266" role="bibliographyEntry">
            <para>266.<emphasis role="strong">Deak E, Skov R, Hindler JA, Humphries RM.</emphasis> 2015. Evaluation of surrogate disk tests for detection of ciprofloxacin and levofloxacin resistance in clinical isolates of <citetitle><emphasis>Salmonella enterica. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>3405–3410.</para>
          </listitem>
          <listitem id="ch0094s000000li0267" role="bibliographyEntry">
            <para>267.<emphasis role="strong">Liss MA, Johnson JR, Porter SB, Johnston B, Clabots C, Gillis K, Nseyo U, Holden M, Sakamoto K, Fierer J.</emphasis> 2015. Clinical and microbiological determinants of infection after transrectal prostate biopsy. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">60:</emphasis>979–987.</para>
          </listitem>
          <listitem id="ch0094s000000li0268" role="bibliographyEntry">
            <para>268.<emphasis role="strong">Johnson JR, Polgreen PM, Beekmann SE.</emphasis> 2015. Transrectal prostate biopsy-associated prophylaxis and infectious complications: report of a query to the emerging infections network of the infectious diseases society of america. <citetitle><emphasis>Open Forum Infect Dis</emphasis></citetitle> <emphasis role="strong">2:</emphasis>ofv002.</para>
          </listitem>
          <listitem id="ch0094s000000li0269" role="bibliographyEntry">
            <para>269.<emphasis role="strong">Liss MA, Nakamura KK, Peterson EM.</emphasis> 2013. Comparison of broth enhancement to direct plating for screening of rectal cultures for ciprofloxacin-resistant <citetitle><emphasis>Escherichia coli. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>249–252.</para>
          </listitem>
          <listitem id="ch0094s000000li0270" role="bibliographyEntry">
            <para>270.<emphasis role="strong">Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM.</emphasis> 2012. Colistin: an update on the antibiotic of the 21st century. <citetitle><emphasis>Expert Rev Anti Infect Ther</emphasis></citetitle> <emphasis role="strong">10:</emphasis>917–934.</para>
          </listitem>
          <listitem id="ch0094s000000li0271" role="bibliographyEntry">
            <para>271.<emphasis role="strong">Jerke K, Lee MJ, Humphries RM.</emphasis> 2016. Polymyxin susceptibility testing: a cold case reopened. <citetitle><emphasis>Clin Microbiol Newsl</emphasis></citetitle> <emphasis role="strong">38:</emphasis>69–77.</para>
          </listitem>
          <listitem id="ch0094s000000li0272" role="bibliographyEntry">
            <para>272.<emphasis role="strong">Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J.</emphasis> 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">16:</emphasis>161–168.</para>
          </listitem>
          <listitem id="ch0094s000000li0273" role="bibliographyEntry">
            <para>273.<emphasis role="strong">Ling Z, Yin W, Shen Z, Wang Y, Shen J, Walsh TR.</emphasis> 2020. Epidemiology of mobile colistin resistance genes mcr-1 to mcr-9. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">75:</emphasis>3087–3095.</para>
          </listitem>
          <listitem id="ch0094s000000li0274" role="bibliographyEntry">
            <para>274.<emphasis role="strong">Bell DT, Bergman Y, Kazmi AQ, Lewis S, Tamma PD, Simner PJ.</emphasis> 2019. A novel phenotypic method to screen for plasmid-mediated colistin resistance among <citetitle><emphasis>Enterobacteriales. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>e00040-19.</para>
          </listitem>
          <listitem id="ch0094s000000li0275" role="bibliographyEntry">
            <para>275.<emphasis role="strong">Büdel T, Clément M, Bernasconi OJ, Principe L, Perreten V, Luzzaro F, Endimiani A.</emphasis> 2019. Evaluation of EDTA- and DPA-based microdilution phenotypic tests for the detection of MCR-mediated colistin resistance in <citetitle><emphasis>Enterobacteriaceae. Microb Drug Resist</emphasis></citetitle> <emphasis role="strong">25:</emphasis>494–500.</para>
          </listitem>
          <listitem id="ch0094s000000li0276" role="bibliographyEntry">
            <para>276.<emphasis role="strong">Fenwick AJ, Bergman Y, Lewis S, Yee R, Uhlemann AC, Cole N, Kohner P, Ordak C, Green DA, Schuetz AN, Humphries R, Simner PJ.</emphasis> 2020. Evaluation of the NG-Test MCR-1 lateral flow assay and EDTA-colistin broth disk elution methods to detect plasmid-mediated colistin resistance among Gram-negative bacterial isolates. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>e01823-19.</para>
          </listitem>
          <listitem id="ch0094s000000li0277" role="bibliographyEntry">
            <para>277.<emphasis role="strong">Volland H, Dortet L, Bernabeu S, Boutal H, Haenni M, Madec JY, Robin F, Beyrouthy R, Naas T, Simon S.</emphasis> 2019. Development and multicentric validation of a lateral flow immunoassay for rapid detection of MCR-1-producing <citetitle><emphasis>Enterobacteriaceae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>e01454-18.</para>
          </listitem>
          <listitem id="ch0094s000000li0278" role="bibliographyEntry">
            <para>278.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2020. Polymyxin Breakpoints for <citetitle><emphasis>Enterobacterales</emphasis></citetitle>, <citetitle><emphasis>Pseudomonas aeruginosa</emphasis></citetitle>, and <citetitle><emphasis>Acinetobacter</emphasis></citetitle> spp. <citetitle><emphasis>MR01 CLSI Rational Document.</emphasis></citetitle> CLSI, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0094s000000li0279" role="bibliographyEntry">
            <para>279.<emphasis role="strong">Nordmann P, Jayol A, Poirel L.</emphasis> 2016. Rapid detection of polymyxin resistance in <citetitle><emphasis>Enterobacteriaceae. Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">22:</emphasis>1038–1043.</para>
          </listitem>
          <listitem id="ch0094s000000li0280" role="bibliographyEntry">
            <para>280.<emphasis role="strong">Lescat M, Poirel L, Tinguely C, Nordmann P.</emphasis> 2019. A resazurin reduction-based assay for rapid detection of polymyxin resistance in <citetitle><emphasis>Acinetobacter baumannii</emphasis></citetitle> and <citetitle><emphasis>Pseudomonas aeruginosa. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>e01563-18.</para>
          </listitem>
          <listitem id="ch0094s000000li0281" role="bibliographyEntry">
            <para>281.<emphasis role="strong">Girlich D, Naas T, Dortet L.</emphasis> 2018. Comparison of the superpolymyxin and ChromID colistin R screening media for the detection of colistin-resistant <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> from spiked rectal swabs. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">63:</emphasis>e01618-18.</para>
          </listitem>
          <listitem id="ch0094s000000li0282" role="bibliographyEntry">
            <para>282.<emphasis role="strong">Nordmann P, Jayol A, Poirel L.</emphasis> 2016. A universal culture medium for screening polymyxin-resistant Gram-negative isolates. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>1395–1399.</para>
          </listitem>
          <listitem id="ch0094s000000li0283" role="bibliographyEntry">
            <para>283.<emphasis role="strong">Wilkins TD, Thiel T.</emphasis> 1973. Modified broth-disk method for testing the antibiotic susceptibility of anaerobic bacteria. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">3:</emphasis>350–356.</para>
          </listitem>
          <listitem id="ch0094s000000li0284" role="bibliographyEntry">
            <para>284.<emphasis role="strong">Simner PJ, Bergman Y, Trejo M, Roberts AA, Marayan R, Tekle T, Campeau S, Kazmi AQ, Bell DT, Lewis S, Tamma PD, Humphries R, Hindler JA.</emphasis> 2019. Two-site evaluation of the colistin broth disk elution test to determine colistin <citetitle><emphasis>in vitro</emphasis></citetitle> activity against Gram-negative bacilli. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>e01163-18.</para>
          </listitem>
          <listitem id="ch0094s000000li0285" role="bibliographyEntry">
            <para>285.<emphasis role="strong">Humphries RM, Green DA, Schuetz AN, Bergman Y, Lewis S, Yee R, Stump S, Lopez M, Macesic N, Uhlemann AC, Kohner P, Cole N, Simner PJ.</emphasis> 2019. Multicenter evaluation of colistin broth disk elution and colistin agar test: a report from the Clinical and Laboratory Standards Institute. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>e01269-19.</para>
          </listitem>
        </itemizedlist>
        <orderedlist role="notesList">
          <listitem role="noteEntry">
            <para><anchor id="ch0094s000000a0119"/><link linkend="ch0094s000000a0001">*</link>This chapter contains information presented in <ulink url="ch0093#ch0093s0001">chapter 75</ulink> of the 12th edition of this <emphasis>Manual</emphasis>.</para>
          </listitem>
        </orderedlist>
      </sect2>
    </sect1>
  </chapter>
